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Chapter 1
The skin function and structure
The skin is the largest organ of the human body with a surface area of about 1.5 m2 in 
adults.1 It provides a protective barrier between the body and the external environment 
by preventing excessive transepidermal water loss (TEWL) (inside-to-outside barrier) 
and the entry of pathogens, allergens, and irritants (outside-to-inside barrier).2-4 
Besides this function, the skin is a sensory organ and has an important function in 
thermoregulation and pain.5,6 Finally the skin is a highly immunogenic organ with a 
high density of antigen presenting cells.
The skin consists of three main morphological layers, from inside to outside: the 
subcutaneous fat tissue (hypodermis), the dermis, and the epidermis (Figure 1). The 
dermis contains blood vessels, nerve endings, hair follicles, and sweat glands. The 
main cell type is the fibroblast which produces collagen fibers and elastin to give the 








Precursor lipids and 
enzymes stored in LBs 
The most prevalent cell type in the epidermis is the keratinocyte, but the epidermis 
also contains melanocytes, Langerhans cells, and Merkel cells. The keratinocytes in the 
epidermis are connected by tight junctions.3 The epidermis is divided into four strata, 
depending on the stage of differentiation. These strata are (from inside to outside) the 
viable stratum basale (SB), stratum spinosum (SS), and stratum granulosum (SG), and 
the non-viable stratum corneum (SC), with the SC being the outermost layer (Figure 
1). Keratinocytes proliferate in the SB and, after escaping from the basal layer, start 
to differentiate and migrate upwards to the SC. Keratinocytes ultimately become 
flat enucleated, terminally differentiated cells called corneocytes.9 At the surface, 
the corneocytes are shed in the desquamation process. As a consequence, the SC 
is completely renewed in about 4 weeks.10,11 During the differentiation process, the 
keratinocytes start to generate lamellar bodies (LBs) containing lipids and enzymes. 
Figure 1. Structure of the skin with dermis and epidermis. The epidermis is subdivided in four strata, the 
stratum basale, the stratum spinosum, the stratum granulosum, and the stratum corneum. Keratinocytes 
migrate upwards from the stratum basale towards the stratum corneum where they are shed. The details are 
showing lamellar bodies containing CERs and enzymes, and the extrusion of the lamellar bodies at the SG-





r 1This process starts in the SS and is accelerated in the SG. Most of the lipids stored in 
the LBs are the precursors of the SC lipids. The LB content is extruded at the SG-SC 
interface, where the precursor lipids are converted by enzymes to its final form (see 
below).12,13
Structure of the stratum corneum
The SC is 10-15 µm thick and contains about 10-20 corneocyte layers14-16, in which 
the corneocytes are connected by corneodesmosomes.3,13,17,18 Each corneocyte is 
surrounded by a highly impermeable cornified envelope consisting of a protein layer 
toward which a monolayer of lipids is chemically attached.3,4 The corneocytes are 
embedded in an extracellular lipid matrix which is the only continuous structure in 
the SC. Therefore, molecules always have to pass the lipid matrix when penetrating 
the skin.19-21 
The structure of the SC is often referred to as a “brick-and-mortar” structure with the 
bricks representing the corneocytes and the mortar representing the lipid matrix, 
respectively.22 The lipids in the extracellular matrix are highly ordered in lipid layers 
(lamellae) stacked on top of each other. The lamellae are oriented approximately 
parallel to the skin surface (Figure 2). Two lamellar phases have been identified in 
SC by using small-angle X-ray diffraction (SAXD). The long periodicity phase (LPP) 
has a repeat distance of about 13 nm, and the short periodicity phase (SPP) has a 
repeat distance of about 6 nm.23-27 In vitro studies indicated that the LPP is important 
for a proper skin barrier function.24,28 Within the lamellae, lipids can adopt a very 
dense orthorhombic, a less dense hexagonal, or a disordered liquid phase (Figure 2). 
In healthy human SC, a large fraction of lipids adopt the orthorhombic packing, while 
a minor lipid fraction forms a hexagonal packing.27,29-31 A more dense lipid packing is 
considered beneficial for the skin barrier function.24,30 
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Figure 2. Organization of the lipids within the stratum corneum lipid matrix. A) Schematic overview of 
the epidermal morphology. B) The corneocytes are embedded in the lipid matrix in a brick-and-mortar 
structure. C) The lipids in the matrix are stacked in lamellae in between the corneocytes. D) More details of 
the lipid lamellae. E) Two lamellar phases are identified with a repeat distance (d) of either 13 nm (LPP) or 
6 nm (SPP). F) Within the lamellae, the lipids are organized in either an orthorhombic, hexagonal, or liquid 
packing (from top to bottom).
Extracellular lipid matrix in the stratum corneum
The main lipid classes in the extracellular lipid matrix are cholesterol, free fatty acids 
(FAs), and ceramides (CERs) in approximately equimolar ratio.32-34 FAs in the lipid matrix 
have a wide chain length distribution. The most abundant FAs in the SC are those with a 
chain length of 24 and 26 carbon atoms.35-37 In healthy skin, FAs are primarily saturated, 
but also mono-unsaturated FAs (MUFAs) are detected.37 When focusing on the CERs, a 
wide variety in structural diversity is observed. CERs consist of a sphingoid base linked 
to a fatty acid chain. To date, at least 18 CER subclasses have been identified in the 
human SC (Figure 3).32-34,38-43 These subclasses are named according to their molecular 
structure. The acyl chain can either be non-hydroxylated (N), α-hydroxylated (A), or 
ω-hydroxylated (O). The latter can be linked to another fatty acid chain through an 






Figure 3. Ceramide subclasses in the stratum corneum lipid matrix. CERs consist of a sphingoid base 
coupled to a FA, which can both vary in molecular structure. CERs are named according to their molecular 
structure. The acyl chain can either be non-hydroxylated (N), α-hydroxylated (A), ω-hydroxylated (O), or 
esterified ω-hydroxylated (EO), whereas the sphingoid base is either a sphingosine (S), dihydrosphingosine 
(dS), phytosphingosine (P), 6-hydroxysphingosine (H), or dihydroxy dihydrosphingosine (T). 
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The sphingoid base is either a sphingosine (S), dihydrosphingosine (dS), phytosphingosine 
(P), 6-hydroxysphingosine (H), or dihydroxy dihydrosphingosine (T). In addition to 
their variation in molecular structure, a wide variety in total carbon chain length is 
observed in CERs. 
The lipid composition in the SC is important for the barrier function of the SC.44 For 
example, the presence of CER EO in the SC is essential for the formation of LPP25,45-48 
and it enhances the assembly of lipids in orthorhombic domains.45,48 
Lipid synthesis
Several SC lipids can be taken up by the keratinocytes from dietary sources, e.g. 
essential FAs diffuse into the plasma and are taken up via FA binding protein and FA 
transport protein.49 The same occurs for cholesterol. However, most SC lipids are (also) 
synthesized by the keratinocytes (de novo synthesis). Several enzymes are involved in 
the lipid synthesis from the viable epidermis to the SC layer. 
FA with a chain length up to 16 carbon atoms (C16, palmitic acid) are synthesized 
by fatty acid synthase using acetyl-coenzyme A and malonyl-coenzyme A. FA C16 is 
elongated in the endoplasmic reticulum by a membrane-associated elongation system 
using four enzymes, which catalyze a condensation step, a reduction step, a dehydration 
step, and another reduction step, respectively. Per elongation cycle, two carbon atoms 
are linked to the FA carbon chain.50 A series of 7 elongases (ELOVL) is involved in the 
first condensation step, starting with ELOVL 6 which catalyzes the elongation of FA 
C16 to FA C18. Subsequently, ELOVL 3, 1, and 4 catalyze the elongation to FAs with 
chain lengths C20, C26 and >C26, respectively.50,51 Besides elongation, the FAs can be 
converted to MUFAs by stearoyl-coenzyme A desaturases. The elongation of MUFAs 
is catalyzed by ELOVL 3, 7, and 1, whereas ELOVL 5 is involved in the elongation 
of polyunsaturated FAs (PUFAs).50,51 ELOVL 2 is not expressed in skin tissue.50 The 
synthesized FAs are either transformed to phospholipids and stored in LBs, or used for 
CER synthesis. The majority of the PUFAs (often essential fatty acids) are taken up by 
keratinocytes from their environment by FA binding protein and FA transport protein, 
and are not synthesized de novo.49
CERs are synthesized in the endoplasmic reticulum in multiple enzymatic steps. 
First, the enzyme serine palmitoyl transferase condensates L-serine and palmitoyl-
coenzyme A into 3-keto-dihydrosphingosine, which is consecutively reduced to 
dihydrosphingosine. 6 CER synthases are involved in the next step in which a FA is 
acylated to form a ceramide with a dS sphingoid base. Each CER synthase is more 
specific towards a FA chain length or degree of unsaturation. In the final step, the 
dS-ceramides are converted into the S and P CER subclasses by dihydroceramide 
desaturase 1 and 2, respectively. The hydroxylation of the H CER subclass occurs by 
a yet unidentified enzyme. The CERs are transported to the Golgi complex, converted 
into sphingomyelin or glucosyl-CERs, and stored in LBs.42
The LBs contain the lipid precursors (cholesterol, phospholipids, glucosyl-CERs, and 
sphingomyelins) as well as enzymes that convert the lipid precursors into the barrier 
lipids.12,13 The lipids are stacked as lipid layers within the LBs.4 At the interface of the 





r 1the extracellular matrix. During this process, the enzymes start to convert the lipid 
precursors into their final products. Several phospholipases converts the phospholipids 
into FAs, and β-glucocerebrosidase and acidic sphingomyelinase convert the glucosyl-
CERs and sphingomyelins into CERs, respectively.2,4 
Skin diseases with an impaired skin barrier function 
Some of the inflammatory skin diseases with an impaired skin barrier function are, 
for example psoriasis, Netherton syndrome and atopic dermatitis (AD).52-58 Besides 
barrier proteins, an altered lipid composition compared to healthy skin plays a role 
in this reduced skin barrier function. Netherton syndrome is a rare genetic skin 
disorder which is characterized by hair shaft defects, severe atopic manifestations, and 
erythroderma. In the SC of these patients, a lower fraction of the long chain EO-CERs 
is observed in addition to an increased level of short chain CERs, an increased level 
of unsaturated CERs, an increased level of MUFAs and a reduction in mean FA chain 
length. As a result, a higher degree of disordering of SC lipids was observed besides an 
altered repeat distance of the lamellar phases.59 In psoriasis, a chronic inflammatory 
skin disease with abnormal epidermal proliferation, the level of CER EOS is severely 
reduced in lesional areas. This is in combination with a reduction of P-subclass CERs 
and an increase in other S-subclass CERs.60,61 Furthermore, the X-ray diffraction profiles 
suggest shorter repeat distances of the lamellar phases in lesional skin.62 
AD is a chronic, relapsing, noncontagious, inflammatory skin disease characterized by 
xerosis (dry skin), pruritis (itch), and eczematous skin.63 It has a prevalence of about 
20% in children, but also affects 5-10% of the adult population.64-66 Since the discovery 
of mutations in the filaggrin gene (FLG) in 200667, the development of AD is believed 
to be an interplay between a defective skin barrier and the innate and adaptive 
immune response.68 FLG codes for profilaggrin, which is cleaved into 10-12 copies of 
filaggrin.69 In healthy skin, filaggrin aligns and aggregates with keratin filaments and is 
thus involved in the proper formation of the cornified envelope.70 However, mutations 
in FLG are only present in 20-50% of the AD patients supporting the heterogeneous 
nature of the disease.68,71-74 In the past decade, the underlying molecular basis has been 
increasingly understood, mostly with a focus on barrier dysfunction, cutaneous and 
systemic immune abnormalities, and the role of the microbiome. It is now clear that 
all are interconnected, with each abnormality progressively exacerbating another.75 
Numerous studies have demonstrated that skin barrier dysfunction is a critical 
component of AD.37,76,77 This skin barrier dysfunction facilitating the interaction of 
external stimuli (allergens, irritants and pathogens) with skin-resident immune cells 
and driving the cutaneous inflammation.77 These inflammatory responses drive the 
differentiation of naive T-cells, initiate the itch-response, and reduce the expression of 
filaggrin, causing a vicious cycle.78 
The SC lipid composition and organization in AD is extensively described. It is 
characterized by significant reductions in the level of CER EOS55,58,76,79-81 and NP76,80,81, 
an increase in levels of CER NS and AS55,76, and an increase in short chain CERs and 
FAs.37,53,76 Furthermore, a higher fraction of lipids adopting a hexagonal lateral packing 
was detected at the expense of the fraction forming orthorhombic domains37,76,82, as 
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well as a reduction in repeat distance of the lamellar phases.26,76 These observations 
were not related to the presence or absence of mutations in the filaggrin-gene (see 
below)58,76 and were more pronounced in lesional compared to non-lesional AD skin.37 
Overall, in these inflammatory skin diseases, the levels of CER EOS and CER NP are 
reduced, and the level of CER NS is increased. Furthermore, these skin diseases are 
characterized by a reduced average lipid chain length, a higher degree of unsaturated 
lipids, an altered LPP, and a reduction in lipids assembling in an orthorhombic packing.
Vernix caseosa as treatment for atopic dermatitis 
Due to its multifactorial character, AD is difficult to treat properly. Dermatologist 
reached consensus that appropriate skin care is very important and that moisturization 
by the use of lipophilic formulations should be the first treatment strategy to treat dry 
skin of AD patients, but may also be used as an additional protective layer to reduce 
the entrance of allergens to enter the viable skin.83-87 If this treatment is insufficient, 
topical corticosteroids should be used with a step-down approach. This means that 
treatment starts with a potent corticosteroid and if the desired effect is reached less 
potent corticosteroids can be used.83-86 However, topical corticosteroids are associated 
with side effects such as skin atrophy, striae, and contact dermatitis.88 On the contrary, it 
has been suggested that treatment with endogenous skin barrier lipids (e.g. cholesterol, 
CERs, and FAs) might be beneficial for skin barrier repair in skin diseases.89 
A possible treatment suggested for AD is application of vernix caseosa (VC). VC is a 
white, greasy substance covering a fetus during the last trimester of pregnancy, and it is 
developed at the same time as the development of SC in utero.90 VC protects the fetus 
from the amniotic fluid, serves as a lubricant during delivery, and protects the newborn 
from dehydration after being exposed to dry air in the extrauterine environment.91,92 
Furthermore, VC has been suggested to have anti-infective, anti-oxidant, and wound 
healing properties.91,92 
VC is known to consist of 80% water, 10% protein, and 10% lipids.92-95 The lipids in 
VC are barrier lipids (e.g. cholesterol, FAs, CERs) as well as wax esters, sterols esters, 
squalene, triglycerides, and phospholipids.92,94 Of the barrier lipids, the same CER 
subclasses are present in VC as in SC. However, as opposed to SC, CER subclass AH 
is most abundant in VC of infants born at term.94,95 Additionally, FA with chain lengths 
varying between C14 and C32 are present in VC, with the highest abundance of FA 
C16.94,96 Furthermore, the composition of VC varies between boys and girls.96
It has been reported that VC is able to enhance skin barrier repair in mice with a 
severely decreased skin barrier function induced by tape stripping. The recovery time 
of skin treated with VC was only half of the recovery time of untreated skin.97 In a 
subsequent study, it was shown that VC can be replaced by a synthetic mixture (water, 
polymer-based particles, and synthetic lipids) and reach similar barrier recovery in the 
same time period.98 Furthermore, when only the synthetic lipid mixture was applied, 
the barrier recovery was very similar and better than various formulations on the 
market.98 In a wound healing study performed in pigs, a better barrier recovery rate was 
observed in the initial phase after treating the disrupted area with VC compared to no 





r 1rate after 7 days of treatment.99
A significantly higher skin hydration, moisture accumulation and water-holding 
capacity were observed immediately after treating tape-stripped human skin with VC 
compared to no treatment.100 However, after a longer treatment period of 5 days, no 
difference between VC treated and untreated sites were observed regarding barrier 
recovery, skin hydration or dryness.99
Apparently, human skin reacts differently to VC treatment than animal skin. In order to 
further examine the use of formulations based on VC, studies on human skin are needed. 
Clinical studies for testing formulations are time consuming and can be burdensome 
for the subjects. Therefore, human skin models are needed to study skin barrier repair. 
Frequently used existing human skin models are human skin equivalents, which can 
be used to study biological skin processes, to generate skin to treat burn wounds, or 
for irritation screening. However, because of the reduced skin barrier function of these 
models, their use for penetration studies is limited. Furthermore, many available skin 
models are time consuming because of the use of cultured of skin cells rather than 
culturing skin tissue. In this thesis, a skin barrier repair model using excised human skin 




Aim of this thesis
The aim of this thesis was to determine whether a novel VC based formulation effectively 
enhances skin barrier repair in AD patients and normalizes the SC lipid composition 
and organization. In order to achieve this goal, the following studies were performed:
1. An ex vivo human skin barrier repair (SkinBaR) model was developed for 
studying the interactions between topical applied compounds and the skin 
barrier. The SC lipid properties during and after skin barrier repair process were 
examined. The lipid composition and organization in the regenerated SC of 
this SkinBaR model were compared to the lipid composition and organization 
in regenerated SC in healthy human skin in vivo.
2. The effects of a selected number of barrier FAs and/or CER subclasses applied 
in a VC based formulation on the SkinBaR model during skin barrier repair 
were examined. Especially the interactions between the VC components and 
the SC lipid matrix were studied.
3. The effect of the VC based formulation on skin barrier repair in compromised 
healthy skin, and in AD skin was assessed. 
Outline of this thesis
This thesis is divided in three parts, which address the aforementioned objectives.
Part I (Chapters 2, 3 & 4) covers the development of the SkinBaR model using ex vivo 
human skin which is stripped using cyanoacrylate (superglue). The SC is regenerated 
during culture in an incubator. In addition, studies are described focusing on whether 
the barrier properties of the SkinBaR model mimic that of in vivo skin after barrier 
repair.
Part II (Chapters 5 & 6) focusses on the studies performed to investigate the interaction 
of FAs, CERs, or a combination of CERs and FAs in the VC based formulation with the 
SC lipid matrix of the ex vivo SkinBaR model.
Part III (Chapters 7 & 8) describes two clinical studies in which the effect of topical 
application of the VC based formulation during skin barrier repair on i) tape-stripped 
healthy skin and ii) AD skin was examined. 
A more detailed outline of this thesis is provided below:
In Chapter 2 studies are described focusing on the development of the ex vivo human 
SkinBaR model. In this model SC was removed by stripping with cyanoacrylate. 
Subsequently, the SC was regenerated during culturing. The epidermal characteristics 
of the SkinBaR model are described in this chapter. This model may be an attractive 
candidate for testing topical formulations which aim to enhance skin barrier repair.
In Chapter 3, studies are described focusing on the extent of barrier disruption of the ex 
vivo SkinBaR model on the lipid organization of the regenerated SC. The changes in 
the lamellar and lateral lipid organization in the regenerated SC were related to the 
initial depth of stripping.





r 1with the regeneration of SC in humans after tape-stripping the skin. The two models 
for skin barrier repair were compared focusing on lipid composition and organization. 
Furthermore, the changes in lipid composition and organization were compared with 
the SC lipid properties of inflammatory skin diseases described in literature.
In Chapter 5 studies are presented in which the ex vivo SkinBaR model was used to study 
the application of FA in a VC based formulation on the SC lipid organization. More 
specifically FAs with a chain length of 16, 18, or 22 carbon atoms were used. The 
epidermal morphology, lipid organization, and ordering of the SC lipid matrix were 
examined and whether or not the applied FA were incorporated in the SC lipid matrix. 
Liquid chromatography/mass spectrometry (LC/MS) was used to examine whether the 
applied FAs were elongated.
In Chapter 6 studies are described in which two CER subclasses in the VC based 
formulations were applied on the SkinBaR model. The effect of the CER subclasses 
on the lipid organization as well as the mixing properties of the CERs with the SC 
lipid matrix was investigated. Finally, FAs and CERs were combined in the VC based 
formulation.
Chapter 7 describes the application of a VC based lipid formulation containing FAs and 
CERs during skin barrier repair of tape-stripped human skin in a clinical study setting. 
The repair of the skin barrier function was monitored over time. A VC based formulation 
was applied on native and regenerated SC and the SC lipid matrix properties were 
compared.
In Chapter 8, studies are presented in which the same VC based formulation was applied 
on non-lesional and lesional AD skin for a period of two weeks. The skin barrier 
function, lipid composition, and lipid organization were examined before and after 
treatment. 
Chapter 9 provides a summary of the obtained results, describes overall conclusions, and 
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In the studies described in this paper, we introduce a novel ex vivo human skin barrier 
repair model. To develop such a model, we removed the upper layer of the skin, 
the stratum corneum (SC) by a reproducible cyanoacrylate stripping technique. After 
stripping the explants, they were cultured in vitro to allow the regeneration of the SC. 
We selected two culture temperatures 32°C and 37°C and a period of either 4 or 8 
days. 
Results show that after 8 days of culture, the explant generated SC at a similar thickness 
compared to native human SC. At 37°C, the early and late epidermal differentiation 
program was executed comparably to native human skin with the exception of 
the barrier protein involucrin. At 32°C, early differentiation was delayed, but the 
terminal differentiation proteins were expressed as in stripped explants cultured at 
37°C. Regarding the barrier properties, the SC lateral lipid organization was mainly 
hexagonal in the regenerated SC, whereas the lipids in native human SC adopt a more 
dense orthorhombic organization. In addition, the ceramide levels were higher in 
the cultured explants at 32°C and 37°C than in native human SC. In conclusion, we 
have selected the stripped ex vivo skin model cultured at 37°C as a candidate model 
to study skin barrier repair since epidermal characteristics mimic more closely the 
native human skin than the ex vivo skin model cultured at 32°C. Furthermore, the final 
product of the differentiation process, the SC, exhibits a very similar lipid composition 
as in native human skin. Potentially, this model can be used for testing formulations 




The skin being the largest organ of the body (1.5m2 in adults) provides protection for the 
body’s interior against the external environment. The barrier function is mainly located 
in the outermost layer, the stratum corneum (SC).1 The SC provides an excellent barrier 
against excessive water loss (inside-outside barrier) and penetration of pathogens and 
allergens through the skin (outside-inside barrier).2,3 The SC is 10-15 µm thick with 
15-20 corneocyte layers4,5 and its organization has been described as “brick-and-
mortar” structure.6 The bricks represent the terminally differentiated corneocytes and 
the mortar the intercellular lipid matrix surrounding the corneocytes.7,8 The SC lipid 
composition and organization plays an important role in the barrier function of the 
skin because the major pathway for penetration of molecules through the SC is via the 
SC lipid matrix.9-11 The main lipid classes in native human SC are free fatty acids (FAs), 
ceramides (CERs) and cholesterol which form two lamellar phases. These include the 
short periodicity phase (SPP) and the long periodicity phase (LPP) with repeat distances 
of approximately 6 nm and 13 nm respectively.12 Within the lipid lamellae, the lipids 
are mainly organized in a dense orthorhombic packing, although a fraction of lipids 
adopt a hexagonal packing.13,14 Within the epidermal strata, tight junction (TJ) proteins 
are known to contribute to the inside-outside barrier. They form an intercellular barrier 
between the epidermal cells and function to control the selective movement of water 
and ions through the epidermis15 and regulate cell proliferation and differentiation.16,17
Atopic dermatitis (AD), dry skin conditions, 1st degree burns and sunburned skin are 
examples of skin conditions associated with an impaired skin barrier function.18-20 In 
order to develop novel formulations or active components to enhance skin barrier 
repair, in vitro models are required. Currently, skin barrier repair is mainly studied in 
animals. This does not provide an optimal situation for translation into humans as the 
morphology in combination with stratum corneum properties of animal skin varies 
greatly from human skin.21-23 Furthermore, removal of SC from animals results in stress 
and the use of animals in testing cosmetics products and ingredients have been banned 
in the European union since 2009. Consequently, the use of in vitro human skin barrier 
repair models can play an important role in screening formulations.24-27 
Currently, no appropriate in vitro human skin models are available to study skin barrier 
repair. The available human skin equivalents may offer a possibility however, applying 
formulations can only be performed during generation of the human skin equivalents. 
This is very labor intensive and needs dedicated expertise. In addition, an impaired 
barrier induced by tape stripping cannot be performed with human skin equivalents, 
due to the poor epidermal/dermal adhesion.28
In the present study, we introduce an ex vivo human skin model to study skin barrier 
repair. Using a reproducible cyanoacrylate stripping technique to remove SC from 
ex vivo human skin, we investigated the regrowth of SC in vitro by characterizing 
the epidermal morphogenesis, differentiation, SC lipid composition and organization. 
Potentially, this skin barrier repair model can be used for optimizing formulations and 
active ingredients to study their effect on skin barrier repair. The results show that the 
stripped skin cultured for 8 days at body temperature (37°C) or skin temperature (32°C) 
has an actively proliferating and differentiating epidermis resulting in the regeneration 






with the presence of the same SC lipid classes and subclasses as seen in native human 
SC, with some interesting differences. 
Materials and methods 
Stripping of SC with cyanoacrylate 
Human breast skin was obtained from Caucasian skin donors (aged 25-42 years) after 
written informed consent and handled according to Declaration of Helsinki principles. 
The skin was dermatomed at 400 µm using a Padgett Electro Dermatome (Model B, 
Kansas city, KS, USA). 18 mm punch biopsies of the dermatomed skin were used 
as a control. 26 mm biopsies from the dermatomed skin were fixed into a custom 
made stripping device (see Supplementary Figure S1). A single droplet of preheated 
cyanoacrylate (Pattex Gold original, Henkel, Dusseldorf, Germany) at 40°C was spread 
on a 20 mm diameter stainless steel cylinder preheated to 40°C. The cylinder with 
cyanoacrylate was immediately placed on the skin. Standardized pressure was applied 
on the cylinder using a 2 kg weight. After 2 minutes the cylinder was removed in one 
stroke and in alternating directions to ensure even removal of the SC from the skin 
surface. This stripping procedure was repeated until the skin gave a glossy appearance 
indicating that most of the SC has been removed (4-5 strips were required to remove 
the stratum corneum). The unstripped skin at the border of the biopsy was removed 
using a scalpel, yielding stripped biopsies of 18 mm in diameter. From each donor, at 
least one stripped skin biopsy was used as control to analyze the number of corneocyte 
layers remaining on the stripped skin surface by safranin-O-red staining (described 
below). Stripped and non-stripped biopsies were cultured as described below.
Culture procedure
Non-stripped biopsies (served as controls) and stripped biopsies were washed thrice 
in sterile phosphate buffered saline (PBS, Braun, Melsungen, Germany) and placed 
in transwell filter inserts (Corning Life sciences, Amsterdam, Netherlands). The skin 
biopsies (referred to as explants) were cultured at air-liquid interface for 4 days or 
8 days at 37°C or 32°C, 90% relative humidity and 7.3% CO2. The culture medium 
contained DMEM and Ham’s F12 (Invitrogen, The Netherlands) (3:1 v/v) supplemented 
with 0.5 µM hydrocortisone (Sigma), 1 µM isoproterenol (Sigma), 10 µM L-carnitine 
(Sigma), 10 mM L-serine (Sigma), 0.053 µM selenious acid (Johnson Matthey, 
Maastricht, The Netherlands), 0.5 µg/mL insulin (Sigma), 1 µM α-tocopherol acetate 
(Sigma), 1% penicillin/streptomycin, 25 mM vitamin C (Sigma) and a lipid mixture of 
7 µM arachidonic acid (Sigma), 30 µM linoleic acid (Sigma) and 25 µM palmitic acid 




The cultured skin explants and the non-cultured (stripped and non-stripped) control 
biopsies were cryofixed in Tissue-Tek O.C.T.TM (Sakura Finetek Europe B.V., The 
Netherlands). The sections were stained with Safranin-O as described.29 Cryofixed skin 
of 5 µm thickness were stained with 1% (w/v) Safranin-O solution (Sigma) for one 
minute and thereafter incubated in 2% (w/v) KOH solution for 30 minutes to swell the 
corneocytes. Five microscopic images (from three donors) per explant or biopsy were 
taken at 64x magnification.
Morphology and immunohistochemistry
The skin explants and controls were embedded in paraffin, cut at 5 µm thickness 
and stained with haematoxylin (2 mg/ml) and eosin (4 mg/ml) for morphological 
analysis. Immunohistochemical analysis of keratin 10, filaggrin, loricrin, involucrin, 
Ki67, caspase 3, keratin 6, β-glucosylcerebrosidase, steroyl-CoA desaturase and acid-
sphingomyelinase expression was also performed on 5 µm paraffin sections. The 
primary and secondary antibodies are listed in Supplementary Table S1. For further 
details see supplementary materials and methods. 
Lipid extraction and analysis
SC was isolated from the skin explants using trypsin digestion as described by De Jager 
et al.30 Briefly, the explants were incubated overnight in 0.1% trypsin solution at 4°C 
followed by incubation at 37°C for 1 hour after which the SC could be peeled off. Lipid 
extracts from 2 explants per condition, were pooled for lipid analysis. The SC lipids were 
extracted by a modified Bligh and Dyer procedure.31,32 Briefly, liquid-liquid extraction 
from native human SC and cultured stripped and non-stripped explants was performed 
using 3 different ratios of a chloroform/methanol/water mixture (1/2/0.5;1/1/0;2/1/0). 
A 0.25 M KCl solution was added to extract the polar lipids. The extracts were dried 
under a stream of nitrogen gas at 40° C and reconstituted in chloroform/methanol (2:1). 
High performance thin layer chromatography (HPTLC): SC lipid composition was quantitatively 
analyzed by HPTLC33 described in detail in the supplementary materials and methods.
Fourier transformed infra-red spectroscopy (FTIR) and small angle X-ray diffraction 
(SAXD)
FTIR and SAXD measurements were performed as described earlier.34 The SC sheets 
were hydrated for 24 hours over a 27% NaBr solution prior to measurements. FTIR 
spectra were collected with a Varian 670-IR FTIR spectrometer (Agilent technologies, 
CA, USA), containing a broad-band mercury cadmium telluride detector, cooled with 
liquid nitrogen. SAXD patterns were detected with a Frelon 2000 CCD detector at 
room temperature for a period of 10 min using a microfocus as described by Bras et 







All statistical outcomes were determined using GraphPad Prism software and a two-
tailed student’s t-test to analyze the data.
Results
Stripped ex vivo skin generates SC in vitro
The skin was placed in a customized stripping device and using a customized 
metal cylinder coated with cyanoacrylate, the SC was removed sequentially (see 
Supplementary Figure S1). The stripping procedure reduced the SC layers in the ex 
vivo skin explant from 13 ± 2 layers to 4 ± 2 layers (Figure 1A,B) as determined by 
counting the number of corneocyte layers from five different spots of safranin-O 
stained sections. No difference was observed between the amount of SC removed in 
the central or boundary areas of the stripped skin. However, less SC at the furrows in 
the skin was removed compared to the flatter parts of the skin as described previously.36 
After the removal of the SC, these biopsies were cultured to generate SC. After 4 days of 
culturing at 37°C, there was no significant increase in SC layers. However, after 8 days 
of culturing at 37°C, the SC layers of the stripped skin increased to 10 ± 3 layers (Figure 
1B). Decreasing the culture temperature to 32°C resulted in similar observations. 
After 4 days of culture no significant increase in the number of corneocyte layers was 
observed, but after extending to 8 days, the number of corneocyte layers increased 
to 10 ± 2 layers. Non-stripped controls were also cultured in the incubator for 4 and 
8 days at 37°C and 32°C. After 8 days these non-stripped controls generated some 
additional corneocyte layers, but this increase was not as pronounced as with the 
stripped skin (Figure 1B). Since our goal was to develop a skin barrier repair model, 
further analysis was performed using skin explants cultured for 8 days as the number of 
SC layers generated was closer to that in native human skin.
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Skin explants express epidermal differentiation proteins in vitro
Since SC is generated by cultured stripped skin explants, we examined their epidermal 
proliferation, morphology and epidermal differentiation. The proliferation index was 
calculated as the percentage of proliferating cells in the stratum basale by Ki67 staining. 
The proliferation index was drastically reduced in the non-stripped skin explants 
after 8 days of culture at 37°C and 32°C. In stripped explants cultured at 37°C, the 
proliferation was similar to native human skin while at 32°C proliferation was 2 fold 
higher compared to the native human skin (Figure 1C).
The stripped and non-stripped skin explants cultured at 37°C and 32°C show a normally 
differentiated epidermis. However in stripped explants cultured at 32°C, the terminal 
differentiation is not completely executed demonstrated by nuclei remnants in the SC 
(indicated by arrows, Figure 2). 
The early and terminal epidermal differentiation program was correctly executed 
Figure 1. Stratum corneum (SC) layers and proliferation index in cultured ex vivo skin. A) Swollen SC cell 
layers visualized by safranin-O staining. B) The number of corneocyte layers was counted from safranin-O 
stained sections. The cyanoacrylate stripping procedure was efficient to remove the SC which was generated 
after 8 days of culturing at 37°C and 32°C. C) Proliferation index of keratinocytes determined by Ki67 
staining. The non-stripped skin explants cultured at 37°C and 32°C show decreased epidermal proliferation. 
At 37°C, the stripped explants show similar proliferation as in native human skin and at 32°C, a 2x higher 
proliferation than native human skin. Data represent mean ± SEM of four donors. Five microscopic pictures 
were taken per explant analysis. Proliferation index was calculated from the number of Ki67 positive basal 
cells out of 100 counted basal cells from five microscopic images. Scale bar: 30 µm, 64x magnification. 
NHS: native human skin, S: stripped, NS: non-stripped, Epi: viable epidermis, SC: stratum corneum, D: 






in explants cultured at 37°C with the exception of involucrin and to a lesser extent 
filaggrin. Similar to control skin, keratin 10 (K10) was expressed in all suprabasal layers 
of the epidermis while loricrin and filaggrin were expressed in the stratum granulosum. 
However, the number of cell layers positive for filaggrin increased to 2-3 layers in both 
the stripped and non-stripped explants compared to 1 layer in control skin. Conversely, 
involucrin expression in the skin explants was observed in all epidermal layers in 
contrast to the stratum granulosum in native human skin.
Figure 2. Morphology and epidermal differentiation in native human skin compared to non-stripped and 
stripped explants cultured for 8 days. Haematoxylin and eosin staining for morphological overview and 
immunohistochemical staining for keratin 10 (K10), Loricrin (LOR), involucrin (INV) and filaggrin (FLG). The 
stripped and non-stripped explants still display a differentiated epidermis at 37°C but at 32°C parakeratosis 
is observed mainly in the SC of the stripped explants (indicated by arrows). At 37°C, the non-stripped and 
the stripped explants express keratin 10, loricrin and filaggrin with similar localization as in the native 
human skin. The expression of involucrin in stripped and non-stripped explants was shifted to all epidermal 
layers rather than in the stratum granulosum. Non-stripped and the stripped explants cultured at 32°C also 
express filaggrin and loricrin as in native human skin however, the expression of keratin 10 is delayed and 
involucrin is expressed in all epidermal layers as with explants cultured at 37°C. Scale bar: 25 µm. Images 




When the culture temperature was reduced to 32°C, K10 expression was delayed in the 
stripped explants as 2-4 epidermal layers were negative for K10 expression (indicated 
by an arrow, Figure 2). Loricrin and filaggrin were expressed as in native human skin 
in both stripped and non-stripped skin explants. However, the number of cell layers 
positive for filaggrin was also increased in both the stripped and non-stripped explants 
compared to control skin. In addition, involucrin was expressed in all epidermal layers 
in stripped and non-stripped explants cultured at 32°C (Figure 2). 
Analysis of keratin 6 (K6) expression in the explants showed that native human skin 
and non-stripped explants show little or no expression of K6 in the suprabasal layers 
of the epidermis. Conversely, stripped explants cultured at both temperatures showed 
a marked increase of K6 expression in the epidermis (Supplementary Figure S5). 
In addition, the expression of caspase 3 in the stripped and non-stripped explants 
cultured at 32°C and 37°C was very similar to native human skin shown by expression 
of caspase 3 in the entire epidermis in all conditions (Supplementary Figure S5).
In vitro generated SC from stripped skin shows a similar lamellar lipid organization as 
native human SC but differences in the lateral packing
The SC lipid properties of the cultured explants were examined in relation to native 
human SC (the control). The lateral packing was examined using the CH2 rocking 
vibrations of the lipid chains in the FTIR spectra from 0°C-90°C. A hexagonal lipid 
organization is portrayed by a single peak at 719 cm-1 and an orthorhombic lipid 
packing by two vibrations at 719 cm-1 and 730 cm-1 in the spectrum. At 0°C, the lipids 
from native human SC adopt an orthorhombic lateral packing demonstrated by two 
strong contours at 719 cm-1 and 730 cm-1 (Figure 3A). Around 42.5°C ± 2.5°C, the 
orthorhombic packing is converted into an hexagonal packing. This is characterized 
by a transition from a doublet to a singlet at 719 cm-1. The non-stripped skin explants 
cultured at 37°C show an orthorhombic lateral packing until 40.5°C ± 5.3°C (Figure 
3B). However, the stripped explants cultured at both temperatures show a strong peak 
at 719 cm-1 and a small peak at 730 cm-1 at 0°C (Figure 3C,E). The orthorhombic packing 
is only present until 20.7°C ± 1.2°C and 29.3 ± 4.2°C at 37°C and 32°C, respectively 
i.e. the lipids are mainly organized in a hexagonal packing with a small population of 
lipids still forming an orthorhombic packing.
The conformational order of the lipids was also investigated using the thermotropic 
behaviour of the CH2 symmetric stretching frequencies in the spectrum. In a crystalline 
organization (orthorhombic or hexagonal packing) the conformational order is high 
with CH2 symmetric stretching frequencies < 2850 cm-1. In a disordered organization 
(liquid phase), the CH2 symmetric stretching frequencies are ≥ 2852 cm-1. Since the 
order-disorder transition occurs within a temperature range, the mid-point temperature 
at which the lipid domains change from an ordered state to a disordered liquid state 
was determined37i.e. “Mid-point Transition Temperature” (MTT). The results show that 
the MTT of the lipids in the regenerated SC of the stripped skin explants (37°C and 
32°C) is significantly lower than in non-stripped cultured controls and native human 
SC (p<0.05, Figure 3F). The CH2 stretching frequency at skin temperature (32°C) was 
also increased in the stripped skin explants cultured at 37°C compared to the non-






Figure 3. FTIR spectra showing 
the CH2 rocking vibrations in the 
spectra of the stratum corneum (SC) 
of generated stripped explants as a 
function of temperature (0°C-90°C). 
A) Native human SC and B) non-
stripped explants cultured at 37°C 
and D) 32°C, show an orthorhombic 
lateral organization. The peak 
intensity of the 730 cm-1 band is 
reduced in stripped explants cultured 
at C) 37°C and E) 32°C suggesting a 
higher population of lipids adopting 
a hexagonal organization. F) Mid-
point transition temperature (MTT). 
Data represents mean ± SEM from 
three donors, n.s.: not significant, 




conformational disorder in the regrown SC of the stripped explants.
The lamellar lipid organization was also examined in the stripped and non-stripped 
explants in relation to native human skin using SAXD. In native human SC, the diffraction 
profiles show three diffraction peaks indicating the 1st, 2nd and 3rd order diffraction peak 
of the LPP (depicted by 1, 2 and 3,) and crystalline cholesterol domains, indicated by 
an asterisk (*). Peak “2” in native human skin represents both LPP (2nd order) and SPP 
(1st order). The stripped and non-stripped explants cultured at 37°C show a very similar 
profile, and exhibit a 1st - 3rd order diffraction peak of the LPP and crystalline cholesterol 
(Supplementary Figure S3). As the 1st order peak of the SPP is partly obscured by the 
2nd order of the LPP, the presence of the SPP should induce a broadening of this peak. 
However, we could not obtain evidence for this broadening and thus the presence of 
this phase. In addition, the explants cultured at 32°C show similar diffraction profiles 
as in explants cultured at 37°C (data not shown).
Generated SC from stripped explants contain the main SC lipid classes
The SC generated by the explants after stripping contains the main SC lipid classes 
CERs, FAs and cholesterol with some changes in the distribution of these lipid classes 
as analyzed by HPTLC. The generated SC at 37°C and 32°C showed significantly 
higher CER levels respectively compared to native human skin (Figure 4B, p=0.03 and 
p=0.06 respectively, for relative values see Supplementary Figure S4). In addition, the 
non-stripped controls cultured at both temperatures show a similar trend (Figure 4B, 
p=0.04 and p=0.07, for relative values see Supplementary Figure S4). 
All the CER subclasses detectable by HPTLC in native human skin were present in 
the generated SC cultured at both temperatures (Figure 4C, for relative values see 
Supplementary Figure S4). However, some differences exist in the CER distribution of 
the cultured explants in relation to native human SC. At 37°C the levels of CER NS, 
EOH and AS/NH in regenerated SC were significantly increased compared to native 
human SC (p<0.01, p<0.05). Similarly, at 32°C the regrown SC showed significant 
increase in CER NS and AS/NH (p<0.01, p<0.05). The non-stripped explants cultured 
at 37°C and 32°C also have significantly more CER EOH and CER NS respectively than 
native human skin.
We further examined the expression of β-glucosylcerebrosidase (GBA) and acid-
sphingomyelinase (aSmase) involved in the synthesis of CERs from CER precursors. The 
expression of aSmase in the human epidermis shows a gradient from the basal layer to 
the granular layer with the highest expression seen in the granular layer. In all cultured 
explants, the gradient is lost and the expression of aSmase is similar in most epidermal 
layers (Figure 4D). In native human epidermis, the expression of GBA is localized in 
the interface between the granular layer and SC. In explants cultured at 32°C or at 
37°C, the localization of GBA expression is the same as native human epidermis.
Changes in unsaturated FA levels have been shown to be involved in SC lipid 
organization. Therefore, we also examined the expression of steroyl CoA desaturase 
(SCD) which mono-unsaturates FAs. SCD expression is seen in the basal layer of the 
epidermis in native human skin but in non-stripped and stripped explants cultured at 






Figure 4. Stratum corneum (SC) lipid composition and epidermal expression of lipid synthesis enzymes in 
cultured ex vivo skin. A) The lipids were separated according to the solvent system provided in Supplementary 
Table S2. 1-Native human skin, 2-Non-stripped 37°C, 3-Stripped 37°C, 4-Non-stripped 32°C, 5-Stripped 
32°C. B) Absolute levels of cholesterol (CHOL), free fatty acids (FA) and ceramides (CERs). C) Absolute CER 
subclasses in cultured ex vivo skin. The SC from the non-stripped and stripped explants contains all CER 
subclasses in native human SC which are visible by high performance thin layer chromatography (HPTLC). 
D) Immunohistochemical analysis of acid-sphingomyelinase (aSmase), β-glucosylcerebrosidase (GBA) and 
steroyl CoA desaturase (SCD). Data represents mean ± SEM from three donors. Scale bar 25 µm. NHS: native 




The aim of this study was to establish a human skin model to study skin barrier repair 
by i) removal of SC from ex vivo skin and ii) generation of the SC during in vitro 
culturing of stripped skin. We established a reproducible method of SC removal using 
a cyanoacrylate stripping technique which served as a starting point. After 8 days of 
culturing the stripped explants at 32°C and 37°C, the number of SC layers regrown 
was similar to the SC layers before stripping. The recovery of SC to control thickness 
after stripping in vivo ranges from 3-6 days in the arm and leg.38 In addition, barrier 
recovery (calculated by recovery of transepidermal water loss values to baseline) after 
SC removal by tape-stripping in human facial skin reaches ~90% after 1 week and 
100% recovery at 4 weeks.39 Duplan et al. presents an ex vivo human skin model 
for irritation/repair using SDS and vasointestinal peptide. In order to restore native 
epidermal features, the skin is treated with hydroxydecine in culture. Our present study 
examines skin barrier repair by removal of stratum corneum and culturing without the 
addition of a formulation. 
Epidermal morphology and SC layers at the end of the 8 days culture period at 
both temperatures are similar to that of native human skin. However, the stripped 
explants cultured at skin temperature (32°C) exhibit parakeratotic epidermis, a feature 
also observed after repeated tape-stripping in vivo.40 This may occur from increased 
proliferation induced by stripping as nuclei are observed only in the lower layers of 
the SC. Parakeratosis is associated with a hyper proliferative epidermis, delayed K10 
expression, increased involucrin expression and increased number of epidermal cell 
layers positive for filaggrin.40,41 All of these characteristics are observed in stripped skin 
explants cultured at 32°C. Stripped explants cultured at 37°C also display increased 
filaggrin and involucrin expression, but very importantly no parakeratosis and no 
delayed expression of K10 is observed. 
Proliferation (Ki67 expression) of stripped explants cultured at 37°C is similar to native 
human skin but at 32°C, proliferation is double that of native human skin. However, 
the number of SC layers generated after 8 days are similar at both temperatures. This 
may occur from the changes in proliferation index at 4 and 8 days of culture in the 
explants, as observed in a pilot study. At 4 days of culture, proliferation index in 
stripped explants cultured at 32°C is around 1% and 30% at 37°C (data not shown). 
However, after 8 days, the proliferation index is ~40% at 32°C and 12% at 37°C. This 
data suggests the increase in proliferation in stripped explants as a response to the SC 
removal is delayed at 32°C compared to 37°C. In addition, the number of corneocytes 
layers in the SC is an accumulative value and depends on the proliferation rate during 
the whole culturing period.   
The SC lipid properties in the stripped explants show several similarities to native human 
SC. The SC from the stripped and non-stripped explants cultured at 37°C contains the 
main SC lipid classes. However, we observe a significant increase in the absolute 
level of CERs in the explants cultured at 37°C and 32°C. Increase of CER levels also 
occurs in other full-thickness and epidermal human skin equivalents.42 Furthermore, 
when focusing on the CER subclasses, 10 different CER subclasses can be detected, of 
which CER NdS/NS and CER AS/NH cannot be separated. The composition of these 






differences are also noticed. The increase in the level of CERs was accompanied by 
a stronger staining for aSmase suggesting its role in the increased CER levels. ASmase 
catalyzes the conversion of sphingomyelin to ceramides. Sphingomyelin is a precursor 
of CER NS and AS43,44 and both are increased by approximately 2-3 fold in the cultured 
explants compared to native human SC. The change in environmental conditions and 
barrier disruption induces stress in keratinocytes. This may result in increased CERs 
via sphingomyelinases and up-regulation of the activity of serine palmitoyl-transferase 
and/or ceramide synthases in de novo CER synthesis.45,46 
Disruption of the SC also results in the loss of the epidermal calcium gradient which 
is crucial for differentiation.47,48 The loss of calcium gradient affects the expression 
of epidermal differentiation proteins including filaggrin and involucrin and may also 
contribute to the changes in involucrin and filaggrin expression in the cultured skin 
explants.49,50 In non-stripped skin, we still observe increased CER levels and altered 
involucrin expression although there is no barrier disruption. The exact mechanism 
responsible for these changes in non-stripped explants remains unknown. 
SC lipids generated by the stripped explants adopt mainly a hexagonal organization 
as opposed to an abundant orthorhombic organization in native human SC. The 
hexagonal lateral organization is also observed in epidermal or full thickness human 
skin equivalents.51 In these models an increased relative level of MUFAs was detected, 
which may be responsible for the abundant hexagonal packing. 42,51 Using lipid model 
systems we observed indeed that increased levels of MUFA enhances the formation 
of the hexagonal lateral packing.52 Therefore, the hexagonal lipid organization in the 
generated SC in the explants may be attributed to an increased level of MUFAs resulting 
from increased SCD expression. 
Some features of the cultured stripped skin can be observed in barrier related skin 
diseases such as increase in involucrin expression, CER NS, AS and hexagonal lipid 
organization.53-56 However, there are more features which do not resemble diseased 
skin such e.g. increased CER EOS, similar levels of CER NP and filaggrin, loricrin 
expression as in native skin etc. This suggests that the cultured stripped skin cannot be 
used as a diseased skin model. 
We suggest that culture of cyanoacrylate stripped skin explants provides a potential 
model to study i) skin barrier repair ex vivo and ii) investigating the effect of culture 
medium composition and environmental conditions during culture on the restoration 
of the skin barrier. Firstly, the SC lipid properties in regrown SC bear some aspects 
observed with altered skin barrier function56-58 including reduced orthorhombic lipid 
organization and increased lipid conformational disorder of SC lipids. The presence 
of these characteristics in the cultured stripped explants can provide a system where 
formulations can be tested to enhance skin barrier repair. 
Secondly, in the development of 3D in vitro skin models, no human skin equivalent 
fully mimics the SC lipid properties of native human skin.51,59,60 Our model shows some 
advantages over the available human skin equivalents when applied to optimization 
of culture conditions to mimic native human SC properties in vitro. This is because 
the culture period is shorter (14-21 days for human skin equivalents) and does not 
require cell isolation and seeding which saves time and is less labor intensive. It is also 
possible to examine inter-donor changes in these cultures with human skin.
In conclusion, the removal of SC from ex vivo skin and culture for 8 days at 37°C 
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generates an ex vivo human skin model which possesses various similarities in 
epidermal properties to native human skin than at 32°C. Therefore this model has the 
potential to be used in studying skin barrier repair. 
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Figure S1. Stripping of stratum corneum (SC) from ex vivo skin. 26 mm skin biopsies of 400 µm thickness 
are fixed into a custom made cyanoacrylate stripping device. A single droplet of preheated cyanoacrylate 
(40°C) was spread on a 20 mm diameter stainless steel cylinder which was also preheated to 40°C. The 
cylinder with cyanoacrylate was immediately placed on the skin together with a 2 kg weight to achieve a 
standardized pressure for 2 minutes. The cylinder was removed in one move, with alternating directions of 
180° to ensure even removal of the SC on both sides. This stripping procedure was repeated until the skin 
gave a glossy appearance indicating that most of the SC has been removed.
Figure S2. CH2 symmetric stretching frequency at 
32°C in the spectra of the stratum corneum (SC) 
of cultured explants. Data represents mean ± SEM 
from three donors, *p<0.05. NHS: native human 
skin, S: stripped, NS: non-stripped
Figure S3. Representative X-ray diffraction pattern 
of SC from stripped, non-stripped explants and 
native human skin. 1, 2 and 3 indicate the 1st, 2nd 
and 3rd order of the long periodicity phase (LPP) 
respectively. The “2” peak from native human SC 
and non-stripped SC represent both the 2nd order 
of the LPP and the 1st order of the short periodicity 
phase (SPP) Therefore, the repeat distances cannot 
be calculated directly from this diffraction profile. 






Figure S4. Relative levels of SC lipids in cultured explants. A) Cholesterol (CHOL), free fatty acids (FA) 
and ceramides (CERs), B) various classes of CERs. Data represents mean ± SEM from three donors. 
Figure S5. Immunohistochemical staining for Keratin 6 and Caspase 3. Images were taken at 20x 




Table S1. Primary and secondary antibodies for immunohistochemical staining
Primary antibodies
Antibody Clone Dilution Company
Mouse Cytokeratin 10 Ab-2 DE-K10 1:800 Neomarkers, USA
Mouse Filaggrin Ab-1 FLG01 1:800 Neomarkers, USA
Rabbit Loricrin AF62 1:1200 Covance, USA
Mouse Involucrin SY5 1:1200 Sanbio, The Netherlands
Rabbit SCD polyclonal 1:100 Sigma-Aldrich
Rabbit Ki67 SP6 1:800 Neomarkers, USA
Rabbit aSmase plyclonal 1:1000 Abcam, UK
Mouse GBA IgG2a 1:400 Abcam, UK
Mouse α human keratin 6 LHK6B 1:5 Neomarkers, USA
Rabbit Caspase 3 polyclonal 1:50 BD Biosciences
Secondary antibodies






1:300 Jackson immunoresearch 
laboratory, USA
Cy3 (Goad-anti-mouse) (IF) 1:1000 Jackson immunoresearch 
laboratory, USA
Table S2. Solvent system used for barrier lipids analysis by thin layer chromatography
Eluent Composition (v/v) Distance (mm)
1 Dichloromethane/Ethylacetate/Acetone/Methanol (88:8:4:1) 40
2 Chloroform/Acetone/Methanol (76:8:16) 10
3 Hexane/Chloroform/Acetone/Methanol (6:80:12:2) 70
4 Hexane/Chloroform/Hexylacetate/Acetone/Methanol (6:80:0.1:10:4) 95







Dihydrosphingosine (dS) NdS Ads EOdS
Sphingosine (S) NS AS EOS
Phytosphingosine (P) NP AP EOP
6-hydroxy sphingosine (H) NH AH EOH
The human stratum corneum (SC) contains 4 sphingoid bases (dihydrosphingosine (dS), Sphingosine (S), 
phytosphingosine (P) and 6-hydroxy sphingosine (H)) and three acyl chains (non-hydroxy fatty acid (N), 
α-hydroxy fatty acid (A) and esterified ω-hydroxy fatty acid (EO)). Together, these result in the 12 ceramide 






Supplementary materials and methods
Morphology and Immunohistochemistry
The skin sections (except the sections stained for aSmase) were incubated in sodium 
citrate buffer (pH 6) for 30 minutes at 95°C for antigen retrieval. The sections stained 
for aSmase were incubated in sodium citrate buffer (pH 6) for 5 minutes at 110°C in 
an autoclave (Laboratory autoclave, model A275, Zirbus technology, Germany) for 
antigen retrieval. Thereafter, all sections were blocked with 2.5% normal horse serum 
(Vector laboratories Burlingame, CA) for 20 minutes and incubated overnight at 4°C 
with the primary antibody diluted in 1% bovine serum albumin (BSA) in PBS. 
Staining procedure with amino-ethylcarbazole: Subsequently, the sections were incubated for 
30 minutes at room temperature with the secondary antibody (Vector laboratories 
Burlingame, CA) and the ABC reagent (Vector laboratories Burlingame, CA) for 30 
minutes and 10 minutes for Caspase 3. The sections were washed with 0.1M sodium 
acetate buffer and incubated in amino-ethylcarbazole (Sigma) dissolved in N,N-
dimethylformamide (1 g/250 mL) (Sigma) with 0.1% hydrogen peroxide for 30 minutes 
at room temperature. All sections were counterstained with haematoxylin. 
Staining procedure for immunofluorescence: Sections were incubated with the appropriate 
secondary antibody for 1 hour at room temperature and mounted using DAPI 
Vectashield (Vector laboratories Burlingame, CA). 
Proliferation index: Five microscopic images per explant or biopsy (from three donors) were 
taken at 20x magnification. For each image, the number of basal cells were counted 
and the proliferation index was calculated as the percentage of Ki67 positive cells 
within the basal layer of the epidermis.
High performance thin layer chromatography (HPTLC)
To identify the different classes of lipids, co-chromatography of a standard lipid mixture 
was performed. This included six subclasses of synthetic CERs (EOS, NS, EOP, NP, AS 
and AP (Evonik, Germany)), FAs (stearic acid, tricosanoic acid, palmitic acid, behenic 
acid, arachidonic acid, cerotic acid and lignoceric acid (Sigma)) and cholesterol 
(Sigma). The ceramide nomenclature is according to the terminology of Motta et al.1 
and Masukawa et al.2 which is used throughout this article (Supplementary Table S3). 
Lipid quantification by HPTLC: The standard lipid mixture and extracted lipids were sprayed 
on a silica gel plate (Merck, Germany) using a Camag Linomat IV device, (Muttenz, 
Switzerland) within a concentration range of 4 µg - 30 µg. Variation in the amounts 
of sprayed standard lipids allowed the calculation of calibration curves for lipid 
quantification. The lipids were separated using organic solvent mixtures at specific 
running distances (Supplementary Table S2). The plate was stained with a copper 
acetate-copper sulfate solution (3:1) and charred at 170°C for 15 minutes. The images 
were obtained with a GS800 calibrated densitometer (Bio-Rad, CA, USA) and analyzed 
with quantity-one software 4.6.5 (Bio-Rad, CA, USA). The amount of each lipid class 
was determined from a non-linear fit of the calibration curve from its synthetic lipid 
counterpart. This provided the relative levels of the various lipid classes. The absolute 
values were provided by weighing the SC before and after extraction.
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Fourier transformed infra-red spectroscopy (FTIR) and small angle X-ray diffraction 
(SAXD)
The SC sheets were hydrated for 24 hours over a 27% NaBr solution and sandwiched 
between AgBr windows (Pier-optics, Japan). The spectra were collected using a Varian 
670-IR FTIR spectrometer (Agilent technologies, CA, USA), equipped with a broad-
band mercury cadmium telluride detector, cooled with liquid nitrogen. The spectra 
were collected in transmission mode, as a co-addition of 256 scans at 1 cm-1 resolution 
during 4 minutes from 0°C-90°C at a frequency range of 600-4000 cm-1. The spectra 
was deconvoluted using enhancement factor of 1.7, half-width of 5 cm-1, and analysed 
using Bio-Rad Win-IR Pro 3.0 software from Biorad (Biorad laboratories, MA, USA).
The samples were hydrated as described above and SAXD patterns were detected 
with a Frelon 2000 CCD detector at room temperature for a period of 10 min using 
a microfocus as described by Bras et al.3 From the scattering angle, vector q was 
calculated from the following equation q= (4πsinθ)/λ. θ is the scattering angle and λ is 
the wavelength of the X-ray. 
Supplementary references 
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human stratum corneum. J Lipid Res 2008: 49: 
1466-1476.
3. Bras W, Dolbnya IP, Detollenaere D, et al. 
Recent experiments on a small-angle/wide-
angle X-ray scattering beam line at the ESRF. 
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Previously, a skin barrier repair model was developed to examine the effect of 
formulations on the lipid properties of compromised skin. In this model, the lipid 
organization mimics that of several skin diseases with an impaired skin barrier and 
a less dense lateral lipid organization. Additionally, parakeratosis was occasionally 
observed. In the present study, we investigated if the extent of initial barrier disruption 
affects lipid organization and parakeratosis in regenerated SC. 
After barrier disruption and SC regeneration the fraction of lipids adopting a less dense 
lateral organization gradually increased with increasing degree of barrier disruption. 
Only when 75% of the SC was removed, parakeratosis and a change in lamellar 
organization were observed. This demonstrates the possibility to use the skin barrier 
repair model to study the effects of formulations on compromised skin in which the 





The skin barrier function is located in the uppermost layer of the epidermis, the stratum 
corneum (SC). This layer consists of corneocytes embedded in a lipid matrix.1 The lipids 
form two crystalline lamellar phases with repeat distances of 13 nm (long periodicity 
phase, LPP) and 6 nm (short periodicity phase, SPP), see Figure 1.2-4 Within the lipid 
lamellae, the lipids mainly adopt a dense orthorhombic lateral packing in healthy 
skin.5-8 In several skin diseases, the barrier function is affected, e.g. atopic dermatitis, 
lamellar ichthyosis, Netherton syndrome, and psoriasis.9 The reduced barrier function 
is characterized by e.g. a higher fraction of SC lipids that adopts a hexagonal lateral 
packing compared to healthy skin.10 The change in barrier function in several skin 
diseases depends on the severity of the disease.9-11 
Figure 1. Lipid organization in the SC. A) Schematic overview of the skin, B) A brick-and-mortar structure 
is mimicking the corneocytes embedded in the lipid matrix, C) In between the corneocytes, the lipids are 
stacked in lamellae, D) Detail of the lipid lamellae, E) Perpendicular to the lamellae, the lipids are organized 
in a lateral packing. This can be either orthorhombic, hexagonal, or liquid (top view), F) The lipid lamellae 






Recently, a human skin barrier repair model was developed which can be used to 
study the interactions of topical formulations with the SC during skin barrier repair.12 
This model is referred to as the SkinBaR model and exhibits several characteristics 
of the lipid composition and organization in SC of diseased skin, such as Netherton 
syndrome, lamellar ichthyosis, and atopic dermatitis. In this model, the SC is removed 
by stripping ex vivo human skin and regenerated during a culture period of 8 days. In 
our previous studies, occasionally nuclei were observed in the regenerated SC after 
culturing, which is known as parakeratosis. Parakeratosis is also observed in several 
skin diseases with a disturbed barrier13, wound healing14, and after tape stripping in 
vivo.15 It is caused by abnormal keratinocyte maturation. We hypothesize that the 
degree of barrier disruption influences the rate at which the barrier is repaired and 
may therefore be associated with the presence of parakeratosis and the extent the 
lipid organization in the SC lipid matrix changes, mimicking more closely the lipid 
organization in SC of diseased skin. If this is the case, the SkinBaR model could be 
used to study the effects of barrier repair formulations on various levels of altered lipid 
organization, mimicking several aspects of the lipid organization in diseased skin. The 
formulations can be applied during or after barrier regeneration.16 
The aim of this study was to induce several degrees of barrier disruption by stripping 
ex vivo human skin and regenerating the SC during culture. We intended to mimic 
multiple levels of skin disease severity as analyzed by the morphology and lateral and 
lamellar lipid organization which are indicative for the skin barrier function. 
Methods
Chemicals
Cyanoacrylate (Bison, Goes, the Netherlands) was bought in a local shop. Xylene was 
purchased from Biosolve (Valkenswaard, the Netherlands), 4% buffered formaldehyde 
was acquired from Added Pharma (Oss, the Netherlands), paraffin, haematoxylin, 
and eosin were obtained from Klinipath (Duiven, the Netherlands). DMEM, Ham’s 
F12, and penicillin/streptomycin were purchased from Fisher Scientific (Waltham, 
Massachusetts, USA). Bovine serum albumin, sodium bromide, ethanol, acetone, 
trypsin, trypsin inhibitor, selenious acid, hydrocortisone, isoproterenol, L-carnitine, 
L-serine, insulin, α-tocopherol acetate, vitamin C, arachidonic acid, linoleic acid, and 
palmitic acid were purchased from Sigma-Aldrich (Zwijndrecht, the Netherlands). 
Stripping and culturing of ex vivo skin
Human abdomen or mamma skin from three donors (age 20, 30, and 67) was obtained 
after abdominoplasty or breast reduction, from a local hospital, after written informed 
consent, and was used within 12 hours after cosmetic surgery. The subcutaneous 
fat was removed with a scalpel, and the skin was wiped with 70% ethanol and 
Millipore water. Subsequently, the skin was dermatomed to a thickness of 600 µm 
(D80 Dermatome, Humeca, Borne, the Netherlands), punched in circles (ø=26 mm), 
clamped in a custom made device, and stripped with preheated cyanoacrylate on 
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a preheated metal cylinder as described before.12 SC was stripped by removing the 
cylinder in one stroke. The stripping procedure was repeated to remove either 25%, 
50%, or 75% of the SC. After 75% of the SC was removed the skin appeared shiny. 
Typically, 6-8 strips were needed to reach a shiny appearance of the whole sample, 
varying between skin donors. Cultured non-stripped (0%) skin and native skin (e.g. 
non-stripped and not cultured) were used as control. Per donor, the different conditions 
were cultured in duplo.
The stripped ex vivo skin was cultured at the air-liquid interface for 8 days in a deep 
6-well culturing plate (Organogenesis, Canton, MA, USA), as previously described.12 
The samples were either cryofixed, paraffin embedded, or SC was isolated.
Isolation of SC
SC was isolated from the (cultured) skin by trypsin digestion. The skin was placed in 
0.1% trypsin solution in PBS and kept overnight at 4°C, followed by one hour at 37°C. 
Trypsin is a proteolytic enzyme which is used to separate SC from the epidermis.17 SC 
was peeled off, washed in 0.1% trypsin inhibitor, and twice in Millipore water. SC 
sheets were stored over silica gel under argon until use. SC was used for either infrared 
spectroscopy measurements or X-ray diffraction measurements.
Safranin-O red and heamatoxylin and eosin staining
To examine the number of corneocyte layers 5 µm cryofixed sections were stained 
with 1% (w/v) Safranin-O solution for 1 minute followed by 20 minutes incubation 
in 2% (w/v) KOH solution. Haematoxylin and Eosin (HE) staining was performed on 
5 µm paraffin sections to examine the morphology. After Safranin-O and HE staining, 
at least 3 light microscopy images were taken per culture condition at 20x and 63x 
magnification. 
Fourier transformed infrared spectroscopy
Fourier transformed infrared (FTIR) spectroscopy was used to examine the lateral lipid 
packing of isolated SC samples as a function of temperature (0-90°C). The samples 
were placed over a 27% NaBr solution in D2O for 24 hours at room temperature, 
reaching a final hydration level of around 20% in the SC, and sandwiched between 
two AgBr-windows. Spectra were obtained using a Varian 670-IR FTIR spectrometer 
(Agilent Technologies, Santa Clara, USA), as described before.16 
The onset temperature of the ordered-disordered transition was obtained from the peak 
positions of the CH2 symmetric stretching vibrations in the FTIR spectra. Peak positions 
were plotted as a function of temperature. The intercept of two regression lines fitted 
to the linear parts of the graph was calculated which describes the onset transition 






Small angle X-ray diffraction
Small angle X-ray diffraction (SAXD) was employed to examine the lamellar organization 
of the SC lipids. Measurements were performed at the European Synchrotron Radiation 
Facility (Grenoble, France) using the Dutch-Belgian beamline (station BM26B). 24 
hours prior to the measurements, SC samples were hydrated over a 27% NaBr solution 
at room temperature reaching a hydration level of about 20%. A custom made sample 
holder was used to orientate the samples parallel to the X-ray beam. Diffraction data 
was collected at room temperature on a Pilatus 1M detector for a period of 5 or 10 
minutes, as described earlier.18 The scattering vector (q) was calculated using the 
scattering angle (Θ) and the wavelength (λ) by q=4π sin Θ/λ. The spacing of the lamellar 
phase can be calculated from the position of the peak maxima (q) using 2π/q. 
Statistical analysis
One-way ANOVA with post hoc correction for multiple comparisons or with a post-
hoc trend test was used to analyze the data using GraphPad Prism 7 (San Diego, CA, 
USA). All differences are described relative to native human skin. 
Results
Human skin cultured after various degrees of barrier disruption results in complete SC 
regeneration 
After staining with safranin-O, the number of corneocyte layers was determined for at 
least 3 different spots per image and at least 3 images were taken per culturing condition 
for each skin donor. Per condition, the results of the three donors were pooled. Native 
human skin showed 11.0 ± 4.0 (mean ± SD) corneocyte layers, whereas after removing 
of the SC until the skin surface appeared shiny 3.1 ± 2.8 SC cell layers remained on the 
viable epidermis, meaning that about 75% of the corneocyte layers was removed. The 
number of strips needed to remove 75% of the SC was reduced to ¾ and ½ in order 
to obtain less stripped skin. This resulted in skin with either 5.0 ± 3.4 (=50% stripped) 
or 7.7 ± 4.4 (=25% stripped) remaining corneocyte layers on the viable epidermis, see 
Figure 2A. All stripped samples had a significant lower number of corneocyte layers 
than the native SC (p<0.001). A post-hoc test showed that there is a linear trend with 
decreasing number of corneocyte layers for the samples prior to culture (slope: -2.6, 
p<0.0001). After the 8-day culturing period, the number of corneocyte layers in the 
regenerated SC is significantly increased to 10.8 ± 3.6, 10.3 ± 2.6, and 11.2 ± 3.1, for 
75%, 50%, and 25% stripped SC, respectively, which is comparable to the number of 
layers in native human skin before stripping. 
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Figure 2. Number of corneocyte layers and morphology. A) The number of layers in native SC (Nat.), 
stripped SC, and regenerated SC after culturing. Bars represent Mean ± SD. Morphology of B) Native skin, 
and C-E) Stripped and cultured skin with regenerated SC. SC was stripped away for 25%, 50%, and 75%, 






Parakeratosis is visible when the majority of the SC is removed
The morphology of the cultured skin sections was visualized using HE staining. The 
staining revealed that after removing 75% of the SC and subsequent culturing, prominent 
parakeratosis is observed (see arrows in Figure 2E), mainly in the top layers of the 
regenerated SC. Furthermore, spongiosis with an irregular keratinocyte distribution in 
the epidermis was observed in skin with SC that was regenerated after 75% of the SC 
was removed. After 50% or 25% of the SC was removed, the regenerated SC did not 
exhibit parakeratosis or major differences in morphology. 
Lateral lipid organization changes gradually with number of removed corneocyte layers 
The lipid organization of the stripped and regenerated SC was examined and compared 
to native SC. The lateral lipid packing was examined using the CH2 rocking vibrations 
in the FTIR spectra in a temperature range between 0°C and 90°C. A hexagonal lateral 
lipid packing is characterized by a single contour positioned at a wavenumber of 719 
cm-1, while an orthorhombic packing is characterized by a doublet positioned at 719 
and 730 cm-1. All spectra were scaled at the difference between the absorption at 719 
cm-1 (peak position) and the absorption at 715 cm-1 (base). This difference in absorption 
was kept constant in all spectra. In this way relative peak heights of the peak at around 
730 cm-1 could be compared between samples.
Figure 3 shows representative FTIR spectra of one donor. As shown in Figure 3A, in 
native SC two strong contours were observed at 719 and 730 cm-1 at 0°C, indicating 
that the lipids adopt an orthorhombic lateral lipid packing. The contour positioned at 
730 cm-1 started to decrease in intensity at around 34°C and disappeared at around 
48°C, indicating a phase transition from an orthorhombic to a hexagonal lateral lipid 
packing. The intensity of the peak at 730 cm-1 at 0°C gradually decreased when 25% to 
50% and 75% of SC was removed before culturing. When increasing the temperature, 
the peak at 730 cm-1 disappeared between 30°C and 48°C (25% of SC was stripped), 
and 20°C and 36°C (50% of SC was stripped) in the FTIR spectra of regenerated 
SC. After removing of 75% of the corneocyte layers and regeneration of the SC, the 
orthorhombic to hexagonal transition occurred between 8°C and 30°C as monitored by 
the disappearance of the 730 cm-1 in the corresponding FTIR spectrum.
Lipid ordering only affected when significant amount of SC is removed
The conformational ordering of the lipids was examined using the thermotropic behavior 
of the CH2 symmetric stretching vibrations in the FTIR spectrum in a temperature range 
of 0-90°C. Fully extended lipid chains show a high conformational ordering, which 
is characterized by a CH2 stretching vibration peak position at wavenumbers below 
2850 cm-1. When lipids have a high conformational disordering, e.g. when lipids are 
in liquid state, the peak position is shifted to wavenumbers higher than 2852 cm-1. The 
onset transition temperature was determined as described above.
The CH2 symmetric stretching vibrations obtained from representative data of one 
donor are plotted as a function of temperature in Figure 3E. The wavenumber at 10°C 
and the onset transition temperatures are mean values of the spectra of the three donors. 
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At 10°C, a wavenumber of 2848.81 ± 0.01 cm-1 (mean ± SD) was observed in native 
SC. The wavenumbers of cultured control skin, and after regeneration of 25% and 50% 
of the SC were comparable to native SC (p=0.74, p=0.35, and p=0.39, respectively). 
Only when 75% of the SC was removed, the wavenumber at 10°C was increased to 
2849.38 ± 0.25 cm-1 (p=0.04). This indicates that, even at low temperatures, the lipid 
ordering of the regenerated SC is affected.
Furthermore, the stretching vibrations are used to compare the onset transition 
temperatures of the ordered-disordered phase transition. For native SC the onset 
transition temperature was 72.5 ± 3.6°C (mean ± SD). Furthermore, at around 30-40°C, 
a small shift in wavenumber is observed, indicating an orthorhombic to hexagonal 
transition. Lipids in the SC of cultured control skin (0% of SC was stripped) showed 
similar temperature dependence as native SC with a transition temperature of 68.9 
± 4.7°C. After regeneration of the SC after 25% or 50% of the SC was stripped, the 
onset temperatures of the ordered-disordered phase transition were 68.9 ± 2.9°C and 
67.9 ± 1.3°C, respectively. These onset transition temperatures were not statistically 
significant different from that of native SC. However, SC regeneration after 75% of 
the SC was removed, resulted in a different temperature dependence of the CH2 
stretching vibrations. The onset of the ordered-disordered phase transition took 
place at a statistically significant lower temperature of 62.9 ± 2.1°C (p=0.01). This is 
apparent from the line in Figure 3E which is shifted to the left and increases to higher 
wavenumbers at lower temperatures. Furthermore, the small shift in wavenumber at 
around 30-40°C was not observed in regenerated SC after 50% or 75% of the SC was 
stripped.
The lamellar repeat distance decreases only after removing most of the SC
The lamellar organization in the lipid matrix was examined using SAXD. Figure 4 shows 
SAXD patterns of a representative donor of native SC and SC that was regenerated 
after stripping and culturing. Two weak diffraction peaks (indicated by I and III) and 
one strong peak (indicated by II) can be observed. The LPP contributes to all three 
peaks, whereas the SPP only contributes to peak II. The peak corresponding to phase 
separated cholesterol is marked by an asterisk. The peak position (q) of the main peak 
(II) was used to examine whether a difference in lamellar spacing was induced by SC 
disruption. The spacing of the lipids in the stripped and regenerated SC was compared 
to the spacing of native SC of the same donor. In this way, a mean difference was 
obtained. The spacing in native SC was 6.3 ± 0.1 nm (mean ± SD). The difference in 
spacing was 0.05 nm for the SC of the cultured control sample (0% of SC was stripped) 
and for regenerated SC after 25% or 50% of the SC was stripped this difference was 
-0.06 nm. None of these changes were statistically different. However, when SC was 
regenerated after 75% of the SC was removed, the difference in spacing was -0.23 nm, 
which was statistically significant different from native SC (p=0.001). Furthermore, the 
intensity of diffraction peaks I and III decreased substantially, indicating a reduction in 
the presence of the LPP. Additionally, a shoulder appears close to the position of peak 






Figure 4. A typical example of SAXD patterns of native SC and regenerated SC after stripping and culturing. 
The peak positions (q) are indicative for the spacing of the lipid lamellae. The 1st, 2nd, and 3rd order peaks of 
the LPP are labeled with I, II, and III, respectively. The first order of the SPP also contributes to peak II. Phase 
separated cholesterol is labeled with *. 
Figure 3. CH2 rocking vibrations and CH2 stretching 
temperature dependence. FTIR spectra showing CH2 
rocking vibrations as function of temperature (0-
60°C) of A) native human skin, B) 25% stripped and 
regenerated SC, C) 50% stripped and regenerated 
SC, and D) 75% stripped and regenerated SC. E) 
Temperature dependence of the CH2 symmetric 
stretching vibrations of native human SC and 
regenerated SC after stripping and culturing. Peak 
positions of the CH2 stretching vibrations peak are 




In this study we showed that in regenerated SC of the SkinBaR model we can on 
demand gradually decrease the fraction of lipids adopting a dense orthorhombic lateral 
packing by varying the initial degree of barrier disruption. The obtained changes in 
lipid lateral packing compared to native SC are very similar to that observed in SC of 
several inflammatory skin diseases.9-11 These results indicate that the SkinBaR model 
can be used to study skin barrier repair formulations that aim to normalize the SC lipid 
organization in diseased skin. The degree of disruption also influenced the presence 
of parakeratosis, as we showed that parakeratosis was only present in the examined 
models when 75% of the SC was removed, resulting in 3 remaining corneocyte 
layers before the skin started to regenerate the SC. Additionally, parakeratosis was 
predominantly observed in the upper corneocyte layers. This strongly indicates that 
only during generation of the initial corneocyte layers parakeratosis is induced, 
probably as a fast response to repair the skin barrier after disruption. Independent 
of the degree of barrier disruption, the number of corneocyte layers after 8 days of 
regeneration was comparable to that in SC of native skin. This indicates that the 
degree of disruption affects the rate of regeneration, and that the skin is still viable. 
Previous observations have shown that the proliferation rate, as examined by fraction 
of Ki-67 positively stained nuclei, immediately after SC removal was higher than the 
proliferation rate after a longer recovery period.12,15 It is known that cultured skin does 
not desquamate and that the corneocyte layers accumulate during culture.19 However, 
this is believed to be of little influence on the SkinBaR model since the non-stripped 
cultured SC showed a non-significant increase of only 1.4 corneocyte layers during 
culturing indicating that the formation of the SC is inhibited.
When focusing on the lateral lipid organization, the lipid density, which is the fraction 
of lipids forming an orthorhombic lateral packing, of the regenerated SC decreased 
when the degree of barrier disruption was increased. At skin temperature (32°C), in 
the FTIR spectrum no contour at 730 cm-1 was observed when 75% of the SC was 
regenerated, demonstrating that at this temperature the lipids had adopted a hexagonal 
packing. However, when removing less corneocyte layers, the contour at 730 cm-1 was 
visible as a shoulder (after 50% of SC was stripped) or as a peak (native or after 25% 
of SC was stripped) at 32°C. An indication of the lipid ordering is provided by the CH2 
stretching vibrations. When comparing these stretching vibrations of regenerated SC 
after 75% of SC was stripped to that of regenerated SC after less intensive disruption of 
SC, the onset temperature of the ordered-disordered phase transition was significantly 
lower and the position of the CH2 vibrations at 32°C were at higher frequency. These 
observations suggest a less ordered organization of the lipids in the regenerated SC 
after 75% SC removal, even at low temperatures. Also the lamellar organization 
was only affected in regenerated SC after 75% of the SC was removed. These results 
indicate that the lateral lipid packing is more responsive to barrier disruption than the 
conformational ordering and the lamellar organization. 
Previously, a more abundant presence of lipids adopting a hexagonal packing has been 
related to a higher level of mono-unsaturated fatty acids (MUFAs)20, and shorter fatty 
acid (FA) and ceramide (CER) chain length.21 In the SkinBaR model, both an increased 






CERs are derived from a chemical linkage of a MUFA to a sphingoid base.23 The 
enzyme stearoyl-CoA desaturase catalyzes the conversion of saturated FAs to MUFAs. 
In the SkinBaR model, we have demonstrated an extended stearoyl-CoA desaturase 
expression compared to native human skin, suggesting also an increased level of 
MUFAs.12
Similar changes in lipid organization and composition have been observed in atopic 
dermatitis skin. In lesional and non-lesional skin of atopic dermatitis patients a higher 
fraction of lipids adopts a hexagonal lipid organization, which coincides with a higher 
fraction of MUFAs and a reduced chain length of FAs and CERs.10,24,25 These changes are 
more pronounced in lesional skin than in non-lesional skin.10 Besides atopic dermatitis, 
several other skin diseases are characterized by a disrupted skin barrier.9,11 Again, the 
extent of barrier disruption may vary depending on the severity of the disease. This may 
be of influence on the effect of topically applied barrier repair formulations. 
The results in this study show that the degree of barrier disruption of the SkinBaR 
model can be controlled and that the changes in lipid organization and the level of 
parakeratosis depend on the initial extent of barrier disruption. This means that if less 
corneocyte layers remain before regeneration is initiated, the deviations in lateral and 
lamellar lipid organization compared to native SC are more substantial. This variation 
in the degree of deviation of the lipid organization in the SkinBaR model can be used 
in studying the effect of barrier repair formulations on the lipid organization. In this 
way the SkinBaR model can serve as a model for the lipid organization in several 
skin diseases of which the lipid organization deviates in a similar manner from that in 
native human skin. Previously, other skin models (the human skin equivalents) have 
been used to test topical formulations.26 However, the 8-day culturing period of the 
SkinBaR model is less time-consuming than a culturing period of 2-3 weeks often used 
to generate human skin equivalents.27-29 Furthermore, it is a challenge to influence 
the lateral packing of the skin equivalents by modifying the culture conditions27,30,31, 
while the lateral packing of the SkinBaR model can be adjusted on demand. Unlike 
these human skin equivalents, the SkinBaR model offers the possibility to apply topical 
barrier repair formulations directly after several degrees of barrier disruption and study 
the lamellar and lateral lipid organization of regenerated SC. 
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Ex vivo regenerated stratum corneum (SC) can be used as a model to study the barrier 
function of compromised skin. Yet, details about how close the regenerated SC model 
mimics the lipid properties (e.g. lipid composition and lipid ordering) of the in vivo 
situation are not known. Here, we examined whether human ex vivo regenerated 
SC showed similar lipid properties as human in vivo regenerated SC, since lipid 
properties in SC affect the barrier function. Both in vivo and ex vivo regenerated SC 
had an altered ceramide subclass composition, with increased levels of S subclass and 
decreased levels of P subclass ceramides, a reduced mean ceramide chain length, and 
a higher level of unsaturated ceramides. Overall, regenerating SC ex vivo showed more 
pronounced changes compared to the in vivo response. One of the purposes of these 
models is to use them to mimic compromised skin of inflammatory skin diseases. The 
altered lipid properties in compromised skin were comparable to those observed in 
several inflammatory skin diseases. The ex vivo model simulates the barrier properties 
of the in vivo model and both models showed many similarities with altered lipid 




The main skin barrier function is located in the uppermost epidermal layer, the stratum 
corneum (SC), consisting of terminally differentiated corneocytes embedded in a lipid 
matrix.1 A proper lipid organization and lipid composition in this matrix are important 
for a well-functioning skin barrier.2-4 The SC barrier lipids (e.g. ceramides (CERs), fatty 
acids, and cholesterol) are mainly assembled in a dense orthorhombic lateral packing 
while a smaller lipid fraction adopts a less dense hexagonal packing.5,6 The SC CER 
fraction consists of a specific set of CER subclasses defined by their sphingoid base 
and acyl chain. Both chains can vary in carbon chain length and polar head group, 
resulting in a wide array of differently structured CER species, see Figure S1. 
Tape-stripped healthy human skin in vivo is used as a model to study skin with a 
compromised barrier. This model has been employed to study several aspects of 
inflammatory skin diseases7, to examine the penetration of compounds through the 
skin8,9, to increase the bioavailability of topical products in the deeper epidermal 
layers10, and to generate a compromised skin barrier to examine the biological processes 
of skin barrier repair.11,12 One of these processes is restoring the lipid composition and 
lipid ordering (lipid properties) in the SC. However, little is known about the effect of 
barrier disruption by tape-stripping on the lipid properties of the regenerated SC, and if 
the regenerated SC lipid properties mimic healthy or diseased skin.
An alternative model to study skin barrier repair is by using stripped ex vivo skin 
which regenerates SC over time in the incubator (skin barrier repair (SkinBaR) model).13 
Several aspects of the lipid properties of this model have been studied and are known 
to mimic to some extent the lipid properties of inflammatory skin diseases.13,14 
However, it is unknown to what extent the CER composition of the SkinBaR model 
reflects that of tape-stripped and regenerated human skin in vivo. In the present study 
we examine the regenerated SC lipid properties of the ex vivo SkinBaR model and of 
in vivo tape-stripped and regenerated skin, in order to determine if the SkinBaR model 
can potentially replace skin barrier repair studies in clinical settings. 
The SC of five skin conditions were examined: SC from CtrlIn-vivo and RegIn-vivo were 
obtained from healthy in vivo control skin and regenerated tape-stripped skin, 
respectively. SC from CtrlSkinBaR, CulSkinBaR, and RegSkinBaR were obtained from ex vivo 
control skin, cultured skin, and regenerated cyanoacrylate-stripped skin, see Figure 1. 
The results show that the CER subclass composition and CER chain length of RegSkinBaR 
SC reflect those observed in RegIn-vivo SC. Both models show that regeneration alters 
the CER composition and mimics important aspects encountered in inflammatory skin 







To examine if SC regeneration induced changes in CER profile, and whether ex vivo 
is differently affected compared to in vivo, the SC CER composition of the tape-strips 
obtained in the in vivo study and the isolated SC of the SkinBaR model were quantified 
using liquid chromatography/mass spectrometry (LC/MS). In the present study we 
quantified the ceramide subclasses, (see Figure S1) as well as the mean total chain 
length (MCL, total number of carbon atoms sphingoid base and acyl chain). We present 
those parameters that correlated with skin barrier function in previous studies.3,15-17 
These parameters were CER subclass, the CER MCL, and the level of CERs with a total 
chain length of 34 carbon atoms (C34 CERs). 
Ceramide subclass profile and MCL change due to SC regeneration
The CER subclass profiles of the 5 different skin conditions were examined. Figure 2 
shows an altered CER profile due to regeneration (differences of RegIn-vivo vs. CtrlIn-vivo 
and RegSkinBaR vs. CulSkinBaR, respectively). Both regenerated models showed increased 
levels of S subclass CERs, whereas all three P subclasses and NH subclass CERs were 
decreased. The levels of AH subclass CERs were only affected in the RegSkinBaR samples 
and not in the RegIn-vivo samples. No variation in the dS CER subclasses was observed. 
All CER O subclasses increased in both RegIn-vivo and RegSkinBaR samples. Table S1 shows 
the results of the linear mixed model (LMM) analysis which indicated that the increased 
S subclasses and decreased P and NH subclasses in the regenerated SC (both in vivo 
and SkinBaR) compared to their respective controls were statistically significant.
CER subclasses showed similar trends in both RegIn-vivo and RegSkinBaR, but in the RegSkinBaR 
samples the changes were more pronounced. An exception were changes in the acyl-
CERs (EO subclasses) which showed inverse effects in the SkinBaR model (decrease 
Figure 1. Explanation of the skin samples. The SC of five different skin conditions were examined. The first 
two conditions were obtained from in vivo skin. The first condition is healthy in vivo control skin (hereafter 
called CtrlIn-vivo). The second condition is tape-stripped and regenereted in vivo skin (named RegIn-vivo). The 
other three conditions are obtained from ex vivo skin. These are a control condition for the ex vivo skin 
(called CtrlSkinBaR), non-stripped cultured ex vivo skin (CulSkinBaR), and ex vivo skin that was stripped and 
cultured for regeneration (RegSkinBaR). 
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Figure 2. In vivo and SkinBaR model ceramide profiles and mean ceramide chain length. A-B) The total 
molar amount of all CERs was set at 100%. Bar show the relative molar abundance of the CER subclasses 
in mol%. N=15 for in vivo samples, N=3, 6, and 9 for CtrlSkinBaR, CulSkinBaR, and RegSkinBaR, respectively. C) The 
mean carbon atom chain length of all CERs. D) Correlation of the mean CER chain length with the predicted 
mean carbon chain length (for residuals: see Figure S3). Dotted lines: 95% confidence interval. Bars: mean ± 






in regenerated SC) compared to in vivo skin (increase in regenerated SC). When the 
EO and O CERs within each sample type were combined, there was only a minor 
difference in total (EO and O) CERs induced by regeneration (see Figure 2B and Table 
S2).
Because the total CER chain length is important, the MCL of all CERs was calculated 
(Figure 2C and Table S2). CtrlIn-vivo skin had a MCL of 46.9 carbon atoms, and CtrlSkinBaR 
and CulSkinBaR skin did not show a significant difference. Significant reductions in MCL 
with approximately 0.4 and 1 carbon atom were observed due to regeneration in in 
vivo and SkinBaR skin, respectively (Table S3). 
Increased level of C34 ceramides and unsaturated ceramides in regenerated SC
Another parameter of interest is the level of C34 CERs. CtrlIn-vivo and CtrlSkinBaR had similar 
levels of C34 CERs. Compared to these controls, the mol% C34 CERs was significantly 
increased due to culturing and regeneration. The effect of regeneration was significantly 
larger in SkinBaR samples than in in vivo samples (Figure S2, Table S4). To determine 
if the increase in C34 CERs was subclass independent, the relative amount of C34 
within each subclass was determined. This showed that for each subclass, the mol% 
C34 CERs for CtrlIn-vivo and CtrlSkinBaR did not significantly differ. Within the subclasses, 
the levels of C34 CERs were increased in CulSkinBaR samples compared to the control. 
Furthermore, in both RegIn-vivo and RegSkinBaR, a further increase in the level of C34 within 
the subclasses NS, AS, NH, and AH was observed (Figure 3, Table S4). For the CER 
subclasses NP, NdS, AP, and AdS a similar increase was observed (Figure S2). Due to 
the limited amount of SC acquired by tape-stripping (in vivo), C34 levels of these CER 
subclasses fall below the detection limit. 
Figure 3. Level of C34 ceramides and unsaturated ceramides in the SC of the in vivo study and SkinBaR 
models. The total amount of all CERs was set at 100%. A) The level of C34 per CER subclass. B) The level of 
the mono-unsaturated CERs in mol%. Data of 3 donors was analyzed, indicated by different shades of gray. 
Bars: mean ± SD, * p<0.05 compared to its respective control.
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As C34 CERs together with EO CERs with exceptional long chain lengths have been 
shown to influence the MCL, we investigated whether a LMM with the parameters EO 
CERs and C34 CERs could be used to predict the MCL (Table S5). A high correlation 
between the predicted and measured MCL was observed (Figure 2D), indicating 90% 
of the variation in MCL could be explained by the percentage EO CERs and C34 CERs.
Another important parameter of the CER composition is the relative amount of mono-
unsaturated CERs (MuCERs). Although MuCERs were detected in in vivo tape-strip 
samples, these were mostly below the limit of quantification. The MuCER percentages 
of the three SkinBaR sample groups were compared using an LMM (Table S6). In 
CtrlSkinBaR SC 2.8 mol% MuCERs were present. This fraction significantly increased to 
4.4 mol% in CulSkinBaR samples (p=0.04) and to 8.0 mol% in RegSkinBaR SC (p<0.01), see 
Figure 3B. 
Regeneration does not affect lipid ordering 
The lipid ordering was analyzed using Fourier-transform infrared spectroscopy (FTIR). 
For the SkinBaR samples, CH2 stretching vibrations in the FTIR spectra could be 
obtained over a temperature range from 0 to 90°C. In order to compare the results 
obtained from the in vivo study and the SkinBaR model, the lipid ordering was 
examined using the center of gravity of the CH2 stretching vibration peak in the FTIR 
spectra at skin temperature (32°C), see Figure 4A. A peak position below 2850 cm-1 
indicates a conformational ordering of the lipids. If the peak position is increased to 
wavenumbers above 2852 cm-1, the lipids in the stratum corneum are mainly in a 
conformational disordered state. In spectra from both CtrlIn-vivo and RegIn-vivo samples, 
the CH2 peak was positioned at 2848.7 cm-1. For the CtrlSkinBaR and CulSkinBaR samples 
the peak position was located at wavenumbers of 2849.2 cm-1 and 2849.3 cm-1, 
respectively, which was significantly higher than in the in vivo samples. Although the 
peak position of RegSkinBaR is substantially higher than that of CtrlSkinBaR, this difference 
was not statistically significant in the LMM (Table S7).
Figure 4. Center of gravity of the CH2 stretching vibrations of in vivo study and SkinBaR skin models 
and correlation of predicted values for the CH2 stretching peak with observed values. A) The center of 
gravity of the CH2 stretching peak positions of the FTIR spectra at skin temperature of 32°C. Bars: mean ± 
SD, ‡ CtrlSkinBaR is different from CtrlIn-vivo (LMM: p<0.05). B) The linear mixed model used to predict the CH2 
stretching peak includes C34 CERs, EO CERs, and two CER subclass ratios (for residuals: see Figure S4). 






Using ceramide composition data to predict the lipid ordering
As the lipid disordering in SC of the SkinBaR model was higher compared to the 
conformational ordering in SC in the clinical setting, the relation between ceramide 
composition and lipid conformational ordering in (regenerated) SC was examined. This 
will provide insight in how the CER composition contributes to the lipid ordering. To 
obtain insight in the contribution of parameters related to ceramide composition, these 
were used to make a predictive model for the lipid ordering (i.e. CH2 stretching peak 
position). We included the following ceramide related parameters in a LMM (Table S8): 
C34 and EO percentage (together being an MCL predictor) and the following subclass 
molar ratios: (dS+P+H)/S (excluding EO ceramides) and N/A, the former ratio correlated 
with barrier function in a previous study.18 For more details about the subclass ratios, 
see Supplementary Methods. Figure 4B depicts the actual CH2-peak position compared 
to the predicted position. The r2 indicates that 83% of the variation was explained, with 
normally distributed residuals. This model showed that the combination of these CER-
related parameters could, to a large extend, predict the lipid conformational ordering 
in SkinBaR and in vivo samples.
Discussion
In general, skin models have been used to i) model either healthy or diseased skin,7,19,20 
ii) examine treatment by formulations or active compounds,8,9 iii) to study the dynamic 
process of SC regeneration,11,12 iv) to study biological processes in the skin, and v) 
for screening of toxicity and irritation of compounds. Previously, we developed the 
SkinBaR model that has the potential to be used for multiple of these purposes.13 
However, the regenerated SC CER composition and lipid organization of this model 
have not been evaluated in detail and the correlation to an in vivo tape-stripping 
method is unknown. Therefore, the aim of this study was to examine to what extent 
the lipid matrix properties of the ex vivo and in vivo compromised skin models are 
comparable, and to determine if ex vivo models can (partly) replace clinical studies 
with regards to skin barrier repair. 
In general, the changes in CER levels and lipid properties in the RegSkinBaR samples were 
very similar, but more pronounced than in the RegIn-vivo samples as discussed below. 
i) Both regenerated SC models showed a decrease in CER P subclasses and 
increase in S subclasses compared to control SC samples. This might be 
caused by an imbalance in activity of the enzymes acid sphingomyelinase and 
β-glucocerebrosidase, both involved in post-synthetic modification of CERs.21 
Although the expression of these enzymes was not affected in the SkinBaR 
model,13 the activity can be altered.22 With regard to properties of the CER 
chains, both the RegSkinBaR and RegIn-vivo samples showed a decreased CER MCL, 
and an increase in levels of C34 CERs, while the level of unsaturated CERs was 
predominantly increased in RegSkinBaR SC. In agreement with the elevated level 
of unsaturated CERs, the expression of Stearoyl-CoA desaturase was increased 
in the SkinBaR model.13 
ii) The only substantial difference between the in vivo model and the SkinBaR 
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model was the change in level of EO CERs, which was increased in the RegIn-
vivo samples and decreased in the RegSkinBaR samples.
iii) The lipid ordering was not significantly affected by regeneration in both in vivo 
and ex vivo conditions. This might be due to less deep stripping in the present 
study compared to previous studies. Previously, lipids in the regenerated SC 
of the SkinBaR model were less ordered when almost all SC was removed.14 
Although the difference in CH2 stretching peak position between CtrlIn-vivo and 
CtrlSkinBaR was significant, different spectrum collection methods could have 
played a role. However, as the lipid composition could be used to accurately 
predict the lipid ordering, the difference mainly originated from a difference in 
lipid composition. These variances in lipid composition might have originated 
from the different method of SC sample collection, i.e. only tape 5-8 for in 
vivo conditions vs whole SC for ex vivo conditions, a similar difference as 
performed in collection of the FTIR data.
The tape-stripping method has been developed and used for several purposes, such 
as to specifically study the dynamic process of SC production,23 to determine the 
penetration of topically applied products,24 and to increase the bioavailability of these 
products in the deeper epidermal cell layers. As barrier function recovery of stripped 
healthy skin takes at least 14 days,25 tape-stripped skin is also a suitable model to study 
skin barrier repair.  Previously, it has been shown that in both in vivo and SkinBaR skin 
the proliferation rate immediately after barrier disruption is higher than after a recovery 
period of several days.7,13 However, in the SkinBaR model, the proliferation rate was 
at its normal level after 8 days of culturing,13 whereas in in vivo skin, the proliferation 
rate remained elevated for at least 10 days.7
It has been shown that tape-stripping healthy skin induced parakeratosis,7 and induced 
an inflammatory response by secretion of cytokines.26,27 Furthermore, in both AD and 
psoriasis pro-inflammatory cytokines are secreted.28,29 Therefore, tape-stripped healthy 
skin has been used as an alternative for several inflammatory skin diseases.7 During 
skin barrier repair of healthy in vivo skin, this inflammatory response slows down the 
repair process.30 The lack of this systemic response in the SkinBaR model therefore 
substantiates the rapid barrier repair process. This also indicates that, during skin 
barrier repair, the in vivo skin is closer to skin homeostasis. 
In contrast to the differences in proliferation rate and cytokine excretion, the expression 
pattern of proliferation proteins is very similar during in vivo and ex vivo skin barrier 
repair.7,13
When comparing the lipid properties of regenerated SC to that in SC of inflammatory 
diseased skin, many similarities can be observed. When compared to AD skin, these are 
i) similar changes in CER subclasses,15 ii) a decreased MCL,31 iii) an increase in levels of 
C34 CERs,15,31 and iv) an increased level of unsaturated lipids.32 Most of these changes 
correlated with an impaired skin barrier function.3,15,17 Although the degree of changes 
vary, many of these alterations in CER composition have also been observed in other 
inflammatory skin diseases like psoriasis, and Netherton syndrome.33,34 Additionally, a 
less dense lipid packing observed in RegSkinBaR SC14 also corresponds to findings in SC 
of these inflammatory skin diseases: a higher fraction of lipids adopting a less dense 
hexagonal lateral packing has been reported.35






samples, and multiple samples of the same donor were used to generate the cultured 
and regenerated samples. Ideally, skin of the same participants is used for both the 
in vivo and SkinBaR experiments. However, the SkinBaR samples are difficult to 
culture with small biopsies. Furthermore, multiple biopsies of one donor would be 
required. This is difficult to achieve. Lastly, the lipid properties of both models were 
compared to skin of inflammatory skin diseases based on data found in literature. In 
future experiments, the SkinBaR model should be directly compared to non-lesional 
and lesional diseased skin in the same experiment to minimize difference between 
measurements. 
In conclusion, this study shows that the changes in lipid properties in both the RegSkinBaR 
and RegIn-vivo models are very similar and mimic the lipid properties in inflammatory 
skin diseases. This concerns changes in CER subclass profiles, MCL, level of CER 
unsaturation, and conformational ordering. Therefore, the SkinBaR model can be used 
to predict the in vivo response with regards to the lipid composition after application 
of topical barrier repair treatments aiming to restore the normal CER composition. By 
doing so, the need for clinical studies is reduced. 
Materials and methods
Compromised in vivo skin barrier
15 healthy Caucasian volunteers (7 male, 18-29 years) participated in the study. The 
study was approved by the ethical committee of Leiden University Medical Center 
and performed according to the Declaration of Helsinki. Volunteers signed written 
informed consent. To exclude interference with topical products, the volunteers were 
asked not to use soaps or cosmetics on their ventral forearms during the whole study 
period. After a 1-week washout period, the SC barrier was disrupted by tape-stripping 
an area of 3.5 x 2.5 cm on the ventral forearm using D-Squame tape (CuDerm, Dallas, 
TX). Consecutive tape-strips were used until transepidermal water loss (TEWL) values 
over 60 g/m2/h were reached and the skin had a shiny appearance.23 An AquaFlux 
AF200 (Biox, London, UK) was used to monitor the TEWL. To obtain SC after the 
16-day recovery period, 21 tape-strips were harvested at the regenerated site and a 
control site using polyphenylene sulfide tape (Nichiban, Tokyo, Japan). The first tape-
strip (tape 0) was discarded. An infrared spectrum was recorded after each second 
tape-strip in order to examine the lipid organization (see below). 
Ex vivo human skin (SkinBaR) model
Ex vivo human skin was obtained from a local hospital, used within 12 hours after 
surgery, and handled according to the Declaration of Helsinki principles. The skin 
was cleaned, processed, stripped, and cultured as described before.13 SC was isolated 
and SC sheets were stored over silica gel under argon atmosphere until use for CER 
extraction or infrared spectroscopy (see below).
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Ceramide analysis by LC/MS
Lipid extraction, LC/MS measurements, and quantification of the tape-strips and 
SC sheets was performed as described elsewhere.18 The obtained tape-strips were 
punched to Ø 16 mm, and extracted using a modified 4 step Bligh and Dyer at 40°C. 
Extracts of tapes 5-8 were combined in one sample. After extraction and evaporation 
of the extraction solvents, samples were dissolved in heptane:chloroform:methanol 
(95:2.5:2.5)(v:v:v). CERs were analyzed using an Acquity UPLC H-class (Waters, 
Milford, MA) connected to an XEVO TQ-S mass spectrometer (Waters, Milford, MA). 
Processing and post-processing were performed as described before.18 The total molar 
amount of all CERs was determined quantitatively and used to calculate the molar 
percentage of each individual CER. The analyzed CER subclasses are depicted in 
Figure S1, synthetic CERs that were used for calibration are listed in Table S9.
SC lipid lateral organization and conformational ordering
FTIR was used to examine the SC lateral lipid organization and the conformational 
ordering of the SC lipids of in vivo and ex vivo skin samples.36 All FTIR spectra were 
recorded using a Varian 670-IR spectrometer (Agilent Technologies, Santa Clara, CA). 
For more details, see the Supplementary Methods.
Statistical analyses
SPSS (v23, IBM, New York, NY) was used for group-wise comparisons using LMMs 
with nested terms. LMMs were used because of the advantages of i) analysis of multiple 
variables and their interactions in one model, ii) advanced data pairing (e.g. multiple 
conditions within one subject) can be examined, iii) the ability to handle missing data, 
and iv) the use of nested variables. LMMs were used to examine differences between 
the CtrlIn-vivo and CtrlSkinBaR samples, and the change in the parameter (effect size) of 
culturing and regeneration of SC. For more details, see Supplementary Methods.
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Figure S1. Ceramides subclasses in the stratum corneum lipid matrix. CERs consist of a sphingoid base 
coupled to a FA, which can both vary in molecular structure. CERs are named according to their molecular 
structure. The sphingoid base can either be a sphingosine (S), dihydrosphingosine (dS), phytosphingosine 
(P), 6-hydroxysphingosine (H), whereas the acyl chain is either non-hydroxylated (N), α-hydroxylated (A), 
ω-hydroxylated (O), or esterified ω-hydroxylated (EO). Both the sphingoid base (blue) and the fatty acid 
chain (black) can vary in the number of carbon atoms.
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Parameter NS NP NH AS AP AH EOS EOP EOH OS OP OH
Intercept (CtrlIn-vivo) 9.6 22.4 16.6 4.7 11.8 13.9 4.3 0.8 2.4 0.5 0.1 0.7
Regenerated 5.4* -6.3* -1.9* 4.9* -2.0* 0.4 1.1* -0.1* 0.2 0.5* 0.2* 0.1*
SkinBaR -2.6 6.1* -0.8 -1.4 2.6 -3.5* -0.9 1.0* 0.4 -0.2 0.3* -0.3*
Cultured 8.8* -8.0* -1.9 5.6* -3.0* 0.2 0.2 -0.5* -0.6* -0.8* 0.0 0.3*
SkinBaR(Cul.(Reg)) 8.2* -0.0 -2.1 -0.8* -1.8 -3.0 -1.1* -0.4* -1.1* 0.7* -0.1 -0.1
Parameter EO O EO and O
Intercept (CtrlIn-vivo) 7.9 1.3 9.2
Regenerated 1.1* -0.8* 2.0*
SkinBaR 0.9 -0.2 0.6
Cultured -1.1* 1.2* 0.1







Table S1. Outcome of the linear mixed models for several CER subclasses. The intercept indicates the 
mol% of selected CER subclass in the CtrlIn-vivo situation. The effect size indicates the amount in mol% with 
which the variable changes the intercept. Multiple effect sizes can be added to obtain an estimate (see 
Supplementary Figure 5). * p<0.05.
Table S2. Outcome of the linear mixed models for CER subclasses EO and O. The intercept indicates the 
mol% of the CER subclasses in the CtrlIn-vivo situation. The effect size indicates the amount in mol% with 
which the variable changes the intercept. * p<0.05.
Table S3. Outcome of the linear mixed models for ceramide chain length. The intercept indicates the 
average number of carbon atoms of the CERs in CtrlIn-vivo situation. The effect size indicates the number of 





















Intercept (CtrlIn-vivo) -0.8 1.6 10.6 1.4 1.3
Regenerated 1.4* 1.2 1.8* 0.9 1.4
SkinBaR 0.1 1.4 -0.1 -0.7 -0.3
Cultured 1.4* 3.1* 0.5 0.2 0.7
SkinBaR(Cul.(Reg)) 1.3* -0.2 2.0 -0.2 1.3
Parameter Predicted MCL
Intercept 45.3
EO CER mol% 0.2*
C34 CER mol% -0.3*
Figure S2. Amount of C34 ceramides in the SC of the clinical study and SkinBaR models. The total amount 
of all CERs was set at 100%. Left: The level of C34 CERs as percentage of the total CER content. Right: The 
level of C34 CERs as mol% within each subclass. C34s in these subclasses could only be detected in SkinBaR 
samples and not in in vivo samples. Bars: mean ± SD.
Table S5. Outcome of the linear mixed models predicting the mean carbon chain length. The effect size 
indicates the change of the MCL relative to the intercept for a single variable. For example, add the effect size 
of EO CERs to the intercept for each mol% EO CERs in the sample (e.g. EO CER percentage for the sample 
is 9: add 9*0.2 to the intercept). * p<0.05.
Table S4. Outcome of the linear mixed models for C34 ceramides. The intercept indicates the average 
number of carbon atoms of the CERs in CtrlIn-vivo situation. The effect size indicates the mol% with which the 
















Figure S3. Residuals of the linear mixed model predicting MCL
Table S6. Outcome of the linear mixed models for mono-unsaturated ceramides in the SkinBaR SC 
conditions. The intercept indicates the level of MuCERs in the CtrlSkinBaR situation. The effect size indicates 
the change of the MuCER level relative to the intercept. * p<0.05.
Table S7. Outcome of the linear mixed models for lipid ordering in the SC matrix. The intercept indicates 
the average peak position of the stretching vibrations at 32°C in the CtrlIn-vivo situation. The effect size indicates 






Parameter Stretching peak 
position at 32°C
Intercept 2848.3
mol% C34 CERs (C34) 0.2*
mol% EO CERs (EO) 0.0
Ratio between CER subclasses 
((dS+P+H)/S)
0.1
Ratio between CER subclasses 
(N/A)
0.0
Table S8. Outcome of the linear mixed models predicting the peak position of the CH2 stretching peak 
of the FTIR spectrum. The effect size indicates the change of the MCL relative to the intercept for a single 
variable. For example, add the effect size of EO CERs to the intercept for each mol% EO CERs in the sample 
(e.g. C34 CER percentage for the sample is 3: add 3*0.2 to the intercept). * p<0.05.





For culturing the SkinBaR skin model the following chemicals and materials were used: 
Cyanoacrylate (Bison, Goes, the Netherlands) was locally purchased, DMEM, Ham’s 
F12, and penicillin/streptomycin were obtained from Fisher Scientific (Waltham, 
Massachusetts, USA), bovine serum albumin, sodium bromide, ethanol, acetone, 
trypsin, trypsin inhibitor, selenious acid, hydrocortisone, isoproterenol, L-carnitine, 
L-serine, insulin, α-tocopherol acetate, vitamin C, arachidonic acid, linoleic acid, and 
palmitic acid were purchased from Sigma-Aldrich (Zwijndrecht, the Netherlands). 
For SC lipid extraction and LC/MS analysis the following solvents were purchased: 
methanol and chloroform were obtained from Lab-Scan (HPLC grade, Gliwice, Poland), 
isopropanol and ethanol were bought from Biosolve (UPLC grade, Valkenswaard, 
the Netherlands), and heptane was acquired from Actu-All (HPLC grade, Oss, the 
Netherlands). The synthetic CERs listed in Table S9 were used as calibrators for LC/MS 
analysis. 
Ceramides
N(24)dS(18) 1 A(24)S(18) 1
N(18)dS(18) 1 A(R)(22)S(18) 1
N(24)dS(18) 1 A(R)(16)S(18) 1
N(24)S(18) 2 N(24)P(18) 2
N(22)S(18) 1 N(22)P(18) 2
N(20)S(18) 1 N(16)P(18) 2
N(18)S(18) 1 E(18:2)O(30)S(18) 2
N(16)S(18) 1 E(18:2)O(27)S(18) 2
N(24deu)S(18) 2 E(18:2)O(30)P(S18) 2
A(R)(24)P(18) 1 E(18:2)O(27)P(18) 2
1 Avanti polar lipids (Alabaster, USA)
2 Evonik Industries (Essen, Germany)
Inclusion and exclusion criteria for in vivo study
Prior inclusion, a dermatologist checked whether the volunteer was eligible for 
participation. Exclusion criteria were: (history of) dermatological disorders, chronic 
inflammatory disease, use of systemic drug therapies, abundant hair or unnatural 
abnormalities on the ventral forearm, (history of) drug abuse, and pregnancy. 
Table S9. Synthetic ceramides that were used as calibrators for LC/MS analysis. Numbers in brackets 






Stratum corneum isolation from ex vivo skin
SC was isolated from the ex vivo skin samples by placing the skin overnight in a 0.1% 
trypsin solution in PBS (pH 7.4) and 1 hour at 37°C. Subsequently, the SC was peeled 
off, washed in 0.1% trypsin inhibitor solution, and twice in Millipore water.
FTIR analysis
All measurements were performed on a spectrometer equipped with a broadband 
mercury-cadmium-telluride detector and cooled with liquid N2. Dry air constantly 
purged the sample compartments. Due to practical reasons, spectra for the in vivo SC 
and the SkinBaR SC were collected in reflection and transmission mode, respectively. 
In vivo samples: In order to measure the lipid organization in the SC on the arms of the 
volunteers, attenuated total reflection FTIR (ATR-FTIR) was used. The spectrometer was 
connected to an external ATR accessory with a single reflection diamond (GladiATR, 
PIKE technologies, Maddison USA). Each spectrum was an average of 150 scans with 
a spectral resolution of 2 cm-1 measured at skin temperature. The instrument software 
Resolutions Pro 4.1 (Agilent Technologies) was used for data treatment. The center 
of gravity of the CH2 symmetric stretching peak was determined at 90% of the peak 
height to determine the lateral ordering of the lipids. The centers of gravity 5 spectra 
were combined (e.g. after tape 2-10, and after tape 12-20) for analysis. The lateral lipid 
packing was analyzed by using the CH2 scissoring vibrations. The full width at half 
maximum (FWHM) was determined in the second derivative of the spectra. Again, 5 
spectra were combined for analysis.
SkinBaR samples: 24 hours prior to data collection, the isolated SC sheets were hydrated 
over a 27% NaBr solution in D2O at room temperature. After hydration, the SC sheet 
was sandwiched between two AgBr-windows and measured in transmission mode. 
During the measurement, the sample temperature increased from 0 to 90°C. Spectra 
were recorded during 2 minutes at a 1°C interval, and as a co-addition of 128 scans 
using 1 cm-1 resolution. The center of gravity of the CH2 symmetric stretching peak at 
skin temperature (32°C) was determined as described above. The lateral lipid packing 
was determined from the CH2 rocking vibrations. 
Statistical analysis
Linear mixed models were used in order to compare the means of several variables 
regarding CER composition and lipid organization between the five sample groups. 
The linear mixed models in this paper are used to calculate the effect sizes of the 
conditions ‘Cultured’ and ‘Regenerated’ compared to the controls. The formula 
y=a1x1+a2x2+…anxn+b is used, in which ‘a1’, ‘a2’ and ‘an’ are effect sizes, ‘b’ is the 
intercept (= calculated mean of control situation), each ‘x’ depicts a specific condition, 
and ‘y’ is the calculated mean of the variable in the sample group. 
The conditions ‘SkinBaR’, ‘cultured’, and ‘regenerated’ are included in the model to 
calculate the mean of each sample group. Each condition can either be 1 (yes) or 0 
(no), e.g. CtrlIn-vivo samples are not cultured (0), not regenerated (0), and not SkinBaR 
model (0), and are therefore described by the intercept. In order to obtain the value for 
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the regenerated samples of the in vivo study (RegIn-vivo), add the value for ‘Regenerated’ 
to the intercept. Similarly, add the value of ‘SkinBaR’ to the intercept to obtain the 
estimate for the CtrlSkinBaR samples. Since CulSkinBaR samples are described by both 
cultured and SkinBaR, both values of ‘SkinBaR´ and ‘Cultured’ need to be added to 
the intercept.
The RegSkinBaR samples are per definition also cultured (no non-cultured regenerated ex 
vivo samples exist). Therefore, a nested term was created in which this connection is 
described. So, RegSkinBaR samples are cultured (1), regenerated (1), SkinBaR model (1), 
and cultured(regenerated) (=nested term; 1), and thus all effect sizes need to be added 
to the intercept in order to obtain the correct calculated mean value. The nested term 
is also used to describe the difference between the effect sizes of RegIn-vivo samples and 
RegSkinBaR samples, since the effect size does not need to be similar. For an example 
calculation, see Figure S5.
To obtain a predictive model for the CH2 stretching peak position, a simple linear 
mixed model was build using summarizing lipid parameters as covariant. We chose 
variables that have previously been used or are expected to affect the lipid ordering. 
C34 and EO percentage were chosen, as both have been related to lipid organization1 
and they are predictors of the average chain length1 therefore omitting the mean chain 
length in the model. Ratios between the subclasses have been shown to affect the lipid 
organization.2-4 Here, two ratios were chosen that are expressions of sphingoid bases, 
as EO ceramides are included as a separate factor these were left out of these ratios. 
The model uses these 4 parameters as covariant and has intercept set as a random 
variable of sample donor.
Figure S5. Sample overview and explanation of linear mixed models with example calculation. Linear 
mixed models were used to interpret the data described throughout this paper and to compare outcomes 
between the different sample types. In all cases, the values obtained from the control site in the in vivo 
study (CtrlIn-vivo) are indicated by the intercept. All other values are changes relative to the intercept. Example 
calculations show the level of CER NS in each sample group with values obtained from the linear mixed 
model described in Table S1. P-values below 0.05, depicted by * in tables S1-S8, indicate a significant 
change compared to the CtrlIn-vivo (=intercept). All intercepts were statistically different from 0, and therefore 
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dFA Perdeuterated fatty acid
ELOVL Elongation of very long chain fatty acids





Form(d)FA16 FA formulation with (deuterated) palmitic acid
Form(d)FA18 FA formulation with (deuterated) stearic acid
Form(d)FA22 FA formulation with (deuterated) behenic acid
FTIR Fourier transform infrared spectroscopy
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TEWL Transepidermal water loss
VC Vernix caseosa
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In several skin diseases both the lipid composition and organization in the stratum 
corneum (SC) are altered which contributes to the impaired skin barrier function 
in patients. One of the approaches for skin barrier repair is treatment with topical 
formulations to normalize SC lipid composition and organization. Vernix caseosa, a 
white cheesy cream on the skin during gestational delivery, has shown to enhance 
skin barrier repair. In the present study, we examined how a fatty acid containing 
formulation mimicking the lipid composition of vernix caseosa interacts with the lipid 
matrix in the SC. The formulation was applied on ex vivo human skin after SC removal. 
Subsequently, the ex vivo human skin generated SC during culture. The effect of fatty 
acid (FA) containing formulations on the lipid organization and composition in the 
regenerated SC was analyzed by Fourier transformed infrared (FTIR) spectroscopy 
and liquid chromatography/mass spectroscopy (LC/MS), respectively. FTIR results 
demonstrate that the FAs are intercalated in the lipid matrix of the regenerated SC 
and partition in the same lattice with the endogenous SC lipids, thereby enhancing 
the fraction of lipids forming an orthorhombic (very dense) packing in the SC. LC/MS 
data show that the topically applied FAs are elongated before intercalation in the lipid 




Stratum corneum (SC) forms the main barrier for diffusion of compounds through the 
skin. This upper skin layer consists of corneocytes, embedded in a lipid matrix.1 The 
main lipid classes in SC are free fatty acids (FAs), ceramides (CERs), and cholesterol 
(CHOL).2-4 In between the corneocytes, lipids are organized in lamellae forming 
either a long periodicity phase or short periodicity phase.5-7 In these lipid lamellae, 
lipids are assembled in either a dense orthorhombic packing, a less dense hexagonal 
packing or a loosely packed liquid phase, also referred to as the lateral packing8-12, see 
Supplementary Figure 1. In healthy subjects, the majority of the lipids adopts the dense 
orthorhombic packing.9 
The skin barrier function is decreased in multiple skin diseases, e.g. lamellar ichthyosis, 
psoriasis, Netherton syndrome, and atopic dermatitis (AD).13 For instance, AD is a very 
common disease characterized by clinical features such as red, dry and itchy skin, 
in which the correlation between SC lipid organization and skin barrier function is 
extensively described.14 Evidence has been reported that the reduction in lipid chain 
length in SC of lesional and non-lesional skin of AD patients correlated with this 
reduced skin barrier function.15-18 Related to these changes in composition, lipids in 
SC of AD patients adopt a more hexagonal lateral lipid packing compared to healthy 
skin.19 Changes in lipid organization and barrier function are also observed in other 
skin diseases.13 It might be possible to restore skin barrier defects and optimize lipid 
composition and organization with topical application of lipid formulations. 
To develop topical formulations to treat impaired skin barrier, often animal skin or 
clinical studies are used as no proper ex vivo skin models are available. However, 
this is far from optimal because animal skin is different from human skin20 and in a 
formulation development phase only a limited number of formulations can be tested 
in clinical settings. Therefore, recently an ex vivo human skin barrier repair (SkinBaR) 
model has been developed that can be used to study the effect of formulations on skin 
barrier repair.21 In this model, the SC is removed by stripping. Subsequently, stripped 
skin is cultured during which the skin generates SC. The regenerated SC of this model 
has several characteristics in SC lipid composition and organization mimicking AD, 
e.g. an increased level of lipids forming a hexagonal packing and an altered CER profile 
that in several aspects mimics the CER subclass composition observed in lesional and 
non-lesional AD skin.21 Furthermore, recently it has been observed that the level of 
shorter chain length CERs is increased in this ex vivo model mimicking that in SC of 
AD patients.22
In previous studies, topical formulations were developed based on vernix caseosa 
(VC), a white cheesy film which is formed during the last trimester of pregnancy. VC 
contains the barrier lipids FAs, CERs, and CHOL in addition to sterol esters, wax esters, 
triglycerides, and squalene and has been shown to enhance barrier repair in mice.23-25
Because of the barrier repair properties of VC, we question whether VC components 
form an extra layer on the skin surface or will be incorporated in the SC lipid matrix 
during barrier repair. To study this, synthetic perdeuterated and protiated fatty acids 
(dFAs and FAs, respectively) in a formulation mimicking many aspects of the VC, 
referred to in this paper as FA formulation, were applied on the SkinBaR model and the 






FAs are incorporated in the SC lipid matrix and that FAs with a shorter chain length 
are elongated.
Materials and methods
Composition of FA formulations
Formulations consist of super sterol esters, Miglyol 812 (triglycerides), squalene, 
CHOL, and FAs in a weight ratio of 50.5, 37.6, 6.7, 3.7, and 1.5%, respectively. With 
regard to FAs, formulations contained either palmitic acid (FA16), stearic acid (FA18) or 
behenic acid (FA22). FAs were either protiated or perdeuterated. The control formulation 
contains all lipids except FAs. For preparation and application of formulations see 
supplementary material. 
Preparation and culturing of ex vivo skin
Human abdomen or mamma skin was obtained after surgery from a local hospital 
and handled according to principles of the Declaration of Helsinki. Ex vivo skin was 
used within 12 hours after surgery. Subcutaneous fat was removed, the skin was wiped 
with 70% EtOH and Millipore water, and dermatomed to a thickness of 600 µm (Deca 
Dermatome, DePuy Healthcare, Leeds, UK). SC was removed by sequential stripping. 
By using 6-8 strips, the skin became shiny indicating most of the SC was removed. After 
stripping of SC, the skin was cultured as described in the supplement. 
Studies were performed with 5 different conditions at least in triplicate:
i) Native skin (non-cultured)
ii) Cultured skin
iii) Stripped and cultured skin
iv) Stripped and cultured skin + control formulation
v) Stripped and cultured skin + FA formulations containing either protiated or 
deuterated a) FA16, b) FA18, or c) FA22 (Form(d)FA16, Form(d)FA18, and Form(d)FA22, 
respectively)
After 8 days of culturing, skin was harvested and processed for embedding in paraffin, 
cryofixation in Tissue-Tek O.C.T.TM (Sakura Finetek Europe B.V., Alphen aan den Rijn, 
The Netherlands), and SC isolation (see supplement). 
Fourier transform infrared spectroscopy
Fourier transform infrared spectroscopy (FTIR) was used to examine the conformational 
ordering and lateral packing of the lipid matrix in native and regenerated SC with and 
without FA formulation. SC samples were hydrated at room temperature for 24 hours 
over a 27% NaBr solution in D2O, resulting in a final hydration level of around 20% 
in the SC. All FTIR spectra were recorded using a Varian 670-IR FTIR spectrometer 
(Agilent Technologies, Santa Clara, USA), equipped with a broadband mercury-
cadmium-telluride detector. For further details see supplement.
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Liquid chromatography mass spectrometry 
The lipid composition of SC was examined using liquid chromatography/mass 
spectrometry (LC/MS). Only saturated FAs with even carbon chain length were applied 
and analyzed.
Lipid extraction was performed on isolated SC samples using a modified Bligh and 
Dyer method (Boiten et al., unpublished observations). The lipids were stored in 
chloroform/methanol (1:2) at 4°C until use. The samples were analyzed using a LC/MS 
method optimized for detection of FAs. The detailed analysis method is described in 
the supplement.
All LC/MS data was analyzed and processed using MassLynx and TargetLynx software 
(V4.1 SCN951, Waters, USA).
Statistical analysis
One-way ANOVA with Tukey multiple comparisons post-hoc test was used to analyze 
the data using GraphPad Prism 6 software (Graphpad software Inc., San Diego, CA, 
USA).
Results
FAs from formulations are incorporated in newly formed SC 
To determine conformational ordering of the lipids, thermotropic behavior was 
examined of CH2 symmetric and CD2 asymmetric stretching vibrations in the FTIR 
spectrum. When the chains are fully extended and show a high conformational 
ordering, peak positions of the CH2 and CD2 stretching vibrations in the FTIR spectrum 
are below a wavenumber of 2850 and 2195 cm-1, respectively. When the lipids show 
conformational disordering (e.g. if lipids are assembled in a liquid state), peak positions 
are shifted to wavenumbers higher than 2852 and 2196 cm-1 for CH2 symmetric and 
CD2 asymmetric stretching vibrations, respectively. The onset transition temperature 
at which the ordered-disordered shift starts can be determined from the thermotropic 
response. Peak positions of stretching vibrations are plotted against temperature. Two 
linear regression lines were fitted to the linear parts before and after the onset of the 
ordered-disorder transition, and the intercept of the two lines was determined. This 
procedure was used for both SC samples and formulations alone.
Figure 1A depicts CD2 asymmetric stretching vibrations of FormdFA16, FormdFA18, and 
FormdFA22 as a function of temperature. All three formulations are disordered already at 
20°C, but some ordering is observed in FormdFA22 at low temperatures.
CD2 and CH2 stretching vibrations of control SC and after topical application of 
FormdFA16, FormdFA18, or FormdFA22 on stripped skin are plotted in Figure 1B-E. 
We first focus on CH2 stretching vibrations of native and regenerated SC. These 
show a small shift at around 40°C attributed to the orthorhombic to hexagonal phase 
transition.26 A further increase in temperature results in a shift in the spectrum due 






Figure 1. Peak positions of CH2 symmetric 
stretching and CD2 asymmetric stretching 
vibrations of FTIR spectra plotted as a function 
of temperature. A) Asymmetric stretching 
vibrations of CD2 groups in FormdFA16, FormdFA18, 
and FormdFA22 start at 0°C with a frequency of 
2196.8, 2195.6 and 2194.7 cm-1, respectively. 
This indicates that dFA16 in the formulation 
adopts a liquid packing already at low 
temperatures. For FormdFA18 and FormdFA22, the 
dFAs show some ordering at low temperatures. 
The CD2 stretching vibrations show a shift in 
wavenumber reaching a wavenumber of 2197 
cm-1 indicating a transition to a more disordered 
state. B) The CH2 symmetric stretching 
vibrations of native SC and regenerated SC show 
a small shift at around 40°C (orthorhombic to 
hexagonal phase transition). Another phase 
transition from ordered to disordered is 
observed at around 60-70°C. C-E) SC on which 
FormdFA16, FormdFA18, or FormdFA22 was applied, 
respectively. CH2 stretching vibrations show a 
similar profile as native SC and regenerated SC. 
CD2 stretching vibrations of the formulations 
show a wavenumber of around 2194 cm-1 
at 0°C, increase gradually to around 2195 
cm-1 at approximately 60°C, followed by a 
steep increase to circa 2197 cm-1 at 90°C. 
F) Onset temperature of ordered-disordered 
phase transition of SC lipids of regenerated SC 
determined by thermotropic response of CH2 
or CD2 stretching vibrations with and without 




transitions are also observed in the same temperature ranges in regenerated SC on 
which FA formulations were applied (Figure 1C-E, open circles).
When focusing on the CD2 asymmetric stretching vibrations in the FTIR spectrum, the 
ordered-disordered phase transition is located at around 60°C. 
Figure 1F shows temperatures at which the ordered-disordered transitions start. 
Onset transition temperatures are obtained from CH2 symmetric and CD2 asymmetric 
stretching vibrations. As indicated in the table, the temperature at which the transition 
starts is highest in native SC. After stripping and regeneration, with or without a 
formulation, the onset temperature of the ordered-disordered transition are comparable, 
but significantly lower than in native SC. Onset transition temperatures of regenerated 
SC and SC with various formulations were not statistically significant different from 
each other (see Supplementary Figure 3). 
Onset transition temperatures of the ordered-disordered phase transitions obtained from 
CD2 stretching vibrations of dFA in the topically applied formulations were compared 
to those obtained from CH2 stretching vibration of the corresponding SC. There was no 
significant difference between CH2 and CD2 onset transition temperatures indicating 
that the thermotropic response of the protonated and deuterated stretching vibrations 
are very similar. 
Topically applied deuterated FAs and protiated SC lipids participate in one lattice 
The lateral organization of the lipids in the SC was analyzed using CH2 rocking vibrations 
of FTIR spectra in a range from 0 to 90°C. Lipids adopting a hexagonal packing display 
only one vibration in the rocking mode in the FTIR spectrum at a position of around 
719 cm-1. When lipid chains assemble in an orthorhombic packing, adjacent chains 
in rocking modes interact via short-range coupling, resulting in splitting of contours. 
This results in two peaks at wavenumbers 719 and 730 cm-1. When deuterated chains 
participate in the same lattice as the protiated chains, deuterated chains interfere 
resulting in a reduction of short-range coupling and thus a reduction in intensity or 
even a disappearance of the 730 cm-1 peak. All spectra of SC samples are displayed 
with a similar ratio between the lowest point at around 715 cm-1 and the top at around 
719 cm-1. 
The FTIR spectrum of regenerated SC (Figure 2A) shows a reduction in intensity of the 
730 cm-1 band at 0°C compared to native SC (Supplementary Figure 5), indicating a 
reduced level of lipids adopting an orthorhombic lipid packing. The 730 cm-1 band 
starts to decrease in intensity at 20°C and disappears at around 42°C demonstrating a 
shift in phase transition to a lower temperature range than in native SC. 
In order to investigate whether formulations with only protiated lipids increased the 
lateral packing density, these formulations were applied on the SkinBaR model. As 
can be observed in Figure 2C, CH2 rocking vibrations in the FTIR spectrum of SC 
after application of FormFA16 shows a strong peak at 719 cm-1 and a less strong peak 
at 730 cm-1, even relatively lower than in regenerated SC. However, after topically 
applying FormFA18 and FormFA22 (Figure 2E/G) the relative intensity of the band at 730 
cm-1 compared to that of the 719 cm-1 band is higher, indicating that these FAs increase 
the level of lipids forming an orthorhombic packing. FormFA22 has the strongest increase 






Figure 2. FTIR spectra showing CH2 rocking vibrations of SC lipids with and without topical application of 
FA formulation, as a function of temperature (0-60°C). A) regenerated SC, B) regenerated SC with topical 
application of control formulation, C-H) regenerated SC with topical application of C) FormFA16, FormdFA16, E) 
FormFA18, F) FormdFA18, G) FormFA22, and H) FormdFA22, respectively. 
Figure 3. FTIR spectra showing CD2 scissoring vibrations of SC lipids after application of FA formulation 
containing dFAs as a function of temperature (0-60°C). A) FormdFA16, B) FormdFA18, C) FormdFA22.
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presence of FAs in the formulation. After application of control formulation the relative 
intensity of the 730 cm-1 band is lower than in regenerated SC (Figure 2B), while the 
relative intensity of the 730 cm-1 band after topical application FormFA22 is comparable 
to that of regenerated SC.
The next question is whether topical FAs are partitioning in the same lattice as SC lipids 
or that applied FAs form separate orthorhombic domains in the lipid matrix. In order 
to investigate this, rocking vibrations were also examined after topical application of 
formulations with dFAs. For all three formulations containing dFAs the relative peak 
intensity of the band at 730 cm-1 is decreased compared to the formulations with the 
respective protiated FAs (Figure 2D/F/H). However, for FormdFA16, the relative intensity 
of the peak at 730 cm-1 is also lower than in regenerated SC.
The reduced intensity of the 730 cm-1 band in the spectrum suggests that dFAs from the 
formulation are not forming separate domains, but are partitioning in one lattice with 
protiated lipids from the SC. 
To confirm the incorporation of dFA in the lipid matrix, CD2 scissoring vibrations were 
also examined. A doublet at peak positions of around 1086 and 1090 cm-1 indicates 
phase separated orthorhombic domains, a singlet at around 1088 cm-1 denotes that 
short-range ordering between the deuterated chains does not occur demonstrating 
partitioning of deuterated lipids in the same lattice as SC lipids. In Figure 3, the singlet 
scissoring vibration at around 1088 cm-1 indicates a mixing between deuterated lipids
and protiated skin lipids, as pure FA16, FA18 and FA22 assemble in an orthorhombic 
lateral packing. 
Topically applied deuterated FAs are elongated in the epidermis 
We analyzed topical application of FormdFA16, FormdFA18, and FormdFA22 to examine 
whether dFAs are used in epidermal lipid biosynthesis. Using LC/MS it was demonstrated 
that dFA16 was present in substantial levels. Interestingly, dFA16 with an elongated 
protiated chain were observed (Figure 4), showing a similar profile as endogenous FAs 
with the most abundant chain lengths FA24D31 and FA26D31 (elongated with eight and ten 
CH2 groups, respectively). 
Topical application of FormdFA18 also resulted in elongation of deuterated lipids. 
However, dFA18 has 35 deuterated ions which overlaps with the chloride adduct of 
the endogenous FA and cannot be fully separated (difference in retention time of 0.06 
min). No elongation was observed after addition of FormFA22.
Discussion and conclusion
The skin barrier function of for instance AD patients is reduced, as indicated by e.g. 
transepidermal water loss (TEWL) values that are significantly higher in lesional and 
non-lesional skin than in healthy skin.27-30 Several studies report differences in lipid 
composition in lesional and non-lesional AD skin compared to control skin. This 
concerns both chain length and levels in subclasses of CERs and FAs.15,31,32 In more 
recent papers it was described that an increase in TEWL in lesional and non-lesional 






patients, thereby reducing the level of lipids adopting an orthorhombic packing.16,17,33 
These results suggest that normalizing lipid composition and organization in the skin 
barrier offers a possibility to improve the skin barrier. We selected a FA formulation 
based on VC, which contains barrier lipids CER, FA and CHOL. In previous studies, 
it was shown that natural and synthetic VC applied on mouse skin from which the SC 
was removed enhanced barrier repair as monitored by TEWL.23,25 In the present study, 
we examine whether FAs incorporated in the formulation affect lipid organization and 
composition in human SC after topical application. For this reason, no CERs were 
included in the present formulation. 
Since the number of formulations that can be screened in a clinical setting is limited, 
alternatives mimicking the in vivo situation as closely as possible are required. For drug 
formulations animal studies are sometimes performed, whereas this is not allowed for 
cosmetic ingredients and final products in the EU. Furthermore, animal skin is different 
from human skin regarding morphology and barrier properties.20 As an alternative, to 
screen topical formulations on enhancing skin barrier repair, recently we developed 
the SkinBaR model.21 This model is based on ex vivo human skin from which SC was 
removed. As previously reported, after 8 days of culture during which SC regenerates, 
the viable epidermis shows normal expression of early and late differentiation markers. 
This indicates that this model may serve as an alternative for clinical studies to monitor 
the effect of formulations on skin barrier repair. 
The SkinBaR model has several features that mimic lipid composition and organization 
of AD skin, namely i) the fraction of lipids in a hexagonal packing is increased at the 
expense of lipids in an orthorhombic lateral packing19,34, ii) the levels of CER subclasses 
NS, EOS and AS are increased compared to native skin.15,17
In this study, FTIR was employed using deuterated and protiated FAs in formulations to 
examine whether FAs are incorporated in the SC lipid matrix and whether FAs partition 
in the same lattice as SC lipids. To examine this, asymmetric CD2 and symmetric 
CH2 stretching vibrations of lipids in formulations and SC after application of these 
formulations were used. When formulations were applied on the SkinBaR model, 
CD2 asymmetric stretching frequency shift follows the temperature dependence of 
Figure 4. AUC of LC/MS peaks of dFAs after application of FormdFA16. Gray bars represent dFA16 and 
elongated FAs from FA22D31 and longer. Black bars represent endogenous FAs present in the SC lipid matrix. 
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CH2 frequency shift of protiated lipids in SC instead of that of only formulation, the 
transition of which is located at substantial lower temperatures. This is a first indication 
that applied dFAs after removal of SC are incorporated in the SC lipid matrix during 
SC regeneration. 
In order to obtain further evidence whether (d)FAs are incorporated in the same lattice 
as SC lipids, information on rocking frequencies was also required. After topically 
applying FA formulations with protiated FAs during SC regeneration, the relative 
intensity of the peak located at 730 cm-1 is increased compared to regenerated SC on 
which control formulation was applied. This increase in intensity is more substantial 
when topical formulations containing FAs with a longer carbon chain (compare 
FormFA22 with FormFA16) is applied. This suggests that after application of FA formulations 
an increased fraction of lipids form an orthorhombic organization in the SC matrix. 
However, it is also possible that applied FAs form separate domains within the SC lipid 
matrix. 
Therefore, the next question to answer is whether FAs from formulations are partitioning 
in one lattice with SC matrix lipids or form separate domains. A first indication is 
provided by the rocking vibrations after replacement of FAs by dFAs in the formulation: 
The relative intensity of the peak located at 730 cm-1 is decreased after application of 
dFAs compared to their protiated counterparts, indicating that short-range coupling of 
CH2 is disturbed by incorporation of dFA in the same lattice. To obtain more evidence, 
CD2 scissoring vibrations were also examined. Here it is very important to notice that 
pure FA16, FA18, and FA22 adopt an orthorhombic lateral packing and thus will have 
a doublet in the FTIR spectrum.35 In SC, only a singlet around 1088 cm-1 is observed, 
demonstrating that no phase separated FA domains are formed and that thus the lipids 
partition in one lattice with the SC lipids.
Until now, no information is available whether topically applied FA that are 
incorporated in the SC lipid matrix, are also modified by epidermal enzymes. In 
order to investigate this, LC/MS was employed. Using dFAs in the topical formulation 
enabled tracking of applied dFA and enzymatically modified products. No elongation 
of dFA22 was observed, suggesting that this FA remains in the regenerated SC and does 
not reach the viable epidermis. However, very interestingly, addition of dFA16 resulted 
in elongation of dFA with 6 or more carbon atoms up to a chain length of at least 30 
carbon atoms. However, elongation products with 18 and 20 carbon atoms were not 
observed. The most abundant elongation product has 24 carbon atoms, of which 16 are 
deuterated, which is in accordance with the most abundant FA in SC of healthy skin.16 
These results confirm that lipids from the formulation are not only incorporated in 
regenerated SC, but are also used in lipid synthesis of the newly formed SC lipid matrix. 
Furthermore, this indicates that elongation of applied dFA16 is performed similarly to 
that of endogenous FA16. In healthy skin, FA16 is produced de novo or obtained from 
the diet and elongated to FA18 by the enzyme elongase 6 (ELOVL6). Subsequently, 
FA18 is further elongated by ELOVL1 and ELOVL4, to chain lengths up to C28:0, and 
>C30:0, respectively.36,37 Our results suggest that ELOVL1, 6, and possibly ELOVL4, 
are able to elongate not only endogenous protiated FAs, but also topically applied 
(partially) deuterated exogenous FAs. Furthermore, the results suggest that elongation 
of FA16 by ELOVL6 is the rate limiting step, since FA16 is present but the elongation 






that dFAs used as medium supplement during generation of human skin equivalents 
are incorporated in SC of the generated skin.38 Both studies indicate that elongation 
of exogenous FAs is possible. However, this study shows a new approach for barrier 
repair by topical formulations.
The lamellar lipid organization was studied using small angle X-ray diffraction (results 
not shown). With this method it is possible to determine the repeat distances of the 
lamellar phases in SC. Our studies did not show major differences in lamellar repeat 
distance after application of formulations, indicating that the lamellar lipid organization 
is not influenced by topical application of this formulation. However, crystallization of 
the formulation was detected occasionally as indicated by a sharp peak in the profile. 
As the peak positions at the X-ray diffraction curve matched the peak positions of pure 
FAs sprayed on a membrane, this indicates that FAs in the formulations sometimes 
crystallize on the SC surface. This crystallization may be induced by the SC surface, 
since no crystallization is observed in the formulation itself. 
SC lipids of AD patients adopt a less orthorhombic lateral lipid packing compared to 
healthy skin19, which correlates with increased TEWL values in these patients.17 This 
illustrates the importance of the orthorhombic packing for the skin barrier function. In 
the present study we used the SkinBaR model, which resembles skin barrier diseases in 
several aspects.21 We showed that after topical application of FA formulations containing 
FAs on the SkinBaR model, an increased fraction of lipids adopt an orthorhombic 
packing compared to regenerated SC. Therefore, we can hypothesize that this FA 
formulation has the potential to enhance skin barrier repair in vivo in patients with a 
reduced orthorhombic packing, such as observed in AD patients. To the best of our 
knowledge, this is the first study reporting that topically applied FAs are incorporated 
in the SC lipid matrix, that the FAs participate in one lattice with endogenous lipids of 
newly formed SC, and that the FAs are involved in the epidermal lipid biosynthesis in a 
similar way as endogenous FAs. We demonstrate two different approaches, depending 
on FA chain length, that affect the SC lipid barrier using topical formulations: I) a 
slightly more pronounced presence of the orthorhombic packing induced by FA16, 
which is processed and partially elongated to increased chain lengths and II) we do not 
have evidence that FA22 become part of the epidermal lipid biosynthesis, however long 
chain FAs show a significant higher fraction of lipids adopting a orthorhombic lateral 
lipid packing. This is in line with previously reported results, showing an increase in 
abundance of FAs with chain length ≥22 carbon atoms is correlated with a reduced 
TEWL and a more ordered lateral lipid packing in SC of AD patients.16
We show that it is possible to improve skin barrier function by topical application of 
FAs. Therefore, future studies may focus on further optimization of the formulation by 
using combinations of barrier lipids and testing the formulation in a clinical setting. 
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Super sterol esters were kindly provided by Croda (Cowick Hall, UK), triglycerides 
(Miglyol 812) were supplied by Cremer Oleo (Witten, Germany). Perdeuterated palmitic 
acid was purchased from Sigma, perdeuterated stearic acid, perdeuterated behenic 
acid, and perdeuterated lignoceric acid were purchased from Cambridge Isotope 
Laboratories (Tewksbury, MA, USA). Cyanoacrylate (Bison, Goes, the Netherlands) 
was bought locally. Haematoxylin was obtained from J.T. Baker (Anvator, Center 
Valley, PA, USA). Xylene was obtained from Biosolve (Dieuze, France), 4% buffered 
formaldehyde was purchased from Added Pharma (Oss, the Netherlands), paraffin was 
acquired from Klinipath (Duiven, the Netherlands). DMEM, Ham’s F12, and penicillin/
streptomycin were purchased from Fisher Scientific (Waltham, Massachusetts, USA). 
Squalene, cholesterol, eosin, bovine serum albumin, sodium bromide, ethanol, 
acetone, trypsin, trypsin inhibitor, selenious acid, hydrocortisone, isoproterenol, 
L-carnitine, L-serine, insulin, α-tocopherol acetate, vitamin C, arachidonic acid, 
linoleic acid, palmitic acid, stearic acid, behenic acid, myristic acid, arachidic acid, 
tricosylic acid, lignoceric adic, cerotic acid, montanic acid, melissic acid, oleic acid, 
linoleic acid, linolenic acid, gondoic acid, erucic acid, and acetic acid were purchased 
from Sigma-Aldrich (Zwijndrecht, the Netherlands). Myristoleic acid and palmitoleic 
acid were purchased from Fluka (Buchs, Zwitserland). 2-Hydroxydocosanoic acid, 
22-Hydroxydocosanoic acid, 2-Hydroxytricosanoic acid, and 2-Hydroxytetracosanoic 
acid were bought from Larodan (Solna, Sweden). Pentacosylic acid was purchased 
from TCI Europe (Zwijndrecht, Belgium). Acetonitrile, methanol, and 2-Propanol were 
purchased from Biosolve (Valkenswaard, The Netherlands). Heptane was bought from 
Supplementary Figure 1. Lipid organization in the SC. A) Schematic overview of the skin, B) The corneocytes 
are embedded in the lipid matrix in a brick-and-mortar structure, C) The lipids in the matrix are stacked in 
lamellae in between the corneocytes, D) Detail of the lipid lamellae, E) Perpendicular to the lamellae, the 




Actu-All Chemicals (Oss, The Netherlands), Chloroform was obtained from Macron 
Fine Chemicals (Gliwice, Poland), and Ultra purified water was obtained from Purelab 
Ultra purification system (Elga Labwater, High Wycombe, UK). All solvents were HPLC 
grade or higher.
Preparation of formulations
Formulations were prepared as follows: FAs and CHOL were dissolved in 
chloroform:methanol (2:1), super sterol esters were dissolved in chloroform and 
squalene was dissolved in acetone; miglyol 812 was used undissolved. All components 
were pipetted in the required ratio in a small glass vial to achieve the predetermined 
composition and left to dry under a stream of nitrogen at 40°C for approximately 3 
hours. 
For homogeneous distribution of the lipids in the formulation, 100 mg of the lipid 
mixture was mixed for 5 minutes at 500 rpm by transferring it into a small mixing tube 
of a modified automatic ointment-mixer Topitec® (WEPA, Germany).1 
Stripping and culturing of ex vivo skin
The detailed stripping and culturing procedures are described in Danso et al.2 Briefly, 
dermatomed skin was punched in circles with a diameter of 26 mm and clamped in 
a custom made device. A metal cylinder with cyanoacrylate, both preheated to 40°C, 
was applied on the skin for 2 minutes with a pressure of 0.7 kg/cm2. The cylinder was 
removed in one stroke with attached to it a layer of SC. This stripping was repeated 
until the skin had a shiny appearance, indicating that most SC has been removed. 
Subsequently, the skin was placed in a deep 6-well plate on top of a cotton pad and 
a filter. A metal ring with an inner diameter of 15 mm is placed on top of the skin, 
in order for formulations to stay in the middle. FA formulations were spread over the 
back of a small metal vial (diameter 15 mm) and applied on skin by making rotating 
movements at day 0 of the culturing period. A single dose of about 5 mg/cm2 was used 
and left on the skin for the full culturing period of 8 days.
Subsequently, the skin is cultured to regenerate SC for 8 days at 37°C, 90% relative 
humidity and 7.2% CO2. The culture medium is described in Danso et al.2 and was 
refreshed twice a week. 
Isolation of SC
SC was isolated from cultured skin using trypsin digestion. The skin was incubated 
overnight in 0.1% trypsin solution in PBS at 4°C and subsequently at 37°C for one 
hour. SC was peeled off and placed in 0.1% trypsin inhibitor solution in PBS. SC sheets 
were washed twice in Millipore water. SC was stored over silica gel under argon in the 







Fourier transform infrared spectroscopy
Hydrated SC samples were placed between two AgBr-windows and measured in 
transmission mode. SC samples were put under a purge of continuous dry air starting 30 
minutes before data acquisition. Spectra were acquired as a co-addition of 256 scans at 
1 cm-1 resolution during 2 or 4 minutes. The sample temperature was increased from 0 
to 90°C (for samples containing only formulations 0 to 60°C) at a heating rate of 0.25 
or 0.5°C/min. Resolutions Pro 4.1 (Varian Inc.) software was used to calculate CH2 and 
CD2 rocking, scissoring, and symmetrical and asymmetrical stretching vibrations using 
deconvolution.3
Liquid chromatography mass spectrometry 
Two ions per FA were analyzed, namely [M-H]- and [M+Cl]-. Lipid samples were 
dissolved in isopropanol. Sample concentrations were set between 1 and 2 mg/ml total 
lipid. 2 µl of each sample was injected and separated using a reverse phase column 
(Purospher Star LiChroCART, 55x2 mm i.d., 3 µm particle size, Merck (Darmstadt, 
Germany)). A gradient solvent system was used from acetonitrile/water/chloroform/
acetic acid (90:10:2:0.005) to methanol/heptane/chloroform/acetic acid (90:10:2:0.005) 
at a flow rate of 500 µl/min using a Waters Acquity UPLC H-class system (Waters, 
Milford, MA, USA). The UPLC was coupled to a mass spectrometer Waters XEVO 
TQ-S (Waters, Milford, MA, USA) equipped with an atmospheric pressure chemical 
ionization source (probe temperature: 425°C), scanning in negative ion mode using 




Supplementary Figure 2. Morphology of A) native human skin, B) stripped and cultured skin, C-F) stripped 
and cultured skin on which control formulation, FormdFA16, FormdFA18, and FormdFA22 were applied, respectively. 
After culturing the epidermis is slightly thicker compared to native skin and the basal layer is less neatly 
ordered. However, application of formulations did not influence morphology compared to stripped control 
demonstrating that the epidermis is viable after 8 days of culture with and without formulation applied. Scale 
bar: 50 µm
Supplementary Figure 3. Temperature 
at which the ordered-disordered 
transition of SC lipids starts. Per 
condition, calculated from FTIR peak 
positions of CH2 symmetric stretching 
vibrations, for native human and 
regenerated SC, and regenerated SC 
on which the FormFA16, FormFA18 and 
FormFA22 are applied. Native human 
skin had a significantly higher transition 
temperature compared to regenerated 
SC with or without formulations, which 







Supplementary Figure 4. FTIR spectra showing CH2 rocking vibrations of lipids in the formulations as 
a function of temperature (0-60°C). A) FormFA16, B) FormFA18, C) FormFA22, D) super sterol esters and the 
triglycerides at 0°C. Spectra of formulations show three peaks at temperatures below 20°C positioned at 720, 
723, and 729 cm-1. The peaks at 720 and 729 cm-1 indicate that lipids assemble partially in an orthorhombic 
packing. The contour at 723 cm-1 is also observed when triglycerides are examined individually. At elevated 
temperatures, only one band remains, indicative for a hexagonal or liquid lateral packing. Super sterol esters 
show a doublet positioned at around 719 and 730 cm-1. Triglycerides show a singlet at a wavenumber of 
723 cm -1.
Supplementary Figure 5. FTIR spectra showing CH2 rocking vibrations of 
native human skin as a function of temperature. At 0°C, lipids in native 
SC adopt an orthorhombic packing as indicated by two strong peaks at 
719 and 730 cm-1 in the spectrum. When increasing the temperature, 
the 730 cm-1 band starts to decrease in intensity at 34°C and disappears 
around 48°C, indicating the transition from orthorhombic to hexagonal 
lateral lipid packing.
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ELOVL Elongation of very long chain fatty acids
ESRF European synchrotron radiation facility
FA Fatty acid
FormBasic Basic formulation without CERs
FormCOMBI Formulation with CER EOS, CER NS, and FA22
FormEOS Formulation with CER EOS
Form(d)NS Formulation with (deuterated) CER NS
FTIR Fourier transform infrared spectroscopy
LPP Long periodicity phase
SAXD Small angle X-ray diffraction
SC Stratum corneum
SkinBaR Skin barrier repair
SPP Short periodicity phase
TEWL Transepidermal water loss
VC Vernix caseosa
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Purpose: To determine whether formulations containing ceramides (including a 
ceramide with a long hydroxyl acyl chain linked to a linoleate, CER EOS) and fatty 
acids are able to repair the skin barrier by normalizing the lipid organization in stratum 
corneum (SC). 
Methods: The formulations were applied on a skin barrier repair model consisting 
of ex vivo human skin from which SC was removed by stripping. The effect of 
formulations on the lipid organization and conformational ordering in the regenerated 
SC were analyzed using Fourier transform infrared spectroscopy and small angle X-ray 
diffraction.
Results: Application of the formulation containing only one ceramide on regenerating 
SC resulted in a higher fraction of lipids adopting an orthorhombic organization. A 
similar fraction of lipids forming an orthorhombic organization was observed after 
application of a formulation containing two ceramides and a fatty acid on regenerating 
SC. No effects on the lamellar lipid organization were observed.
Conclusions: Application of a formulation containing either a single ceramide or 
two ceramides and a fatty acid on regenerating SC, resulted in a denser lateral lipid 
packing of the SC lipids in compromised skin. The strongest effect was observed after 




One of the major roles of the skin is its protection against penetration of irritants, 
pathogens, and allergens, and prevention of excessive transepidermal water loss 
(TEWL) avoiding desiccation of the body. The skin barrier function is located in the 
uppermost epidermal layer, namely the stratum corneum (SC). SC consists of terminally 
differentiated corneocytes embedded in a lipid matrix. The main lipid classes present 
in the matrix are ceramides (CERs), fatty acids (FAs), and cholesterol (CHOL). This 
lipid matrix is important for a proper skin barrier function.1 The intercellular lipids 
are assembled in two lamellar phases, with a repeat distance of either 13 nm or 6 
nm, referred to as the long periodicity phase (LPP) and the short periodicity phase 
(SPP), respectively.2-6 Within these lamellar sheets, in healthy skin the lipids are mainly 
packed in an orthorhombic packing, while a small fraction of lipids adopts a hexagonal 
packing (Figure 1).7-10 In several inflammatory skin diseases, a higher fraction of the 
intercellular lipids assembles in a hexagonal packing, such as in atopic dermatitis 
(AD).11 This less dense lipid organization is associated with a reduction in lipid chain 
length in SC of AD patients and a reduced skin barrier function.11-14 As the lipids play a 
role in the reduced skin barrier, normalization of the lipid composition and organization 
may improve the skin barrier function. Normalization of the lipid organization may be 
achieved by topical application of lipid formulations.
Figure 1. Lipid organization in the SC. A) Schematic overview of the skin morphology, B) The corneocytes 
are embedded in the lipid matrix in a brick-and-mortar structure, C) The lipids in the matrix are stacked in 
lamellae in between the corneocytes, D) Detail of the lipid lamellae, E) Perpendicular to the lamellae, the 
lipids are organized in a lateral packing. This can be either orthorhombic, hexagonal, or liquid (from left to 
right), F) The lipid lamellae are stacked on top of each other with a repeat distance (d) of either 13 nm (LPP) 
or 6 nm (SPP), G) Molecular structure and nomenclature of the two CER subclasses used in these studies. 






Previously, topical formulations based on vernix caseosa (VC) were developed. 
VC is a white cream that is developed on the fetal skin during the last trimester of 
pregnancy. It serves as a lubricant during delivery and it protects the newborn’s skin 
from dehydration.15 VC contains barrier lipids CERs, FAs, and CHOL, but also other 
lipids such as super sterol esters, wax esters, squalene, and triglycerides. VC enhances 
skin barrier repair in mice.16,17
In order to select the most effective formulation for skin barrier repair, studies are 
required in which the compositions of the formulations need to be altered in a 
systematic way. When performing these studies in vivo, multiple clinical studies and/
or animal studies will be needed. This is very challenging as in clinical studies only a 
limited number of formulations can be investigated. Furthermore, animal skin is very 
different from human skin.18 Therefore, we developed an ex vivo skin barrier repair 
(SkinBaR) model.19 In this model, the SC is removed by stripping and subsequently 
regenerated during an 8-day culturing period. The regenerated SC of the SkinBaR 
model shows several features that are also observed in SC of AD patients, e.g. a higher 
fraction of lipids adopting a hexagonal lateral lipid organization and a CER profile that 
mimics the altered CER subclass composition in AD skin in several aspects.19 Using this 
model, the influence of topical formulations on the lipid organization and composition 
of the SC can be examined in in vitro settings. 
In this study, we used the SkinBaR model to examine whether two CERs of a VC based 
formulation remain on top of the SC, or are incorporated in the lipid matrix of the 
SC during repair, thereby improving the lipid organization. We used protiated and 
partially deuterated CERs. One CER subclass had a very long esterified ω-hydroxy 
acyl chain (Figure 1), referred to as CER EOS. The VC based formulation contains a 
basic formulation (FormBasic) and either a single CER subclass or both CER subclasses 
in combination with a FA. After regeneration of SC, the organization of the lipids 
in the matrix was examined. Our results demonstrate that the applied formulations 
containing a single ceramide are able to enhance the formation of an orthorhombic 
lateral packing and are, at least partly, incorporated in the SC lipid matrix. 
Material and methods
Composition and preparation of formulations
Two subclasses of synthetic CER were used in these studies (Figure 1). One CER subclass 
was the esterified ω-hydroxy acyl chain with 30 carbon atoms in the acyl chain linked 
to a sphingosine base (18 carbon atoms), referred to as CER EOS according to the 
classification of Motta et al.20 The other CER was composed of a non-hydroxy acyl 
chain of 24 carbon atoms linked to a sphingosine base (18 carbon atoms), referred to 
as CER NS. Deuterated CER NS (dCER NS) consists of a perdeuterated acyl chain and 
a protiated base. 
The basic formulation (FormBasic) contained a mixture of super sterol esters, triglycerides 
(Miglyol 812), squalene, and CHOL in a weight ratio of 13.6:10.1:1.8:1. This basic 
mixture is supplemented with either CER EOS, CER NS, or dCER NS. For the exact 
compositions of the formulations and the used abbreviations throughout this paper, see 
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Table 1. The use of dCER NS offers the opportunity to selectively detect the deuterated 
acyl chain of CER NS as CD2 vibrations in the infrared spectrum are shifted to lower 
wavenumbers compared to their protiated counterparts (also see below). In addition to 
the single CER component in the formulation, a formulation with both CER EOS and 
CER NS as well as a FA with a chain length of 22 carbon atoms (behenic acid; referred 
to as FA22) was prepared. Three variations of this formulation were made: i) all lipids 
were protiated, ii) dCER NS was used instead of CER NS, iii) dFA22 (perdeuterated 
chain) was used instead of FA22 (see Table 1). Finally, the basic formulation (FormBasic) 
without CER or FA was examined. 
The formulations were prepared by dissolving the lipids in either chloroform:methanol 
(2:1, used for CHOL, CERs, and FA22), chloroform (super sterol esters), or acetone 
(squalene). Triglycerides were used undissolved. In total 100 mg of the dissolved lipids 
and triglycerides were mixed in the required ratio in a small glass vial and left to dry 
under a stream of nitrogen at 40°C for approximately 3 hours. In order to distribute the 
lipids homogeneously in the formulation, the dried lipid mixture was transferred to a 
mixing tube modified for small scale purposes and mixed for 5 minutes at 500 rpm 
using a modified automatic ointment-mixer TopiTec® (WEPA, Germany).17,21





FormCOMBI 94.5 2 2 1.5
FormCOMBI(dNS) 94.5 2 2 1.5
FormCOMBI(dFA) 94.5 2 2 1.5
Preparation and culturing of ex vivo skin
Human skin was obtained after surgery from a local hospital according to principles 
of the Declaration of Helsinki, and used within 12 hours after surgery. Stripping and 
culturing procedures are described in the supplementary material. Formulations were 
applied in a single dose of about 5 mg/cm2 in a metal ring placed on top of the skin at 
day 0 of the culturing period by rotating movements with the back of a small metal vial 
(ø=15 mm) which was covered with one of the formulations (see Table 1). 
Subsequently, the skin was cultured for 8 days in an incubator during which the SC 
regenerated. The incubator conditions were 37°C, 90% relative humidity, and 7.2% 
CO2. The culture medium was refreshed twice a week. The composition of the medium 
has been described in Danso et al.19
Table 1. The names and composition of the various formulations used in this study. Numbers represent the 






Studies were performed at least in triplicate using the following conditions:
i) Stripped and cultured skin
ii) Stripped and cultured skin + FormBasic
iii) Stripped and cultured skin + FormEOS
iv) Stripped and cultured skin + FormNS or FormdNS
v) Stripped and cultured skin + FormCOMBI, FormCOMBI(dNS) or FormCOMBI(dFA)
Human skin from the same donor served as control. 
After culturing, the skin was harvested and either embedded in paraffin, or SC was 
isolated (see supplementary material). Isolated SC samples were used to examine the 
lipid organization or conformational ordering using either Fourier transform infrared 
spectroscopy (FTIR) or small angle X-ray diffraction (SAXD). Both methods are described 
in the supplementary material. FTIR provides information about the lateral packing and 
conformational ordering, while SAXD is used to obtain information about the lamellar 
organization.
Statistical analysis
T-test and one-way ANOVA with a multiple comparisons post-hoc test were used 
to analyze the data using GraphPad Prism 7 software (GraphPad software Inc., San 
Diego, CA, USA).
Results
Formulations do not influence the morphology of cultured skin
As can be observed in Figure 2, after culturing for 8 days, the epidermis of the stripped 
and cultured skin was slightly thicker than in native skin and the basal layer was less 
compact. The morphology of the stripped and cultured skin on which FormEOS, FormNS, 
and FormCOMBI were applied was comparable to the stripped and cultured skin without 
formulation. This indicates a viable epidermis after 8 days of culturing, also in the 
presence of a formulation. 
Figure 2. Morphology was examined using HE staining. A) Native human skin, B) Skin with stripped and 
cultured SC, C) Stripped and cultured skin on which FormEOS was applied, D) Stripped and cultured skin on 
which FormNS was applied, E) Stripped and cultured skin on which FormCOMBI was applied. Scale bar: 50 µm.
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Ceramides do not influence lateral organization of formulation
CH2 rocking vibrations in the FTIR spectra were analyzed in order to examine the 
lateral lipid organization. When lipids are assembled in a hexagonal packing, only 
one vibration at around 719 cm-1 is visible in the FTIR spectrum. When the lipids 
adopt a more dense orthorhombic lateral packing, short-range coupling occurs due 
to interactions of adjacent protiated chains which results in a splitting of the contours. 
In this case, two peaks are visible at around 719 and 730 cm-1. Deuterated chains 
participating in the same lattice as the protiated lipid chains interfere with the vibrations 
of the protiated chains, thereby reducing the short-range coupling. This is visible as a 
reduction in intensity or disappearance of the peak positioned at 730 cm-1. In order to 
be able to compare the intensity of the peaks, all spectra are displayed with a similar 
ratio between the lowest point at around 715 cm-1 and the top at around 719 cm-1.
First the spectra of the formulations will be reported. CH2 rocking vibrations of FormEOS, 
FormNS, and FormdNS showed a strong peak positioned at 719 and a weak peak at 730 
cm-1, indicating that a small fraction of lipids forms an orthorhombic lateral organization. 
Furthermore, a third peak was observed at a wavenumber of about 723 cm-1 (Figure 
3A-C). This peak can be attributed to the presence of the triglycerides, which showed 
a single peak of the CH2 rocking vibrations at a wavenumber of about 723 cm-1 (Figure 
3D). No differences were observed between the various formulations below 10°C. 
The contour at 730 cm-1 in all formulations started to decrease at a temperature of 
around 10°C and disappeared at 28°C in FormEOS and at 22°C in FormNS and FormdNS. 
This transition is indicative for the disappearance of the orthorhombic lateral packing. 
Above this temperature all formulation showed similar FTIR profiles. When analyzing 
FormBasic (no barrier lipids present), the FTIR profile was characterized by a doublet of 
which the peak at a wavenumber of 730 cm-1 disappeared between 10°C and 28°C 
(results not shown).
The profile of pure CER NS was characterized by a single peak located at around 719 
cm-1, whereas for pure CER EOS a doublet at around 719 and 730 cm-1 was observed 
which was still weakly present at 60°C (Supplementary Figure 1). However, both CER 
containing formulations and the control formulation showed a similar profile until 
10°C, indicating that the CERs do not influence the lateral packing of the formulation 
at low temperatures as far as it can be detected by FTIR. 
Conformational ordering of the lipids is not affected by ceramides in the formulation
The conformational ordering of the lipids was analyzed in order to examine the ordered-
disordered phase transition of the lipids in the formulations. This was determined by 
assessing the thermotropic behavior of CH2 symmetric and CD2 asymmetric stretching 
vibrations in the FTIR spectrum. When lipids show a high conformational ordering, 
indicating that the chains are fully extended, CH2 and CD2 stretching vibration peaks 
are positioned below a wavenumber of 2850 and 2195 cm-1, respectively. Peak 
positions increase to wavenumbers above 2852 and 2196 cm-1, respectively, when 
the lipids have a high conformational disordering, indicating the presence of a liquid 






of the formulations are plotted against temperature (Figure 4). The onset transition 
temperature was determined as described in the supplementary methods section. Figure 
4A shows the temperature dependence of FormBasic, FormEOS, and FormNS, which are 
very similar. At 0°C, the peak positions were located at a wavenumber of around 2849 
cm-1, indicating an ordered lateral lipid organization. The onset transition temperatures 
of the ordered-disordered transition of the formulations were approximately 9-10°C. 
At these temperatures, the CH2 symmetric stretching vibrations started to shift to a 
wavenumber of around 2853 cm-1 at 20°C. These increases in wavenumber were steep, 
representing an ordered-disordered transition. During a further rise in temperature, 
the CH2 stretching vibrations increased gradually until about 2855 cm-1 at 90°C. 
Figure 3. FTIR spectra showing CH2 rocking 
vibrations of lipids in formulations as a 
function of temperature (0-60°C). A) FormEOS, 
B) FormNS, C) FormdNS, and D) Triglycerides.
Figure 4. Peak positions of CH2 symmetric stretching vibrations and CD2 asymmetric stretching vibrations 
of FTIR spectra plotted as a function of temperature (0-90°C). A) CH2 symmetric stretching vibrations of 
FormBasic, FormEOS, and FormNS. B) Asymmetric CD2 stretching vibrations of the deuterated acyl chain of dCER 
NS and in FormdNS.
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Furthermore, a small shift in wavenumber was observed in the profiles of FormEOS 
and FormNS at around 50-60°C (see inset). This might be attributed to a change in 
conformational ordering of CER EOS and CER NS in the formulation (see below). 
The temperature dependence of the CD2 stretching vibrations of the deuterated acyl 
chain of pure dCER NS and in FormdNS is depicted in Figure 4B. At 0°C, the CD2 
asymmetric stretching peak positions of both FormdNS and pure dCER NS were located 
at 2194 cm-1. The onset transition temperatures were 53°C for FormdNS and 91°C for 
pure dCER NS. At these temperatures sharp increases in wavenumbers were observed 
until a wavenumber of around 2197 cm-1 was reached at 64°C and 100°C, respectively. 
The onset transition temperature of pure dCER NS was substantially higher than that of 
FormdNS, indicating that dCER NS interacts with the lipids in the formulation. However, 
the temperature of transition is not similar to that of the protiated chains indicating that 
dCER NS is not homogenously mixing with the other protiated components. 
Influence of topical formulation on lateral lipid organization of regenerated SC
The CH2 rocking vibrations in the FTIR spectrum of native SC showed two strong 
peaks positioned at 719 and 730 cm-1 (Supplementary Figure 2), indicative for an 
orthorhombic lateral packing of the lipids. Figure 5A displays CH2 rocking vibrations 
in the FTIR spectra of regenerated SC, which showed a contour with a strong intensity 
at around 719 cm-1 and a peak with a weak intensity at around 730 cm-1. This indicates 
that a higher fraction of lipids adopted a hexagonal lateral packing compared to native 
SC.
The formulations were applied on the SkinBaR model in order to examine if the 
CERs from the formulations are incorporated in the SC lipid matrix and furthermore if 
they participate in the same lattice as SC lipids. After FormEOS was applied during SC 
regeneration, the peak at 730 cm-1 had a stronger intensity (relative to the intensity of 
the 719 cm-1 peak) than that in the spectrum of regenerated SC, indicating a higher 
level of lipids adopting an orthorhombic lateral packing. After application of FormNS 
during regeneration of SC, the relative intensity of the peak at 730 cm-1 was slightly 
lower than after application of FormEOS, but higher than in the spectrum of the untreated 
stripped and regenerated SC. A gradual decrease of the peaks around 730 cm-1 occurred 
between 12°C and 32°C (regenerated SC), 20°C and 36°C (application of FormEOS), 
and 12°C and 24°C (application of FormNS). This indicates that the orthorhombic to 
hexagonal phase transition took place at lower temperatures than in native SC, but that 
the presence of CER EOS increased the transition temperature slightly.
The next question is whether CERs from the topically applied formulation form separate 
domains in the lipid matrix or that these CERs are partitioning in the same lattice 
as SC lipids. In order to examine this, CH2 rocking vibrations were examined after 
topical application of FormdNS (Figure 5D). The relative intensity of the peak located 
at 730 cm-1 was similar to the relative intensity of the peak visible after application 
of its protiated counterpart. This indicates that dCER NS does not partition in the 
orthorhombic domains. To examine the possibility that CER NS interacts with the 
hexagonal lateral domains, the temperature dependence of the lateral ordering of the 






Similar ordering of lipids in regenerated SC in presence or absence of a formulation
When monitoring the CH2 symmetric stretching vibrations of native, regenerated 
SC, and regenerated SC after application of formulations, very similar temperature 
dependence was observed (Figure 6A). A small shift in vibration frequency from 2849 
to 2850 cm-1 at around 30-40°C was observed in the spectra of native and regenerated 
SC, which is attributed to the orthorhombic to hexagonal phase transition. The start of 
the ordered-disordered phase transitions were observed at temperatures of 69.3°C ± 
4.0 (n=6) for native SC and 64°C ± 1.5 (n=7) for regenerated SC. The onset transition 
temperature after application of FormEOS was not affected compared to regenerated SC 
(62.8°C ± 2.0 , p=0.99 (n=3)), whereas after application of FormNS the onset transition 
temperature was significantly lowered to 58.0°C ± 3.6 (p=0.02 (n=3)).
Figure 6B depicts the temperature dependence of CD2 asymmetric stretching vibrations 
of regenerated SC on which FormdNS was applied. A gradual increase in wavenumber 
was observed between 0°C and 50°C. The onset transition temperature was 56°C 
and the end of the transition occurred at 71.0°C ± 1.9. This is a significantly higher 
temperature than for only FormdNS, which was 62.2°C (Figure 4B, p=0.03). This 
difference in temperature indicates that there is interaction between dCER NS from the 
formulation and the SC lipid matrix.
Figure 5. FTIR spectra showing CH2 rocking vibrations of SC lipids with and without topical application 
of formulation as a function of temperature (0-60°C). A) regenerated SC, B) regenerated SC with topical 




Combining CER and FA in the formulation
The final studies focused on a formulation in which both CER EOS and CER NS were 
included, as well as FA22 (FormCOMBI). First, the formulation was stored for a period 
of 6 months at room temperature during which the physical stability was examined 
at regular time intervals. Polarization microscopy and wide and small angle X-ray 
diffraction (WAXD and SAXD) were used to examine the physical stability. No 
crystals were observed in the microscopy images during and after 6 months of storage 
(results not shown). However, some “Maltese cross” were observed using polarization 
microscopy, which are indicative for lamellar structures. Additionally, diffraction 
patterns confirmed the presence of lamellar structures and showed that a fraction of 
lipids in the formulation adopted an orthorhombic lateral packing at room temperature. 
No additional peaks were observed, indicating that no crystals were present in the 
formulation (results not shown). 
The lateral lipid organization of FormCOMBI with only protiated lipids was examined 
using FTIR (Figure 7A). The contour at 730 cm-1 disappeared in the same temperature 
range as in FormEOS and FormNS. However, the relative intensity of the contour at 730 
cm-1 was higher compared to a formulation with only one CER subclass, indicating 
that a higher fraction of lipids adopted an orthorhombic lateral packing in FormCOMBI. 
When substituting CER NS by dCER NS (Figure 7B) or FA22 by dFA22 (Figure 7C) in 
the formulation, the relative intensity of the peak at 730 cm-1 was reduced compared to 
the formulation with only protiated lipids. This suggests that a fraction of the deuterated 
lipids partitions in the orthorhombic lattice formed by the protiated lipids of the 
formulation (see above).
The thermotropic behavior of the CH2 stretching vibration in the spectrum of FormCOMBI 
with only protiated lipids was highly comparable to the formulations with only one 
CER. However, the onset transition temperature was increased to 16°C (Figure 7D). 
When replacing FA22 by dFA22 the onset transition temperature of the CD2 asymmetric 
stretching vibrations was at 18°C and took place over a large temperature range, 
indicating an order-disorder transition over a large temperature interval. The onset 
transition temperature was somewhat higher than the formulation with protiated lipids, 
but lower than the onset transition temperatures of pure dFA22.22 When substituting 
Figure 6. Peak positions of CH2 symmetric stretching and CD2 asymmetric stretching vibrations of FTIR 
spectra plotted as a function of temperature (0-90°C). A) Symmetric stretching vibrations of CH2 groups in 
native SC, regenerated SC, and regenerated SC on which FormEOS, FormNS, or FormdNS was applied B) The 






CER NS by dCER NS, the onset transition temperature was 55°C (Figure 7E), which is 
also substantially higher than in the protiated formulation in which all lipids contribute 
to this shift, but a lower temperature than for the same transition in pure dCER NS. 
This indicates that a fraction of dFA and dCER NS interacts with protiated lipids, but 
the dCER NS and dFA do no not show a concerted order-disorder transition with 
most of the protiated lipids. This may demonstrate different structural domains in the 
formulation, most probably FA-rich and CER-rich domains.
Incorporation of lipids in regenerated SC
After application of FormCOMBI on regenerating SC, the CH2 rocking vibrations in the 
FTIR spectrum showed two strong peaks at around 719 and 730 cm-1, comparable to 
regenerated SC on which FormEOS was applied (Figure 8). No major differences were 
observed after application of a formulation containing dCER NS instead of CER NS. 
However, after the use of dFA22 instead of FA22, the intensity of the peak at 730 cm-1, 
relative to the intensity at 719 cm-1, was decreased (Figure 8D). This indicates that the 
FA22 from the formulation participates at least partly in the orthorhombic packing with 
the protiated SC lipids. 
The temperature dependence of the CH2 symmetric stretching vibrations after application 
Figure 7. FTIR spectra showing CH2 rocking vibrations of lipids in formulations as a function of temperature 
(0-60°C) and peak positions of CH2 symmetric stretching and CD2 asymmetric stretching vibrations of FTIR 
spectra plotted as a function of temperature (0-90°C). A) FormCOMBI (only protiated lipids) , B) FormCOMBI(dNS) 
(dNS was used) C) FormCOMBI(dFA) (dFA22 was used), D) Symmetric stretching vibrations of CH2 groups in 
FormCOMBI E) The CD2 asymmetric stretching vibrations of FormCOMBI(dNS) and FormCOMBI(dFA).
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of the formulations on regenerating SC was comparable to the temperature dependence 
of regenerated SC without formulation. When focusing on FormCOMBI(dNS), the onset of 
transition of the CD2 asymmetric stretching vibrations and CH2 symmetric stretching 
vibration after application on SC is very similar, but the transition occurs over a smaller 
temperature range in the CD2 asymmetric stretching vibrations (compare Figure 8E 
and 8F). This temperature range is similar to that of the CD2 stretching vibrations in the 
formulation. However, the thermotropic behavior of the CD2 asymmetric stretching 
vibrations of FormCOMBI(dFA) shows a completely different profile. The ordered-disordered 
transition starts at around 26°C, as opposed to 16°C for the formulation only, and 
the transition occurs in a very broad temperature range. This indicates that at least a 
fraction of the dFA from the formulation interacts with the SC lipids, which show an 
ordered-disordered phase transition at around 60-70°C. Furthermore, the contours of 
the CD2 symmetric stretching vibrations indicate the presence of two vibration modes 
(see Supplementary Figure 3) with a main peak at a wavenumber of around 2090 cm-1 
and a shoulder around 2086 cm-1.
Figure 8. FTIR spectra showing CH2 rocking vibrations of SC lipids after application of formulations as a 
function of temperature (0-60°C) and peak positions of CH2 symmetric stretching and CD2 asymmetric 
stretching vibrations of FTIR spectra plotted as a function of temperature (0-90°C). A) Regenerated SC, 
B) Regenerated SC after application of FormCOMBI (only protiated lipids), C) Regenerated SC after application 
of FormCOMBI(dNS), D) Regenerated SC after application of FormCOMBI(dFA), E) Symmetric stretching vibrations of 
CH2 groups in regenerated SC after application of FormCOMBI F) The CD2 asymmetric stretching vibrations of 






Application of CER containing formulation does not influence lamellar lipid organization
The lamellar organization in the lipid matrix was studied using SAXD. The peak 
positions are indicative for the spacing of the lamellae in the SC. The diffraction patterns 
of native and regenerated SC with or without formulation are shown in Supplementary 
Figure 4. All SC samples showed a main peak at a q-position of about 1.0 nm-1, which is 
attributed to the 1st order SPP peak and the 2nd order LPP peak. In some samples, a small 
difference in shape of the peak was observed, but the peak position was not changed. 
Furthermore, sometimes a peak at q=1.9 nm-1 was observed, which corresponds to 
phase separated crystalline CHOL that is present in SC.
Discussion
In the present study, the SkinBaR model that mimics several aspects of the lipid 
organization in AD skin was used to investigate the effect of topical skin barrier repair 
formulations. We demonstrate that after application of formulations containing barrier 
lipids and one CER subclass, a higher fraction of SC lipids adopts an orthorhombic 
lateral packing in the regenerated SC, mimicking more closely the lipid organization 
in native human skin. However, when two CER subclasses were combined with a FA, 
this effect was not observed. 
In inflammatory skin diseases, like AD, the skin barrier function is impaired as 
indicated by an increased TEWL.23,24 Besides changes in protein levels in the epidermis 
in these skin diseases, an altered lipid composition and organization compared to 
healthy skin has also been reported.13,23-31 Particularly the importance of the lipids for 
the skin barrier has been indicated by a strong correlation between increased TEWL 
and reduced chain length of both CER and FA, and a reduced fraction of lipids forming 
an orthorhombic lateral packing.11,13,14 These results show that the skin barrier might 
be improved by normalizing the lipid composition and organization. Previously, 
several skin barrier repair mixtures containing skin barrier lipids CER, FA, and CHOL 
were reported.32-36 However, the precise composition of the formulation is often not 
described.34-36 Furthermore, most studies focus on TEWL and/or skin hydration as 
end point measurements.32-34,36 None of these studies investigated the effect of the 
formulations on the lipid composition and/or organization in SC. This demonstrates that 
little is known about the key interactions of the barrier lipids applied in the formulations 
and the lipid matrix in the SC, which may be an important underlying mechanism for 
skin barrier repair. Therefore, additional research is needed to provide detailed insights 
in these interactions and select the optimal skin barrier repair formulation.
Previously, it has been reported that both natural and synthetic VC applied on tape-
stripped mouse skin enhanced skin barrier repair in vivo.16,17 Based on these findings, 
in the present study we developed formulations containing the barrier lipids CER, FA, 
and CHOL and examined their effect on the SC lipid organization in an ex vivo human 
skin barrier repair (SkinBaR) model. This model mimics more closely the morphology, 
the lipid organization, and the lipid composition of AD than that in mice skin: An 
increased level of short chain CERs and a fraction of unsaturated CERs are present in 
SC of the SkinBaR model, similarly as in SC of AD skin .19,37
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In the present study, the CER containing formulation was topically applied on 
regenerating SC of the SkinBaR model in order to examine whether the lipid 
organization could be normalized toward that in native human SC and whether barrier 
lipids in the formulation participate in the SC lipid matrix or mainly remain on the skin 
surface. In order to examine this, FTIR studies were executed using protiated and (if 
available) a deuterated CER or FA in the formulations. The use of deuterated lipids in 
the formulations applied on the SkinBaR model facilitates more detailed analysis of 
the interactions between the deuterated lipids from the formulations and the SC lipid 
matrix. First, the effect of only one CER subclass in the formulation was examined. 
Subsequently, a formulation with a single FA in combination with the two CER 
subclasses was studied. 
Formulations
The physical stability of the formulations was examined during a period of 6 months. 
During the storage, no crystals were observed. However, when CER NP or CER EOP 
were introduced in the same formulation, crystals were formed (results not shown). 
Therefore, all experiments were performed using CER NS and CER EOS. 
CERs: Examination of the lateral lipid organization and conformational ordering of the 
lipids in the formulation indicated that the presence of both the orthorhombic domains 
and the ordered phase start to disappear at around 10°C. To examine in detail the 
interaction between CERs and the formulation components, deuterated CER NS was 
used. Several observations suggest that dCER NS interacts with the other components 
in the formulation, namely i) the CD2 stretching frequencies show that the onset 
transition temperature to a fluid phase is lower for dCER NS in FormdNS than that of 
pure dCER NS, and ii) no crystals are observed in the formulation during a period of 
6 months. However, replacing CER NS by dCER NS did not result in a decrease in 
the CH2 rocking vibration contour at 730 cm-1. This suggests that dCER NS does not 
participate in the orthorhombic lattice in the formulation. As CER NS itself forms a 
hexagonal lateral packing, it may be that CER NS is located in domains with a hexagonal 
packing. Supplementation of CER EOS did increase the fraction of lipids forming an 
orthorhombic packing and increases the stability of the orthorhombic packing slightly. 
As no deuterated CER EOS is available, it could not be determined whether CER EOS 
is intercalated in the orthorhombic matrix.
FAs and CERs: In addition to the CERs, FA is another candidate barrier lipid to incorporate 
in a formulation. In previous studies, FAs with varying chain length were incorporated 
in the formulation.21 FA22 showed the most abundant change toward a more 
orthorhombic lateral packing and was therefore selected for the present studies.
An important question to answer is whether a combination of CER EOS and CER NS 
with FA22 in the formulation, FormCOMBI, results in an increased fraction of lipids 
adopting an orthorhombic packing. The results obtained from CH2 rocking vibrations 
in the FTIR spectra indicated an increased fraction of lipids adopting an orthorhombic 
lateral packing compared to a formulation with only one CER subclass or FA.21 This is 
in accordance with previous results showing that both CER EOS and (very) long chain 
FA are important for the formation of orthorhombic domains.38-41






formulation, either CER NS or FA22 was replaced by its deuterated counterpart. 
Participation of at least a fraction of both dCER NS and dFA22 in the orthorhombic 
lattice in the formulation was demonstrated by the reduced relative intensity of the 
rocking vibration peak located at 730 cm-1 compared to the formulation with only 
protiated lipids. Interaction of dFA with the other barrier components in the formulation 
is further demonstrated by an increased onset transition temperature of the CD2 
stretching vibrations in FormCOMBI(dFA) compared to that of only dFA in the formulation 
and decreased compared to that of pure dFA.21,22 However, a large difference in onset 
transition temperature of dCER NS (FormCOMBI(dNS)) with dFA22 (FormCOMBI(dFA)) was 
observed. This strongly suggests that at least two different types of domains of barrier 
lipids are present in the formulation, most probably both containing CERs as well 
as FAs, but the domains may be either dCER NS rich (high order-disorder transition 
temperature) or dFA rich domains (lower order-disorder transition temperature).
Interactions between formulations and stratum corneum
After having characterized the formulations, we examined the interactions of the 
formulations with the regenerating SC. After application of FormEOS or FormNS on 
regenerating SC, a higher fraction of lipids adopted an orthorhombic lateral packing 
as indicated by a higher relative intensity of the CH2 rocking peak at 730 cm-1 in the 
FTIR spectrum. The increase in intensity was more pronounced with CER EOS than 
CER NS in the formulation, most probably due to the long acyl chain of the former. 
The increase in the 730 cm-1 relative intensity for FormNS is only encountered when 
the FTIR spectrum in the untreated regenerated SC does not exhibit a 730 cm-1 peak, 
demonstrating the presence of only a hexagonal lateral packing. Based on the similar 
relative intensity of the rocking vibrations after application of FormNS and FormdNS 
there is no evidence that CER NS participates in the orthorhombic packing of the SC 
lipid matrix. Possibly CER NS participates in the hexagonal domains. Therefore, we 
also examined the lipid ordering of the SC lipid matrix after application of FormNS 
and FormdNS. After application of both formulations on regenerating SC, a comparable 
onset transition temperature was observed. This onset transition temperature was also 
comparable to that of FormdNS alone. However, there is a difference in temperature at 
which the ordered-disordered transition terminates, namely 62.2°C for FormdNS and 
71.0°C for regenerated SC treated with FormdNS. This indicates that at least a part of the 
dCER NS interacts with lipids in the SC matrix. 
Finally, FormCOMBI was applied on regenerating SC and analyzed in the same manner. 
Application of FormCOMBI, in which CER EOS, CER NS, and FA22 are combined, did 
not increase the fraction of lipids adopting an orthorhombic lateral packing compared 
to untreated regenerated SC. However, the absence of an increase in the formation 
of the orthorhombic packing is probably due to the high fraction of lipids forming an 
orthorhombic packing in the untreated regenerated SC, making it a bigger challenge to 
increase the fraction of lipids forming an orthorhombic packing. The decreased relative 
intensity of the peak at 730 cm-1 after replacing FA22 by dFA22 in FormCOMBI indicates 
that dFA22 participates in the orthorhombic lattice and is most likely intercalated in the 
SC matrix. Previously, we have reported the application of a formulation containing 
only one FA.21 In that paper we show that dFA participate in the orthorhombic lattice 
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and that it interacts with the SC lipid matrix.21 It seems that this effect has been slightly 
reduced when CERs were added to the formulation. Possibly, CER NS and CER EOS 
interfere with the interaction between FA and the SC lipid matrix probably by stabilizing 
the FA in the formulation and reducing the partitioning into the orthorhombic lipid 
matrix in the SC. In contrast, the reduced peak intensity was not observed when 
CER NS was replaced by dCER NS, suggesting that CER NS is not intercalated in the 
orthorhombic domains in the SC lipid matrix when FA22 and CER EOS are also present 
in the formulation. From the stretching vibrations there is also no evidence that CER NS 
is present in the SC lipid matrix. However, as the ordered-disordered transition of dCER 
NS in the formulation is in a similar temperature range as that of the SC lipid matrix, 
some of the CER NS may still intercalate in the hexagonal packing in the lipid matrix, 
or CER NS may be present in the skin furrows and may still influence barrier repair. 
Several other formulations consisting of CERs, FA, and CHOL report enhanced barrier 
repair for formulations containing CER subclass NP.42-44 However, mainly TEWL was 
used as skin barrier repair parameter, and interaction with SC lipid matrix was not 
examined. In our formulation CER NP crystallizes and therefore CER NP was not 
suitable to be used in the present study. Other studies report formulations in which CER 
subclass AdS was used as CER component. Topical application of these formulations 
resulted in decreased TEWL values and a higher skin hydration after 4 weeks.45,46 
Furthermore, addition of CER AdS to the culture medium of reconstructed human skin 
resulted in increased CER content, mainly caused by an increase of CER EOS, NS, and 
NP.47 
Conclusion 
In conclusion, we show that CERs interact with the other components of a lipid 
formulation, resulting in a higher fraction of lipids adopting an orthorhombic lateral 
packing compared to a formulation without CERs. These interactions were also 
observed for FA and CERs when both lipid classes were present in the formulation. 
After application of the formulation containing either CER EOS or CER NS on 
regenerating SC of the SkinBaR model, a denser lipid packing was observed, suggesting 
that CERs from the formulation interact with the SC lipid matrix. When studying a 
formulation with the three barrier components FA, CER NS and CER EOS, there is 
strong evidence that FA is interacting with the orthorhombic domains in the SC lipid 
domains, while there is no clear indication that CER NS is intercalated within the SC 
lipid matrix. 
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Super sterol esters were kindly provided by Croda (Cowick Hall, UK), triglycerides 
(Miglyol 812) were supplied by Cremer Oleo (Witten, Germany). CER EOS30 and 
CER NS24 were provided by Evonik (Essen, Germany). Deuterated CER NS24 was 
kindly supplied by Evonik Industries AG (Essen, Germany), perdeuterated behenic 
acid was acquired from Cambridge Isotope Laboratories (Tewksbury, MA, USA). 
Cyanoacrylate (Bison, Goes, the Netherlands) was bought locally. Xylene and 
methanol were obtained from Biosolve (Valkenswaard, the Netherlands), 4% buffered 
formaldehyde was purchased from Added Pharma (Oss, the Netherlands), paraffin, 
haematoxylin, and eosin were acquired from Klinipath (Duiven, the Netherlands). 
DMEM, Ham’s F12, and penicillin/streptomycin were purchased from Fisher 
Scientific (Waltham, Massachusetts, USA). Squalene, cholesterol, bovine serum 
albumin, sodium bromide, ethanol, acetone, trypsin, trypsin inhibitor, selenious acid, 
hydrocortisone, isoproterenol, L-carnitine, L-serine, insulin, α-tocopherol acetate, 
vitamin C, arachidonic acid, linoleic acid, and palmitic acid were bought from Sigma-
Aldrich (Zwijndrecht, the Netherlands). Chloroform was obtained from Macron Fine 
Chemicals (Gliwice, Poland). All solvents were HPLC grade or higher.
Stripping and culturing of ex vivo skin
Before dermatoming to a thickness of 600 µm (D80 Dermatome, Humeca, Borne, 
the Netherlands), the subcutaneous fat was removed, and the skin was wiped with 
70% EtOH and Millipore water. SC was removed by sequential stripping as described 
before.1 Briefly, skin was punched (ø=26 mm) and stretched on a custom made 
clamping device. SC was removed by preheated (40°C) metal cylinder with preheated 
cyanoacrylate. During each stripping the metal cylinder was applied on the skin for 2 
minutes with a pressure of 0.7 kg/cm2. This procedure was repeated until the SC was 
removed which is indicated by a shiny appearance of the skin. 
The detailed culturing procedure has been described previously.1,2 In short, the stripped 
skin was placed on top of a cotton pad and a transwell filter insert (Corning Life 
sciences, Amsterdam, Netherlands) in a deep 6-well culturing plate (Organogenesis, 
Canton, MA, USA). A metal ring (inner diameter 15 mm) was placed on the SC side of 
the skin.
Isolation of SC
Trypsin was used to isolate SC from cultured skin. The skin was kept at 4°C overnight 
in 0.1% trypsin solution in PBS, followed by one hour at 37°C. SC was peeled off and 
washed in 0.1% trypsin inhibitor solution in PBS. SC sheets were cleaned twice in 
Millipore water and stored over silica gel under argon in the dark until use. SC was 
used for either infrared spectroscopy measurements or X-ray diffraction measurements.
Fourier transform infrared spectroscopy
The conformational ordering and the lateral packing of the lipids in the SC matrix and 
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the formulations was examined using Fourier transform infrared spectroscopy (FTIR). 
SC samples were hydrated over a 27% NaBr solution in D2O for 24 hours at room 
temperature. FTIR spectra were recorded using a Varian 670-IR FTIR spectrometer 
(Agilent Technologies, Santa Clara, USA), equipped with a broadband mercury-
cadmium-telluride detector. A hydrated SC sample or a formulation was placed 
between two AgBr-windows and measured in transmission mode. Samples were put 
under a continuous purge of dry air starting 30 minutes before the beginning of the 
measurement. Spectra were obtained as a co-addition of 128 scans at 1 cm-1 resolution 
during 2 minutes, during which the sample temperature was increased from 0 to 90°C 
at a heating rate of 0.5°C/min. Resolutions Pro 4.1 (Varian Inc.) software was used to 
analyze the data.3
The peak positions of the CH2 symmetric and CD2 asymmetric stretching vibrations 
in the FTIR spectra were used to determine the onset temperature of the ordered-
disordered transition. Two regression lines were fitted to the linear parts of the graph 
obtained after plotting the peak positions against temperature. The intercept of the two 
regression lines determines the onset transition temperature, as described before.2 The 
end of the ordered-disordered phase transition was determined in the same manner as 
the onset transition temperature.
Small angle X-ray diffraction
The lamellar lipid organization was examined using small angle X-ray diffraction 
(SAXD). Measurements were performed at the European Synchrotron Radiation Facility 
(ESRF, Grenoble, France) at station BM26B. The SC samples were hydrated over a 27% 
NaBr solution during 24 hours prior to the measurements. SC samples were carefully 
oriented parallel to the X-ray beam in a custom made sample holder. SAXD patterns 
were detected with a Pilatus 1M detector at room temperature for a period of 5 or 10 
min as described earlier.4 The scattering vector (q) was calculated from the scattering 
angle (Θ) and the wavelength (λ) by q=4π sin Θ/λ. From the position of the peak maxima 
(q), the spacing of the lamellar phase can be calculated using 2π/q. A peak positioned 
at a lower q-value corresponds to a larger spacing of the lipid lamellae.
Results
Supplementary Figure 1. FTIR 
spectra showing CH2 rocking 
vibrations of pure CER as a function 
of temperature (0-60°C). A) CER 
EOS, characterized by a doublet with 
vibrations at around 719 and 730 
cm-1 B) CER NS, characterized by a 







Supplementary Figure 2. FTIR spectrum showing CH2 rocking vibrations of native SC. Two strong peaks 
are observed at wavenumbers of around 719 and 730 cm-1. The intensity of the peak at 730 cm-1 started 
to decrease at a temperature of around 30°C and the contour disappeared at 48°C. This change in rocking 
profile is indicative for the orthorhombic to hexagonal phase transition.
Supplementary Figure 3. FTIR spectrum showing CD2 symmetric stretching vibrations of Form
COMBI(dFA). The 
shape of the peak indicatest the presence of two types of vibrations, 2090 cm-1 and 2086 cm-1. 
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Supplementary Figure 4. X-ray diffraction patterns of native SC and regenerated SC with and without 
application of formulation. Both SPP and LPP attribute to the peaks at q=1. Phase separated CHOL is 
observed at q=1.8 and indicated by an asterisk. A) SAXD profiles of native SC, regenerated SC, and 
regenerated SC with application of FormEOS and FormNS, B) SAXD profiles of native SC, regenerated SC, and 
regenerated SC with application of FormCOMBI.
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ATR-FTIR Attenuated total reflection Fourier transform 
infrared spectroscopy
AUC Area under the barrier recovery curve
C34 Ceramide with 34 carbon atoms
FWHM Full width at half maximum
LMMs Linear mixed models
PCA Principal component analysis
PC Principal component
SAXD Small angle X-ray diffraction
SC Stratum corneum
SQ SquameScan value
TEWL Transepidermal water loss
VC Vernix caseosa
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Restoring the lipid homeostasis of the stratum corneum (SC) is a common strategy 
to enhance the skin barrier function. Here, we used a ceramide containing vernix 
caseosa (VC) based formulation and were able to accelerate barrier recovery in 
healthy volunteers. The recovery was examined over 16 days by monitoring trans-
epidermal water loss (TEWL) after barrier disruption by tape-stripping. Four skin sites 
were used to examine the effects of both treatment and barrier recovery. After 16 days, 
samples were harvested at these sites to examine the SC ceramide composition and 
the lipid organization. Changes in ceramide profiles were identified using principal 
component analysis (PCA). After barrier recovery, the untreated sites showed increased 
levels of ceramide subclass AS and ceramides with a 34 total carbon atom chain 
length, while the mean ceramide chain length was reduced. These changes were 
diminished by treatment with the studied formulation, which concurrently increased 
the formulated ceramides. Correlations were observed between SC lipid composition, 
lipid organization, and TEWL, and changes in the ceramide subclass composition 
suggesting changes in the ceramide biosynthesis. These results suggest that VC based 
formulations enhance skin barrier recovery and are attractive candidates to treat skin 




Vital functions of the stratum corneum (SC) are preventing excessive water loss from 
the body and protecting the body from the hostile outside environment by acting as an 
inside-out and an outside-in barrier, respectively. The SC is generated by a dynamic 
process in which keratinocytes in the lower layer of the epidermis undergo terminal 
differentiation and transform into corneocytes.1 During this differentiation process, 
lipids are synthesized, stored in lamellar bodies and, at the interface between the viable 
epidermis and SC, these lamellar bodies are secreted in the intercellular regions.2 The 
secreted lipids form an extracellular lipid matrix crucial for a proper skin barrier.3,4 Three 
main lipid classes have been identified: cholesterol, fatty acids, and ceramides. The 
latter constitutes the group of SC lipids that have the most diverse chemical structure. 
Their building blocks are an array of sphingoid bases and acyl chains chemically 
linked together by an amide bond, resulting in 16 ceramide subclasses.5 Both chains 
(the sphingoid base and acyl chain) can vary substantially in carbon chain length. The 
composition of the SC ceramide fraction (the ceramide profile) was correlated with and 
shown to be important for lipid organization and skin barrier function.6-8 In the present 
study, the effect of a ceramide containing formulation on skin barrier recovery, the 
ceramide composition, and lipid organization were studied.
Through the processes of cornification and desquamation, the SC is continuously 
rejuvenated9,10 and can thereby quickly recover the barrier function after disruption.11 
An impaired skin barrier function is encountered in several inflammatory skin diseases; 
one of which is atopic dermatitis (AD). In AD, an inadequate recovery of the impaired 
skin barrier perpetuates the condition. Normalization of the barrier function in AD is 
crucial to reduce the penetration of irritants and allergens into the skin. Application 
of lipophilic formulations that act as an additional barrier is a common treatment.12-15 
Another approach aims at normalization of the ceramide composition.4 Changes in 
this composition were correlated to the reduced skin barrier function in AD.8,16,17 
Previously, ceramide containing formulations have been used to study skin barrier 
repair18-21 and it was reported that the ratios between the three main SC lipids in a 
formulation was important for short term recovery.22 Furthermore, it was suggested 
that long term application could enhance barrier recovery.21 Nonetheless, it is disputed 
whether ceramides in a formulation actually normalize the SC lipid composition or 
remain on the skin surface.23 It has been shown that the orally administered essential 
fatty acids were incorporated in the epidermis.24
How these formulations accelerate barrier recovery is not clearly understood. Therefore, 
the primary aim of this study was to examine how treatment with a formulation during 
barrier recovery affects the SC lipid composition and subsequently lipid organization. 
This was done by examining the normal physiological responses in healthy volunteers. 
In this study, we applied a ceramide containing formulation based on the composition 
of the vernix caseosa (VC). This is a natural ceramide containing formulation that 
serves as a protective lipid film covering the fetus in the last trimester of pregnancy 
and during delivery.25 Previously, it was shown that VC like formulations were able to 
significantly accelerate barrier recovery in mice.26,27 This vernix formulation has the 
advantage that ceramides can be formulated. The formulation is semi-occlusive.28 To 






by tape-stripping, as this is an effective way to remove the barrier and induce barrier 
recovery in healthy skin.27,29-32
Here, it is shown that treatment with the formulation resulted in accelerated barrier 
recovery of tape-stripped skin compared to the untreated tape-stripped skin. In 
regenerated untreated SC, an altered ceramide composition was observed. These 
alterations correlated to a decrease in skin barrier function. When applying the ceramide 
containing formulation, the ceramide composition was modulated towards a ceramide 
composition more closely mimicking that of control skin. Combined, these results 
indicate that barrier disruption induces changes in lipid processing during recovery, 
related to a decreased barrier function and that these changes in lipid processing can 
be modulated by application of the VC formulation.
Materials and methods
Chemicals
The following solvents were used for lipid extraction and analysis: Millipore water 
(18.2 mΩ), HPLC grade methanol and chloroform from Lab-Scan (Gliwice, Poland), 
UPLC grade isopropanol and ethanol from Biosolve (Valkenswaard, the Netherlands), 
and HPLC grade heptane from Actu-All (Oss, the Netherlands). The synthetic ceramides 
listed in Table S1 were used as calibrators for the LC/MS analysis. Trypsin and trypsin 
inhibitor for SC isolation were purchased from Sigma-Aldrich (Zwijndrecht, the 
Netherlands).
Clinical study design
The clinical study was approved by the Leiden University Medical Center ethical 
committee and performed according to the declaration of Helsinki. All volunteers signed 
an informed consent. 8 female and 7 male Caucasian volunteers, age 18 to 29 years 
(mean age 23 years) were recruited and checked by a dermatologist. Volunteers were 
excluded if they had dermatological disorders or a history of dermatological disorders, 
suffered from chronically inflammatory diseases, used systemic drug therapies, had 
abundant hair or unnatural abnormalities on the ventral forearms, had a history of drug 
abuse, or if they were pregnant. All enrolled volunteers completed the clinical study.
Figure 1A depicts the timeline of the study. Before the study commenced, volunteers 
had a one week washout period in which no soaps or cosmetics were applied on 
the ventral forearms. At T0 a site of 3.5 by 2.5 cm of SC was removed at both ventral 
forearms by consecutive tape-stripping using DSquame tape (Cuderm, Dallas, USA). 
The tape-stripping continued until the site appeared shiny33 and a transepidermal water 
loss (TEWL) of > 60 g/m2/h was reached (these sites are further referred to as stripped). 
TEWL was measured using AquaFlux AF200 (BIOX, London, UK). Thereafter, two 
fingertip units of a VC like formulation (composition is shown in Table S2) were applied 
twice daily for 14 days on one ventral forearm (referred to as treated), followed by a 
two day washout period. Treatment allocation to either left or right arm was alternated 
between volunteers. Figure 1B depicts the 4 sites investigated in this study: control 
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(no treatment, no tape-stripping), treated (treated with formulation), stripped (tape-
stripped at T0), and stripped+treated (tape-stripped at T0 and treated with formulation). 
At the final time point (T16) 21 tape-strips, using polyphenylene sulfide tape (Nichiban, 
Tokyo, Japan), were harvested at all 4 sites. The amount of SC on each tape-strip 
was determined by measuring the tape-strips with a SquameScan (Heiland Electronic, 
Wetzlar, Germany). Tape-strip zero was discarded. After every other tape-strip an 
infrared spectrum of the tape-stripped skin region was made (see below). After tape-
stripping, a 4 mm biopsy of both recovered sites was collected, near the site where 
Nichiban tape-strips were harvested, to perform small angle X-ray diffraction (SAXD), 
see below. During the study, TEWL of all sites was monitored at distinct time points, 
these measurements were performed before formulation application.
TEWL measurements to determine barrier recovery
To determine barrier recovery of the stripped sites TEWL was monitored. At each time 
point depicted in Figure 1C, TEWL was measured at three different sections of each site 
(Figure S1). The barrier recovery percentage was calculated by defining the average of 
three TEWL measurements at the non-stripped sites as 100% barrier and TEWL at the 
stripped sites directly after tape-stripping as 0% barrier. The following equation was 
used:26
Recovery% Tn=(TEWL T0-TEWL Tn)/(TEWL T0-Average TEWL non-stripped site Tn)*100
For each volunteer several values were calculated for both the treated and untreated 
stripped sites: I) the recovery percentage of the site at three sections at each time-point, 
II) the mean of the three previous values, III) the area under the barrier recovery curve 
(AUC) of the means over time, using a point-to-point linear fit, IV) using the same 
fit, the time it took to reach designated recovery percentages between 5-100%, with 
increment of 5%, V) the difference in time between the stripped and stripped+treated 
sites at each of the previously mentioned recovery %. Recovery percentages >90% 
were excluded, as only 5 volunteers reached these values at both stripped sites, biasing 
these data.
Figure 1. Study design. A) Timeline of the clinical study (Time points are indicated as T with days as 
subscripts). Volunteers were first screened by a dermatologist (T-7), followed by a one week washout period. 
At T0 the SC was removed by tape-stripping. The formulation was applied 2x daily for 2 weeks followed 
by two days washout. The activities and measurements are indicated at each time point (T-7 till T16). At all 
indicated time-points TEWL was measured, except for T-7. B) The studied sites on the ventral forearms. On 
both arms one site was tape-stripped; on one arm formulation was applied. C) The time-points at which 






Quantification of ceramides by LC/MS
Tape-stripped SC can be used to examine the lipid content by mass spectrometry.34-36 
Samples for ceramide analysis by LC/MS were prepared from tape-strips 5-8 and 
17-20, harvested at the 4 sites on T16. Samples prepared from tape-strips at a depth 
of 5-8 and 17-20 tapes were analyzed separately to determine if the SC ceramide 
composition generated in the initial stage of the recovery process (tapes 5-8) was 
different from that generated in later stages of the recovery process (tapes 17-20). 
Tape-strips were punched to an area of 2 cm2, extracted, analyzed and quantified 
as described in Boiten et al.34 Shortly, a modified 4 step Bligh and Dyer extraction at 
40°C was performed. Extracts were analyzed using an Acquity UPLC H-class (Waters, 
Milford, MA, USA) connected to an XEVO TQ-S mass spectrometer (Waters, Milford, 
MA, USA). Separation was performed on a pva-silica column (5 µm particles, 100 × 
2.1 mm i.d.)(YMC, Kyoto, Japan). Using the calibrators, a response model was build 
and used to quantify the ceramides in the analyzed samples. All data were corrected 
for the cumulative SquameScan value (SQ) of the four tape-strips comprising the 
corresponding sample. The data resulted in quantitative SC ceramide profiles for each 
volunteer, at all 4 sites, and at two depths per site. Ceramides are named according to 
hydrophilic head group (subclass) and chain length (e.g. NS C42, ceramide subclass 
NS with a total chain length of 42 carbon atoms).37 For an overview of subclasses and 
ceramide structures see Figure S2.
Quantitative data were used to calculate several parameters. Ceramides EOS C66 
and NS C40 (supplied in the formulation) were excluded from these calculations. The 
following parameters were calculated:
I) Total amount of the individual subclasses (ng/SQ);
II) Total amount of ceramides with a total chain length 34 carbons (ng/SQ);
III) Mean carbon chain length: (Σ each ceramide (molar amount ceramide x 
carbon chain length))/total molar amout all ceramides;
IV) Percentage of EO ceramides, as ng EO / total ng ceramides.
Lateral organization and conformational ordering of SC lipids
The lateral organization and conformational ordering of the SC lipids were examined 
by attenuated total reflection Fourier transform infrared spectroscopy (ATR-FTIR). FTIR 
spectra were collected using a Varian 670-IR spectrometer (Agilent Technologies, Inc., 
Santa Clara, CA) equipped with a mercury-cadmium-telluride detector and an external 
sample compartment containing an ATR accessory (GladiATR, PIKE Technologies, 
Maddison, WI) with a single reflection diamond. The sample compartment was 
constantly purged with dry air. Each spectrum was an average of 150 scans, with a 
spectral resolution of 2 cm-1. Conformational ordering of the lipids was determined 
using the center of gravity of the peak of the CH2 symmetric stretching vibrations at 90% 
of the peak height. The bandwidth from the second derivative of the CH2 scissoring 
region was selected as a measure for lateral packing of the lipids and determined 
as described before.38,39 CH2 stretching vibration peak position values <2850 cm-1 
indicate an ordered phase, whereas values above 2852 cm-1 indicate a high degree of 
disordering being a liquid phase. The second derivative of the CH2 scissoring region 
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was baseline-corrected between the endpoints of the scissoring region (~1460-1480 
cm-1) and the full width at half maximum (FWHM) was calculated.39 Values of 5 spectra 
(tape 2-10 and tape 12-20) per site per volunteer were used for the analyses.
Small angle X-ray diffraction
SC isolated from biopsies harvested at stripped and stripped+treated sites were examined 
by SAXD. SAXD was used to determine the SC lipids lamellar organization. To isolate 
SC for SAXD analysis, biopsies were placed overnight in a 0.1% trypsin solution in PBS 
at 4°C, followed by one hour incubation at 37°C. The SC was peeled of and washed in 
0.1 % trypsin inhibitor solution in PBS and twice in Millipore water. Dried SC sheets 
were stored under argon and over silica gel until use. All SAXD measurements were 
performed at the European Synchrotron Radiation Facility (Grenoble, France) at station 
BM26B. SAXD patterns were collected on a Pilatus 1M detector at room temperature 
for 5 minutes. The sample-to-detector distance was 2 m. Prior to data collection, 
the SC samples were hydrated over a 27% (w/v) NaBr solution for 24 hours at room 
temperature. The scattering intensity I (arbitrary units) was measured as a function of 
the scattering vector q (in nm-1), defined as: q = 4π sinΘ/λ, in which Θ is the scattering 
angle and λ is the wavelength. From the position of the main peak (referred to as peak 
2 with position q2), the spacing (d) of the lipid lamellae was calculated using d = 2π/q2. 
As in SC this peak position is determined by the structure of the two lamellar phases, a 
change in the spacing indicates a change in these lamellar phases.8
Software and statistical analysis
All LC/MS data were processed using MassLynx and TargetLynx software (V4.1 SCN 
843 Waters Inc.). FTIR data were processed and analyzed using Resolutions Pro 4.1 
(Agilent Technologies, Inc.). Principal component analysis (PCA) is a commonly used 
analysis of lipidomics data sets.40,41 It is a mathematical dimensional reduction that can 
effectively visualize variation and the difference between samples in large data sets 
by reducing all variables to principal components (PCs). PCA was performed using 
Multibase add-in for excel (NumericalDynamics.Com). For PCA, the quantitative 
data obtained from the ceramide analyses were normalized to the total amount of 
ceramides in the samples. The four individual sites (control, treated, stripped, and 
stripped+treated) of each volunteer were defined as PCA samples. All quantified 
ceramides at both depths were defined as variables of that “PCA sample” (total of 584 
variables), thereafter the mean of each ceramide/variable in all “PCA samples” was 
centered at zero (subtracting the mean).
Correlation analysis and point-to-points fits were performed using GraphPad Prism 
(V6.05, Graphpad). Group-wise comparisons were performed using linear mixed 
models (LLMs) in SPSS (V24 IBM). All measurements within the same subject were 
treated as repeated measurement. LMMs were used because these models have the 
advantage that I) the effect size of individual variables and their interactions can be 
examined, and II) they can handle missing data.42 Figure S3 explains how the LMMs 
were used here. All interactions between fixed variables were included in the first run 






are indicated as follows: * (p<0.05), ** (p<0.01), *** (p<0.005) and **** (p<0.001).
Results
Barrier recovery in healthy volunteers
To determine the effect of the formulation on barrier recovery, changes in skin barrier 
over time (measured as TEWL and expressed as recovery %) were examined. Figure 
2A shows a typical example of barrier recovery % as function of time for untreated 
and treated stripped sites of one volunteer. After 16 days, all volunteers had reached 
a recovery % >85 at both sites. For each volunteer the AUC was calculated of both 
the untreated and treated stripped sites (Figure 2B). A larger AUC implies less barrier 
dysfunction during the 16 days. Treatment with the formulation significant increased 
the AUC, indicating increased recovery.
Yet, the AUC does not take into account the kinetics of the recovery process. To 
determine if treatment accelerated barrier recovery, differences in time between 
untreated and treated stripped sites were examined at multiple designated recovery 
percentages (ΔT in Figure 2A). Figure 2C depicts the median and interquartile range 
of ΔT at different recovery percentages for all volunteers. A median of zero would 
indicate no change in recovery time due to treatment. A positive deviation from zero 
was observed at almost all recovery percentages with a spike at 25%, and a steady 
increase above 50%. Treatment significantly accelerated barrier recovery ending with 
a more than two days faster median recovery. As control both the AUC and the ΔT 
were tested for correlation to the TEWL directly after tape-stripping (Table S3). No 
correlations were observed, indicating that these parameters were not dependent on 
the amount of barrier disruption.
Figure 2. The effect of treatment on barrier recovery. A) The typical elapse of barrier recovery over time 
for untreated and treated stripped sites, for a single volunteer. Points are means (±SD) of three measurements 
within one site. Lines are point-to-point connections. The dotted line indicated the difference in time (ΔT) 
between the untreated and treated curve at a designated recovery %. B) The AUCs/1000 for all volunteers. 
Lines connect data points of the same volunteer. A paired t-test showed significant increase at the treated 
sites. C) The ΔT for all volunteers at recovery percentages between 5 and 90 %. The data were non-normally 




Principle component analysis of ceramide profiles
To gain insight into differences between the ceramide profiles of the four different sites 
PCA was performed on the quantitative ceramide data. Figure 3A depicts the variable 
loadings, indicating how strongly each variable (ceramides detected in the samples) 
correlated to PC1 and PC2. If the value is higher (deviates from center of the graph 
in x or y position) it has contributed more to the variation explained by PC1 or PC2, 
respectively. The 10 variables with the highest correlation coefficients are indicated 
in the plot. PC1 and PC2 explained a total inertia (variance) of 66.3%. Figure 3B 
shows the plot of the “PCA samples”, depicting the PC1 and PC2 scores of each “PCA 
sample”. Samples were assigned to clusters corresponding to the 4 sites indicated by 
different colors. Separation between clusters was observed demonstrating that variation 
between the ceramide profiles corresponded to variation between samples of different 
sites. Therefore, changes in ceramide profile due to treatment and tape-stripping can 
be explained by the variable loadings of the PCs.
Clusters of treated sites were separated from untreated sites as depicted in Figure 3B. By 
examining plot 3A it shows that this was due to 4 variables primarily. These variables 
corresponded to the two formulated ceramides (NS C40 and EOS C66), detected in 
samples of both depths. The PCA demonstrated that a large part of the variation in the 
ceramide profiles was due to the two ceramides in the formulation. The increase, due to 
formulation application, of these naturally occurring ceramides was examined. Figure 
S4 shows that the amount at treated sites was increased at both tape-stripping depths. 
An LMM of the logarithm of these amounts confirmed these observations (Table S4).
Next, separation of clusters corresponding to stripped and non-stripped sites was 
investigated. Variables correlating strongly to PC2 were primarily responsible for 
the observed separation. (Figure S5 shows a complete graphic overview of the PC2 
loadings). When examining the loadings of PC2, highly positive correlations were 
Figure 3. PCA of all SC ceramides and the amount of ceramides NS C40 and EOS C66. A) The PCA loading 
plot. Inertia per PC is indicted as % variation. Variables are all ceramides quantified in samples obtained 
from tape-strips 5-8 and samples obtained from tape-strips 17-20, the latter are indicated with a 2 after the 







observed for ceramides of subclass AS and, to a lesser extent, ceramides for subclass NS. 
Highly negative correlations were observed for ceramides from subclass NP. Changes 
in ceramide profile were observed between the different sites. In the next section, 
the results of the PCA were used as leads to investigate if these changes correlated to 
changes in barrier function and the recovery process.
Correlations between ceramide profile and barrier function
To investigate if barrier function correlated to changes in SC ceramide profile, changes 
in ceramides AS and NS, identified by PCA, were correlated to the TEWL at T16 (Figure 
S6 shows the TEWL at T16). Figure 4A and B depict these correlations for the total 
amount of subclass AS. At both depths, a significant positive correlation between the 
amount of subclass AS and TEWL was observed. This illustrates that an increase in 
subclass AS correlated with a reduced skin barrier function. Next, it was examined 
whether stripping, treatment, SC depth, or the interaction between these conditions had 
an effect on the amount of subclass AS using a LMM. The model used stripped, treated, 
and depth as fixed factors, and subject as random factor. Table 1 depicts the effect sizes 
obtained with the model. Figure 4C depicts the mean (±SD) of the amount of subclass 
AS measured at all 4 sites at both depths. Using the model it was determined that 
subclass AS increased significantly at stripped sites. Treatment or depth alone showed 
no significant effects compared to the control. However, at the stripped site treatment 
did have a significant effect. The interaction stripped*treated in Table 1 illustrates this 
effect. When subjected to stripping and treatment the amount of AS changed by the 
effect sizes of stripped and treatment, in addition to both effects the interaction term 
stripped*treated is added. At stripped+treated sites treatment significantly reduced the 
increase in AS observed due to stripping with 81.2 ng/SQ (treatment + stripped*treated). 
Similar results were obtained when examining NS C44 (Figure S7 and Table 1). It was 
decided not to use the total amount of subclass NS, as this value was influenced by 
ceramide NS C40 of the formulation. NS C44 is most abundantly present of the NS 
ceramide subclass members and chosen as a proper representative of subclass NS.
Besides subclasses, ceramide chain lengths, especially ceramides with a total carbon 
chain length of 34 carbons (C34), are known to correlate to barrier dysfunction.17 
Here, a significant positive correlation was observed between the total amount of C34 
ceramides (summation of amounts of NdS, NS, NP, NH, AdS, AS, AP, and AH with a 
total of 34 carbons) and TEWL, at both depths (Figure 4D and E), demonstrating that 
higher levels of C34 ceramides correlate with reduced barrier function at day 16. A 
similar LMM as that of subclass AS and NS C44 was built for C34 ceramides (Table 
1). The total amount of C34 ceramides at the 4 sites at two depths was plotted as the 
mean ±SD in Figure 4F. By using the model a significant increase at the stripped sites 
was observed. Comparable to subclass AS, treatment only significantly affected the 
stripped+treated sites. Treatment reduced the increase in C34 ceramides with 31.6 ng/
SQ compared to stripped sites.
Next, the correlation of each subclass to TEWL was examined (Figure 4G: Pearson 
r for each subclass). This correlation underlined the observations with PCA, where 
subclass NS and AS had a positive correlation and subclass NP a negative correlation 
to PC2. Both subclasses NS and AS have a distinct synthesis route different from 
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subclasses NP and AP, this suggested a ratio dividing the subclasses as follows: 
(NdS+NP+NH+AdS+AP+AH)/(NS+AS). This ratio correlated to TEWL (Figure 4G) even 
for the samples of each site independently. Together, these data showed that I) barrier 
function correlated to the ratio of ceramide subclasses from different synthesis routes, 
II) certain ceramide subgroups are increased in stripped SC, III) the amount of these 
subgroups correlated to TEWL, and IV) treatment is able to reduce the increase of these 
ceramide subgroups that correlate positively to an increased TEWL (AS, NS C44 and 
C34 ceramides).
Figure 4. The effect of treatment on ceramide groups correlating to barrier function. A,B) Correlations 
between TEWL and the amount of subclass AS (ng/SQ). The Pearson r and p-value are indicated (A: Samples 
of tape-strips 5-8 B: Samples of tape-strips 17-20). C) The amount subclass AS (ng/SQ) at all sites at depths 
of both 5-8 and 17-20 tape-strips (mean ±SD). Effect size was determined with a linear mixed model. D,E) 
Correlations between TEWL and the amount of ceramides with a chain length of 34 carbon atoms (ng/SQ). 
The Pearson r and p-value are indicated (D: Samples of tape-strips 5-8 E: Samples of tape-strips 17-20). F) 
The amount of ceramides with a chain length of 34 carbon atoms (ng/SQ) at all sites at depths of both 5-8 
and 17-20 tape-strips (mean ±SD). Effect size was determined with a linear mixed model. G) Pearson r of the 
correlation between TEWL and the total amount of each subclass at all sites at depths of both 5-8 and 17-20 
tape-strips. H) The correlation between TEWL and ratio of subclasses (NdS+NP+NH+AdS+AP+AH)/(NS+AS) 
of both depths, excluding NS C40. Pearson r per site were: control: -0.648 Stripped: -0.808 Treated: -0.729 
Stripped+Treated: -0.694. All statistical outputs of the LMM are found in Table 1.
Table 1. The output of the LMMs per ceramide subgroup. The intercept is the estimated amount at the 
control site at a depth of 5-8 tape-strips. Estimates are in ng/SQ. The effect size is the amount in ng/SQ with 
which the variable changes the intercept. Significance levels of all effect sizes and interaction are given.
Subclass AS Subclass NS C44 C34 ceramides
Estimate p-value Estimate p-value Estimate p-value
Intercept (control) 267.1 <0.001 56.6 <0.001 39.4 <0.001
Effect size Stripped +281,5 <0.001 +56.4 <0.001 +68.0 <0.001
Treated +27.3 0.402 +7.2 0.194 +5.6 0.438
Depth 17-20 -41.3 0.076 -2.1 0.597 -5.2 0.297






Mean carbon chain length and spacing related to the lamellar phases
Previous studies have shown that the main ceramide chain length is an important 
parameter of the SC ceramide fraction.43 For this reason it was decided to study 
whether a correlation existed between mean chain length and both the EO ceramide 
fraction and lamellar spacing. Figure 5A shows the mean chain length of the ceramides 
in samples prepared from tapes 5-8 and 17-20. A similar LMM as for subclass AS 
was made (Table 2). This showed that stripping decreased the mean chain length 
significantly. Treatment was able to increase the mean chain length restoring the mean 
chain length at the stripped+treated sites. The increase in mean chain length of the 
stripped+treated sites could be due to an increase in the fraction of esterified omega-
acyl-ceramide (EO fraction) (Figure S8 shows this correlation per site). Changes in EO 
fraction due to treatment of the stripped site (stripped - stripped+treated) correlated 
to changes in the mean chain length due to treatment of the stripped site (Figure 5B). 
Treatment was able to increase the EO fraction significantly (Figure 5C and Table 2 
show the EO fraction and the output of LMM, respectively).
The carbon chain length of the ceramides could influence the spacing of the strong 
diffraction peak in the diffraction pattern as measured by SAXD. From the position of 
the strong diffraction peak in the X-ray diffraction curve (peak 2), the corresponding 
spacing was calculated (referred to as peak 2 in Figure 5D). A significant increase 
in spacing due to treatment was observed and a positive correlation was observed 
between the mean chain length and the spacing, (Figure 5E). When comparing the 
spacing to TEWL, a correlation was observed between an increased TEWL and a 
decrease in spacing (Figure 5F). Stripping and treatment thus affected the mean chain 
length, which correlated to EO fraction and the lamellar spacing.
Effects of stripping and treatment on lateral packing
Next to the lamellar spacing, the lateral packing is important for a proper barrier 
function. For this reason the effect of treatment and stripping on the lateral packing 
was also examined. All skin sites were studied using ATR-FTIR, where both the CH2 
symmetric stretching vibrations and the CH2 scissoring vibrations were examined. A 
LMM was built for the CH2 symmetric stretching peaks. Stripped, treated, and depth 
were used as fixed factors and subject as random factor (Table 2). A significant increase 
in peak position was observed due to barrier disruption and treatment suggesting a 
slight increase in disordering of the lipids. The effects were stronger deeper in the SC. 
However, the peak position at all sites is located at wavenumbers between 2848.46 
cm-1 and 2848.80 cm-1, indicating an ordered lateral lipid organization at all sites. A 
similar linear mixed model was built for the CH2 scissoring peak. We determined the 
FWHM of the scissoring vibrations. Table S5 depicts the result of this model. At the 
control site the FWHM was significantly decreased at deeper layers (tape-strips 12-20), 
yet, the FWHM was 11.3 cm-1 or higher, indicative for a large fraction of lipids forming 
an orthorhombic lateral packing. No deviation from an ordered structure by treatment 
or stripping was observed.
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4 different sites at two depths excluding the ceramides of the formulation in the calculation. Data were 
compared using a LMM. B) The correlation between changes in fraction EO ceramides and changes in 
the mean chain lengths (carbon atoms) at the stripped site due to treatment (amount at the stripped site 
subtracting the stripped+treated). C) The EO fraction of the samples at the 4 different sites at two depths. 
Data were compared using a LMM. D) The difference between the SAXD peak 2 position in the stripped and 
stripped+treated sites. The differences were tested with a Wilcoxon matched pairs signed rank test. E) The 
correlation between the SAXD peak 2 (nm) and TEWL (g/m2/h) at the end of the study. Pearson r and p-value 
are provided. F) The correlation between the SAXD peak 2 (nm) and the mean chain length (carbon atoms) 
of all ceramides. Pearson r and p-value are provided. G) The wavenumber in cm-1 of the stretching peak 
position. Data were compared using a LMM.
Mean chain length EO fraction Wavenumber cm-1
Estimate p-value Estimate p-value Estimate p-value
Intercept (control) 46.76 <0.001 0.107 <0.001 2848.60 <0.001
Effect size Stripped -0.37 <0.001 +0.011 0.007 +0.02 0.622
Treated +0.33 <0.001 +0.014 <0.001 +0.09 0.013
Depth +0.08 0.366 0.003 0.537 -0.17 <0.001
Interactions Stripped*Depth +0.29 0.021 +0.012 0.043 +0.26 <0.001
Table 2. The output of the LLMs for mean chain length, EO fraction, and stretching peak position. The 
mean chain length and EO fraction were calculated excluding ceramides NS C44 and EOS C66. The the 
wavenumber in cm-1 of the stretching peak position was calculated using the center of gravity at 90% peak 
height. As fixed factors stripped, treated and depth were used. The intercept was the control site at a depth 







In this study we showed that a VC based formulation is able to accelerate the barrier 
recovery of tape-strip disrupted healthy human skin and, for the first time, demonstrate 
that formulations can act by normalizing the SC lipid composition. Multiple effects of 
barrier disruption and treatment on barrier recovery, ceramide composition, and lipid 
organization were examined (Figure 6 provides an overview). Using PCA, samples were 
clustered into groups of treatment and stripped, based on changes in ceramide profile. 
Moreover, correlations of ceramide levels to PC2 had great similarities to correlations 
between ceramide levels and barrier function after barrier recovery. Thus, the loading 
variables for PC2 were a powerful tool to identify ceramides responsible for profile 
changes related to barrier disruption. At the stripped sites after recovery, multiple 
changes in the ceramide profiles were observed. Treatment partially normalized these 
changes in SC ceramide composition caused by barrier disruption. These ceramide 
profile changes correlated to the barrier function, indicating a relation of the changes 
in these lipids and an accelerated barrier recovery process.
Figure 6. An overview of the effects of barrier disruption and treatment. Negative effects are indicated 
with an – sign and positive effects with a + sign. Barrier disruption induces barrier recovery and treatment 
accelerates this process. Changes in the EO fraction, mean chain length, and lamellar spacing showed 
correlations (cor) indicated by the arrows. The changes in lipid composition, organization and subsequent 
effects are indicated. The ratio (dS+P+H)/S, is mainly determined by the enzymes human-dihydro-Δ4-
desaturate (DES1) and human-sphingolipid-C4-hydroxylase (DES2), responsible for the production of 
sphingosine and phytosphingosine ceramides from dihydrosphingosine ceramides, respectively. The arrows 
indicate that barrier disruption changed the lipid synthesis decreasing this ratio and treatment had the 
opposite effect. The correlation of the TEWL at day 16 (T16) to the subclass ratio is indicated, yet, the amount 
of C34 and the SAXD Peak 2 position correlated to TEWL as well.
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When examining barrier recovery, two phases could be distinguished; a first steep 
increase in barrier recovery % after three hours, followed by second gradually 
diminishing barrier recovery rate. Treatment increased the level of the first phase, 
where after three hours a recovery of ~25% was reached compared to ~10% without 
treatment. However, early effects of formulation on barrier recovery measured by TEWL 
can be caused by leftover formulation on the skin27, even though leftover formulation 
was removed prior to TEWL measurement. The second recovery phase was not affected 
by residual formulation on the skin surface, because the formulation was applied after 
TEWL measurement. During the second phase, treatment had a pronounced effect on 
the barrier recovery rate.
One of the aims of the tested formulation was to replenish SC ceramides. Treatment 
caused significant increase in the formulated ceramides level; even at deeper SC 
layers. Although, a 2-day washout period would have removed almost all superficial 
formulation, it cannot be stated with 100% certainty that the applied ceramides 
measured with LC/MS were incorporated into the SC. Some formulated ceramides could 
still be present in folds of the SC. In cultured skin, it was shown that ceramides stay 
in these folds.23 Even though the increase of the formulated ceramides was observed 
at both depths, tape-strips obtained lipid material from various depth of SC44, and 
thus, tape-strips at both depths can contain material from these folds. Nevertheless, 
it has been demonstrated that when treating stripped ex vivo SC with deuterated 
ceramides once, small ceramide amounts were incorporated into the SC lipid matrix 
after regeneration.45 Others have shown that dimeric ceramides are able to diffuse into 
the skin.46 Together with the relatively large increases of the formulated ceramides, it is 
likely that a fraction of the applied ceramides did incorporate into the SC lipid matrix 
and actively enhance barrier recovery.
Multiple studies have used SC lipid containing formulations, either for long or short 
term treatment18-21 and it was shown that the SC lipids ratio in formulations is essential 
for short term barrier recovery.22,47 Visscher et al. tested the effect of 5 days VC treatment 
on TEWL and hydration of tape-stripped SC, but they observed no changes in TEWL 
when comparing with untreated stripped SC.28 In comparison to our study, the barrier 
was less extensively disrupted. Therefore, incomplete SC removal may lead to a lower 
efficacy of the formulation to improve barrier repair. Here, a detailed description of the 
recovery process is provided and, for the first time, insights are given into changes in 
the SC ceramide composition due to treatment. Below, a mechanism is suggested on 
how a VC based formulation affects ceramide synthesis.
At the stripped (non-treated) sites, two prominent changes were observed in the 
endogenous ceramides: I) the amounts of S subclass were increased, and II) C34 
ceramides were increased. The amounts of these ceramide groups correlated to a 
decrease in barrier function. However, from these data it could not yet be deduced if 
these increases were causal or contingent with a decreased barrier function. A plausible 
reasoning is that in a direct response to barrier disruption, the epidermal calcium 
gradient changed2 and a subsequent modulation in gene expression occurred.29 These 
changes in epidermal homeostasis might have affected the SC ceramide processing in 
two ways.
First, in the epidermal lipid biosynthesis, ceramides containing a dihydrosphingosine 






(Figure 6) (biosynthesis of subclass H ceramides has not yet been reported). When 
defining the ratio between the subclasses as: (dS+P+H)/S, this ratio could only change 
if either of the two known lipid biosynthesis pathways changed. The present study 
showed that this ratio was substantially decreased at the stripped sites, indicating 
barrier disruption influenced the specific synthesis pathways of subclasses S and P. 
Importantly, the ratio between the subclasses correlated strongly to TEWL after barrier 
recovery, which suggests that an optimal ratio is important for an optimal skin barrier 
repair. Furthermore, this correlation was site independent, thus, at stripped sites with a 
higher TEWL, synthesis of sphingosine ceramides was preferred over phytosphingosine 
containing ceramides. Treatment was able to favorably change the subclass ratio 
towards a lipid composition that correlated to a more efficient skin barrier recovery, by 
reducing the amount of NS and AS subclasses.
The second change in lipid biosynthesis due to barrier disruption was the increased 
amount of C34 ceramide. These ceramides are produced from the sphingoid and acyl 
building blocks (a C16 or C18 acyl chain and a C16 or C18 sphingoid chain50) and 
do not require additional elongation steps.51 Although these C34 ceramides can be 
produced as a quick first response to mitigate an impaired SC barrier, C34 ceramides 
are “short” chain ceramides which have been shown to reduce skin barrier function.6,52
Altogether, the C34 ceramides and the ratio of ceramide subclasses could function as 
indicators of reduced barrier function and changes in barrier lipid homeostasis. Here, 
we showed that treatment was able to partly diminish the amount of C34 ceramides 
and, by diminishing the amount of NS and AS, able to change the subclass ratio and 
thus the preceding ceramide synthesis. This reduction could be attributed to I) the semi-
occlusive effect of the formulation, in which the formulation acted as an additional 
barrier, II) the presence of excess formulated ceramides reducing the response to 
replenish the ceramides. As a whole, these data show that the formulation partially 
normalized the lipid biosynthesis and directed the SC towards a more functional 
lipid homeostasis. The lipid organization was used to verify if changes in ceramides 
composition were causal to changes in barrier function.
An important characteristic of the SC ceramide fraction is the mean chain length. The 
chain length was reduced when the barrier function is impaired e.g.: in stripped sites 
and AD.8,17 Here, treatment was able to restore the mean chain length at stripped 
sites (excluding the added ceramides). The mean chain length correlated strongly 
to the fraction of EO ceramides and treatment was able to increase the EO fraction. 
At the treated sites, the spacing was slightly increased indicating an increase in the 
repeat distances of the lamellar phases. Furthermore, the spacing correlated to the 
mean chain length and weakly correlated to the EO fraction (data not shown). Taken 
together, the data suggest that treatment influenced the lamellar lipid organization 
through increasing the EO fraction thereby increasing the mean change length (Figure 
6). 
As far as the lateral packing was concerned, our studies showed that a high fraction of 
lipids formed an orthorhombic packing and this was not affected by stripping. For this 
reason the fraction of lipids forming an orthorhombic packing could not be increased 
due to treatment. Changes due to treatment might become more apparent in affected 
skin of AD patients where the fraction of lipids forming an orthorhombic organization 
is decreased compared to that in healthy skin.43 
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To summarize the effects of the VC based formulation on barrier recovery in healthy 
SC, it was observed that treatment: I) accelerated barrier recovery, II) changed the 
lipid synthesis to a more favorable lipid composition by decreasing the amount of C34 
ceramides and changing the subclass ratio (dS+P+H)/S, and increasing the fraction of 
EO ceramides, III) these changes in lipid composition affected the SC lipid organization 
and correlated to the SC barrier function. Interestingly, similar increases in S subclass, 
and increases in the fraction of C34 chain length ceramides were observed in AD.8,17 An 
essential application of this formulation could be in a particular group of AD patients, 
where barrier restoring lipophilic formulations are commonly used.53 Moreover, the 
treatment presented here modulated the alterations in lipid composition observed in 
AD, towards a healthy lipid homeostasis.
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Figure S1. Indication of TEWL measurement sites. The TEWL measurements at the sites were performed 
at three sections of the sites. Here the stripped site is shown which can be identified by the erythroderma. 
TEWL measurements were performed at the sections indicated with black circles. At every time-point TEWL 
was measured at the right, middle, and left section.
Figure S2. General structure of a ceramide. A ceramide can be composed of three parts which determine 
the subclass of the ceramide. The polar head group consists of a sphingoid base and an acyl chain. There 
are 4 different sphingoid bases in human SC: the sphingoid (S), a dihydro-sphingoid (dS), a 4-hydroxy or 
phyto-sphingoid (P), and a 6-hydroxy-sphinogoid (H). The acyl chain of human SC occurs in 3 different 
forms. A non-hydroxyl acyl chain (N), an α-hydroxy-acyl, and a ω-hydroxy-acyl chain (O). In SC a specific 
type of ceramide occurs where the ω-hydroxyl group becomes esterified with a linoleic acid called the EO 
subclass of ceramides. Together these form 16 different subclasses. Both the acyl and sphingoid chain can 
vary in carbon chain length.
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Figure S3. Linear mixed modelling. The LLMs used here compare the effects of treatment, stripping, and 
depth to the control site of the subject. Using subject as a random factor, gives each subjects control site 
(starting point) a different value, so it can start at any random point. It then determines the effect size of the 
fixed factors (treatment, stripping, and depth). ‘Fixed’ means that the model will say that all these effects 
have the same size for each subject and for each time this effect occurs, so also the effect at treatment at 
the stripped site (difference between stripped and stripped+treated). Because a stripped site can respond 
differently to treatment, an interaction term is added to the model, in this case stripped*treated. In this 
model the interaction is the effect size of treatment additional to the effects of stripping and treatment (the 
fixed factors). For most data we were interested in the effect of treatment on the stripped sites. This is the 
sum of the effect sizes of treatment and stripped*treated (illustrated above as the arrow from stripped site to 
Stripped+treated site). In the schematic above it is shown which steps are required to calculate the predicted 
values of the mixed model. The effect sizes are indicated in italics. Here, we were not interested in the mean 
predicted by the model but in the effect sizes of the different factors, as these calculate how the experimental 
conditions changed and if these were significant.
Figure S4. LLM of the formulation ceramides. A,B) Plots of the amounts of NS C40 and EOS C66 (log (ng/







Figure S5. PC2 plot. The two graphs depict the scores/correlation of all ceramides to PC2. The first graph 
shows all ceramides detected in samples 5-8 and the second graph all ceramides detected in samples 17-20. 
Subclasses were given different colors. High positive scores indicate a correlation to the stripped sites and a 
high negative score to the control sites.
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Figure S6. TEWL at day 16. The TEWL (g/m2/h) 
of all 4 sites after 16 days of treatment and/or 
barrier recovery. The red line is the mean value 
and the significance levels that are indicated 
were tested with a 1-way ANOVA with 
Bonferroni post-test.
Figure S7. The amount of NS C44 and the correlation to the TEWL. Pearson r and the corresponding p-value 
are indicated above the data. The amount in ng/SQ of NS C44 at the 4 site and at both depths (5-8 and 17-
20 tape-strips).
Figure S8. Correlation between mean chain 
length and EO fraction. The correlations 
between the mean chain length and the fraction 
of EO ceramides are depicted per site. Each 
site showed significant Pearson correlations 
coefficients: control (0.9817), stripped (0.9565), 






Ceramide Supplier Ceramide Supplier
N(24)dS(18) Avanti* A(24)S(18) Avanti*
N(18)dS(18) Avanti* A(R)(22)S(18) Avanti*
N(16)dS(18) Avanti* A(S)(22)S(18) Avanti*
N(24)S(18) Evonik** A(R)(16)S(18) Avanti*
N(22)S(18) Avanti* A(S)(16)S(18) Avanti*
N(20)S(18) Avanti* A(R)(24)P(18) Avanti*
N(18)S(18) Avanti* E(18:2)O(30)S(18) Evonik**
N(16)S(18) Avanti* E(18:2)O(27)S(18) Evonik**
N(24)P(18) Evonik** E(18:2)O(30)P(S18) Evonik**
N(22)P(18) Evonik** E(18:2)O(27)P(18) Evonik**
N(16)P(18) Evonik** N(24deu)S(18) Evonik**
* Avanti polar lipids (Alabaster AL, USA), ** Evonik Industries (Essen, Germany)
Ingredient Supplier Proportion
Super sterol esters Crodalan SWL Croda, UK 49.72% w/w
Crodamol GTCC miglyol Croda, UK 36.98% w/w
Squalane Galderma 6.63% w/w
Cholesterol USP/NF Croda, UK 3.63% w/w
Palmitic acid (FFAC16:0) Emery 0.83% w/w
Stearic acid (FFA 18:0)) Berg + Schmidt 0.10% w/w
Ceramide NS (C40) Evonik, Germany 1.18% w/w
Ceramide EOS (C66) Evonik, Germany 0.83% w/w
Oxynex LM (anti-oxidant; protection of 
Ceramide EOS) containing:
Merck, Germany 0.10% w/w
DL-γ-Tocopherol (Vitamin E) 0.025% w/w
Lecithin 0.025% w/w
Ascorbyl palmitate 0.020% w/w
Glycerin monostearate 0.020% w/w
Glycerin monooleate 0.0025%w/w
Citric acid 0.0025%w/w
Table S1. List of the ceramides standards used with the corresponding supplier.


































Pearson r -0.26 0.05 0.15 0.20 0.17 -0.15 -0.26 -0.27 -0.34 -0.43































Pearson r -0.50 -0.40 -0.34 -0.34 -0.22 -0.09 -0.06 -0.23 -0.11 0.86
p-value 0.06 0.14 0.21 0.22 0.44 0.76 0.82 0.42 0.71 0.06
Log NS C40 Log EOS C661
Estimate p-value Estimate p-value
Intercept 1.575 <0.001 1.50 <0.001
Effect size Depth -0.135 0.011 -0.135 0.011
Stripped +0.204 <0.001 +0.356 <0.001
Treated +0.580 <0.001 +0.697 <0.001
Interactions Depth*Treated -0.207 0.006 -0.200 0.006
Stripped*Treated -0152 0.040 -0.260 0.040
Calculated 
amount
NS C40 (ng/SQ) EOS C66 (ng/SQ)
Depth 5-8 Depth 
17-20
Depth 5-8 Depth 
17-20
Control 37.62 27.57 38.93 28.54
Stripped 60.13 44.09 88.32 64.76
Treated 142.92 65.12 193.64 89.64
Stripped Treated 160.87 73.29 241.68 111.87
Table S3. Correlations to amount of barrier disruption. The table depict the Pearson r and p-value of the 
correlation between the TEWL directly after barrier disruption and AUC of the barrier recovery curve. It also 
contains the correlations between the difference in TEWLs directly after barrier disruption and the ΔT at 
different recovery %.
Table S4. LLM of the formulation ceramides. The table (A) shows the output of the LLM of the logarithm 
of the amount of NS C40 (ng/SQ) and EOS C66 (ng/SQ). The effect sizes are the changes to the intercept 
(control site tape-strips 5-8), due to the depth, stripping, and treatment. The second part of the table (B) 












Effect size Stripped -0.37 0.19
Treated -0.43 0.08
Depth 12-20 -0.59 0.02
Interactions Stripped*Treated 0.44 0.23
Stripped*Depth 12-20 0.67 0.07
Treated*Depth 12-20 0.47 0.17
Stripped*Treated*Depth 12-20 -1.32 0.01
Table S5. LLM of the effects on the lateral lipid packing. The output of linear mixed models for the FWHM 
of the scissoring peak. The intercept is the estimated amount at the control site at a depth of 2-10 tape-strips. 
Estimates are in cm-1. The effect size is the amount in cm-1 with which the variable changes the intercept. 
Significance levels of all effect sizes and interactions are given.
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ATR-FTIR Attenuated total reflection Fourier transform 
infrared spectroscopy
EASI Eczema area and severity index
MCL Mean ceramide carbon chain length
MuCER Mono-unsaturated ceramide
SC Stratum corneum
SCORAD Scoring atopic dermatitis
TEWL Transepidermal water loss
Keywords
Atopic dermatitis, stratum corneum, emollient, vernix caseosa, monotherapy, clinical 








Background: Skin barrier repair emollients are a commonly used treatment in atopic 
dermatitis (AD). Yet, their mechanistic effects are poorly understood.
Objective: Determining the mechanistic effects of emollient monotherapy on the skin 
barrier lipids in AD patients and assessing the clinical outcome.
Methods: An intra-individual controlled pilot study was performed in which moderate 
to severe AD patients applied a ceramide containing emollient for 2 weeks. The 
SCORAD, local SCORAD, EASI and TEWL were monitored. The changes in ceramide 
composition and lipid organization were performed using mass spectrometry and 
infrared spectroscopy, respectively.
Results: At non-lesional sites improvements in barrier function and lipid parameters 
were observed. Correlations between lipid parameters and barrier function were 
determined. Correlating changes during treatment occurring within the same patient 
showed that changes were equally in size. The AD severity at the start of the study 
correlated to TEWL at the study its end. Yet, monotherapy with the selected emollient 
aggravated the clinical outcome
Limitations: Seven patients were studied in an open label study and no non-treated 
control was included.
Conclusion: Monotherapy with an emollient improved the non-lesional skin barrier, yet, 
was insufficient treatment for severe AD patients. Lipids parameters could be promising 
targets for future clinical research.
Capsule summary
•	 Vernix caseosa based emollient treatment increased barrier recovery in 
healthy volunteers
•	 In AD patients a vernix caseosa emollient improved the non-lesional SC lipid 
barrier, yet, did not prevent lesion formation.
•	 In moderate to severe AD patients, monotherapy with this emollient was 




Emollients are commonly prescribed for treatment of atopic dermatitis (AD), to 
counter xerosis, and enhance skin barrier repair.1,2 A wide variety of emollients are 
available and have three different supposed mechanisms of action. Firstly, emollients 
are thought to function as a supplemental barrier decreasing penetration of irritants, 
allergens, and pathogens and decreasing transepidermal water loss (TEWL). Secondly, 
they increase stratum corneum (SC) hydration by added humectants. Lastly, emollients 
could replenish SC barrier lipids.1,3 These last emollients are a specific group of barrier 
repair emollients.4 Of this group the clinical effects on scoring atopic dermatitis 
(SCORAD), TEWL and skin hydration have been extensively studied.4-9 However, the 
mechanism by which these emollients enhance skin barrier repair and affect the SC 
lipid composition and organization is unknown. This is of particular interest as specific 
emollient components could normalize lipid composition, thereby enhancing barrier 
repair.10,11
Lipids form an integral part of the SC barrier. This barrier can be represented as a brick-
and-mortar structure, with terminally differentiated keratinocytes (corneocytes) as the 
bricks, and the lipids as mortar.12 The lipid matrix is the main route of SC penetration13 
and the lipid constitution is important for a proper barrier formation.14 Three main SC 
lipid classes are known: sterols, free fatty acids, and ceramides. The latter are the most 
diverse group of SC lipids, characterized by different hydrophilic head groups defining 
the subclass, and a large variation in hydrocarbon chain length within these subclasses 
(Figure S1 shows all subclasses relevant for this paper). 
Alterations in composition and organization of SC lipids have been reported in AD15 
and were correlated to a decreased barrier function.16,17 A recent study showed 
that barrier disruption induced similar lipid alteration in regenerated SC of healthy 
volunteers and that a vernix caseosa based emollient treatment ameliorated the lipid 
composition.18 The composition of this emollient was based on the composition that 
was most effective in enhancing barrier repair in mice.19 It is hypothesized that this 
emollient could have a similar beneficial effect in AD patients.
Here, a pilot study is presented in which this vernix caseosa based formulation was 
applied on moderate to severe AD patients as monotherapy. Improvement of lipid 
organization and barrier function at the non-lesional sites was observed for most 
patients. Despite that, the local SCORAD of these patients indicated aggravated AD at 




To determine if the vernix caseosa based formulation, containing ceramides NS 
and EOS, enhanced the skin barrier by improving the SC lipid composition and 
organization, a pilot study with 8 AD patients was performed. Institutional approval by 






and all experiments were performed according to the declaration of Helsinki. Before 
inclusion each patient signed an informed consent. Patients were included when: they 
suffered from AD for ≥2 years and their base-line TEWL was ≥15 g/m2/h on non-lesional 
skin sites. An elevated TEWL was set as selection requirement, as this was associated 
with an altered lipid organization.16 This would enable the ability to determine if the 
emollient could improve the lipid organization. One patient its data was excluded, as 
another treatment was subscribed during the trail.
Study design
The study commenced at T-7: a photograph was taken and the SCORAD, local SCORAD 
(ventral forearms), Eczema area and severity index (EASI), and TEWL (AquaFlux AF200, 
BIOX, London, UK) were determined. For one week patients did not receive any 
systemic treatment or treatment on their ventral forearms. At T0, TEWL was measured 
at non-lesional sites of both ventral forearms and the arm with the highest TEWL was 
selected. A photograph was taken and 12 tape-strips were obtained for ceramide 
analysis (according to Boiten et al.20). Tape-strips were extracted using a modified 
Bligh and Dyer and, thereafter, quantified using LC/MS. After every two tape-strips, an 
infrared spectrum was measured on the stripped site using attenuated total reflected 
Fourier transfer infrared spectroscopy (ATR-FTIR, Agilent Technologies, Inc., Santa 
Clara, CA). In the spectrum the CH2 symmetric stretching peak position of the SC lipids 
was determined, which is a measure for the SC lipids (conformational) ordering.21
Thereafter, patients applied for two weeks 2x daily the vernix caseosa based formulation 
on both forearms (Table S1: formulation composition). During the entire study patients 
were allowed to treat the rest of their skin as they normally would. To minimize the 
burden on the patient, no non-treated control was included. After the treatment period, 
a two-day washout period commenced. Of the non-lesional and lesional sites at T16, 
TEWL, lipid composition and lipid organization were determined. The SCORAD, local-
SCORAD, EASI, and a photograph were taken as well. Figure S2 gives an overview of 
the sites investigated and the timeline of the study.
Statistical analysis
Statistical analyses were performed using SPSS (V24 IBM). Group wise comparisons 
were performed using linear mixed modeling with treatment as fixed factor and lesional 
as a nested factor within treatment (lesional site were always treated and compared 
to non-lesional). Subject paring was performed and patients were set as a random 
variable when comparing sites. Correlations between parameters were examined 
using GraphPad Prism (version 6.05). To determine if correlations were site/treatment 
independent, the correlations were determined using a Linear mixed models without 
subject paring, with site (control, non-lesional, and lesional) as fixed factors and the 




Affected lipid parameters in atopic dermatitis
In the present study mechanistic effects of emollient treatment on SC lipid parameters 
were examined in AD patients. Previously, alterations in AD patients SC lipid 
composition have been observed.15 More recently, treatment with an emollient had 
shown to affect these alterations in lipid parameters in healthy volunteers.18 Five lipid 
parameters important for barrier function were examined: 1) CH2 stretching peak 
position: higher values indicate more disordering in the SC lipids causing a reduced 
barrier function;17 2) Mean ceramide carbon chain length (MCL), a longer MCL was 
correlated to increased barrier function;15 3) fraction of ceramides with a 34 carbon 
chain length, which was associated with a decreased barrier function;15 4) ceramide 
subclasses ratio: (dS+P+H)/S excluding (esterified)omega hydroxyl-ceramides (EO, O 
ceramides). This ratio was shown to decrease with a reduced barrier;18 5) fraction 
of ceramides with a unsaturated carbon chain (MuCER), increased unsaturation was 
correlated to decreased barrier function.22
Figure 1(A-E) depict the 5 parameter as observed in this study. The CH2 stretching 
peak position decreased significantly at non-lesional treated site compared to control. 
No significant changes in MCL, C34, and MuCER amount were observed when skin 
was treated. The subclass ratio (dS+P+H)/S decreased after treatment. The MCL was 
shorter in the lesional site compared to the non-lesional. The decreased stretching peak 
position indicates that the lipid ordering increased which is expected to be beneficial 
for the skin barrier function. The stretching peak position of the treated lesional skin 
is expected to increase but it was not significantly higher than at the control or non-
lesional site.
Changes in clinical parameters due to treatment
Next to pathophysiological changes in SC lipids, the impact treatment had on the disease 
progression was examined. Therefore, two scores of AD severity were determined at 
Figure 1. The changes in lipid parameters between the control site (T0), non-lesional site (T16) and lesional 
site (T16). The last two were treated sites. A) Stretching peak position of the SC lipids in cm-1. B) Mean total 
carbon chain length of the ceramides in carbon atoms. C) Amount of ceramides with a carbon chain length 
of 34 (nmol/sq*10). D) Ceramide subclass ratio as: (dS+P+H)/S excluding acyl-ceramides (EO ceramides), 
E) Amount of mono-unsaturated ceramides (nmol/sq*10).  Significant changes are indicated by the p-value. 
The double brackets show the F-test results for treatment, which takes into account treatment effects in both 






the start (T7) and end (T16) of the study. Figure 2A and B show the SCORAD and EASI, 
respectively. No significant change in either score was observed. As treatment was 
only applied on the ventral forearm, the local SCORAD of that area was determined. 
This parameter increased significantly, also illustrated in Figure 3, in which images of 
each patients arm at three time points are shown, depicting more lesional sites at T16.
During the study the skin barrier function was monitored using TEWL. No significant 
changes in TEWL occurred between the control (T-7), the control (T0) and non-lesional 
treated site (T16). In all patients, TEWL at the lesional sites (T16) was significantly higher 
than at the non-lesional sites. There was a substantial inter-individual difference in 
TEWL values: patient one (P01) had a larger increase in TEWL than all other patients; 
Patient 5 (P05) did not have completely non-lesional sites at the ventral forearm, 
therefore, had an exceptionally high TEWL value at the control site. Altogether, the 
emollient treatment effects on barrier function were diverse but beneficial for most 
patients, i.e. the TEWL decreased for most patients, only the mean difference in TEWL 
was not significant (Figure S3 depicts TEWL changes).
As the main route of TEWL is through the SC lipids, TEWL was correlated to the lipid 
parameters. All these parameters were correlated to TEWL or 1/TEWL (Table 1, Table 
S3 contains correlations between all parameters). Parameters which decrease with an 
increase in TEWL showed to have inverse (1/x) correlations, therefore, 1/TEWL was 
used. These correlations to TEWL or 1/TEWL and inter-correlations of the parameters 
indicate that these lipid parameters and barrier function correspond per patient. 
Exemplified by P05 where TEWL was high and the lipid parameter C34 and MuCER 
were high, and MCL and subclass ratio were low. To further investigate the changes 
during treatment at non-lesional site, the effect size of treatment per patient was studied.
Figure 2. Changes in clinical parameters. A,B,C) SCORAD, EASI and local SCORAD at the start and end 
of the study for all patients, each patient is indicated by a specific color. D) TEWL throughout the study for 
each patient. Non-lesional and lesional sites were both treated and measured at T16. Lesional sites were 
significantly different form all other sites (F-test of mixed model p=0.006).
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Cor. Site Cor. Site Cor. Site Cor. Site Cor. Site
F-test 
p-value
0.001 0.313 <0.001 0.969 0.002 0.821 <0.001 0.447 <0.001 0.146
Slope p-value Slope p-value Slope p-value Slope p-value Slope p-value
Control 8.84 0.107 3.327 0.009 11.531 0.061 0.0124 0.001 0.0140 0.002
Treated 15.78 0.023 3.468 0.007 15.254 0.023 0.0173 <0.001 0.0115 0.001
Lesional 22.49 0.006 3.114 0.004 10.147 0.097 0.0105 0.032 0.0538 0.067
Figure 3. Photographs of the examined ventral forearm of each patient at three time points. Photos were 
taken one week prior the emollient treatment (T-7), at the start of the treatment (T0) and 2 days after the 
treatment period (T16). 
Table 1. Correlations of lipid parameters to barrier function. For each parameter the correlation to either 
TEWL of 1/TEWL is given. The F-test p-values indicated if the correlation (cor) was significant, or that this 







Patient specific treatment effects
As treatment might affect each patient differently, changes during treatment per patient 
were examined. The effect sizes, control (T0) subtracted from the non-lesional site (T16), 
were compared. For each clinical and lipid parameter, Figure 4A depicts if treatment 
had a beneficial effect i.e. towards a better skin barrier or less severe AD. Distinctions 
between patients were observed: P01 had no beneficial effects, whereas treatment 
had the most beneficial effects for P05, although only lesional sites were examined 
in this patient. Furthermore, some changes in parameters coincided for multiple 
patients, in that, if one was beneficial the other was as well: e.g. MCL and EO%, C34 
and TEWL, and MuCER and stretching peak position. Effect sizes of these parameters 
were compared, as shown in Figures 4B to 4E. These correlations in parameters 
showed that during treatment, parameters were similarly affected, either positively or 
negatively (Table S4 shows all correlations). Demonstrating that besides correlating in 
size, parameter changes within a patient correlated as well. Changes in MuCER and 
Stretching coincided, but were not correlating significantly (Figure S4). Changes during 
treatment were not dependent on state of the skin at the control time point, exemplified 
by P05 who showed the most progress with only lesional sites. Altogether, changes 
were subject dependent, yet, not independent of one another. 
However, the AD severity at other body sites could influence the study outcome 
through a systemically induced flare. To examine if the severity of AD at the beginning 
of the study had an influence on the barrier function at the end of the study, the 
SCORAD and EASI scores at T-7 were compared with TEWL at T16 (Figure 5). Significant 
correlations for both SCORAD and EASI were observed. Although the limited data 
points, both correlations indicated that the AD severity had a substantial influence on 
changes in barrier function. No correlations between AD at T-7 and lipid parameters at 
T16 were observed.
Figure 4. Effects of treatment. A) Plot showing if a change during treatment was beneficial (indicated by a 
colored square) or non-beneficial (indicated by the absence of a colored square). Each patient has its own 
color.  The – and + signs indicate if beneficial change in parameters were positive or negative values. B-E) 
effects size of the changes and how they compared to one another. If both are negative or positive for the 
same individual, it indicates if the effects were in a similar direction. The line indicates a linear regression, 




The goal of this study was to determine how monotherapy with a barrier repair 
enhancing vernix caseosa based emollient could improve the SC lipid composition 
and organization. Changes at non-lesional sites showed that for most patients the 
barrier improved during the study. This was accompanied by significant increases 
in lipid ordering, indicating that treatment improved the lipid barrier. However, no 
direct effects of the emollient on ceramide composition parameters were observed. 
This indicates that effects on lipid organization might be due to a combined effect 
of different ceramide parameters or other constituents of the emollients like free fatty 
acids, which were previously shown to incorporate into the SC lipid matrix.23 At the 
control and treated site, the SC parameters examined and the correlations between them 
were comparable to previous studies without treatment.15,16 Here, it is demonstrated 
that these correlations were also valid when treatment was included. Moreover, the 
correlation between changes in parameters during treatment indicated that changes in 
TEWL correlated to changes in C34 ceramides and changes in the lipid conformational 
ordering. The latter also correlated to the (dS+P+H)/S subclass ratio, indicating that a 
change in ceramide subclass could alter the conformational ordering. A trend between 
changes in MuCERs and changes in conformational ordering was observed. 
Previously, we showed that treatment of healthy volunteers with a compromised skin 
barrier decreased C34 amount and increased MCL.18 However, these changes induced 
by barrier disruption and the changes due to treatment (treatment effect sizes, C34: 
0.69, MCL: 0.3 carbons), were significantly smaller than changes observed in the 
present study. In this study, the beneficial effects of the barrier restoring emollient 
had a small impact compared to the larger changes in SC lipid properties induced 
by AD. However, these lipid parameters could be used as targets for future research 
into topical AD treatment to normalize the skin barrier, as changes in these lipids did 
correspond to changes in TEWL (Figure 4C and D).
Aggravation of the disease state was observed in most patients. During the study no 
systemic corticosteroids or immunosuppressants were used. Therefore, a systemic 
Figure 5. Correlations between clinical parameters and skin barrier function. A, B) Correlation between the 
SCORAD and EASI at T-7 and the TEWL at T16, respectively. The r and p-values are the pearson correlation 






immune response, external factors like weather changes, or formulation sensitization 
could have had a major impact on the disease state. Other studies have shown that 
when the AD severity is first reduced by anti-inflammatory treatment, a barrier restoring 
formulation was beneficial.24,25 That the AD severity at T-7 correlated to the barrier at T16 
indicates that the disease state influenced the barrier during the study and strengthens 
the hypothesis that systemic inflammation played a role in the outcome of this study. 
A specific example was P01, who started with the highest SCORAD of all patients but 
relative normal barrier function and lipid parameters, both barrier function and lipid 
parameters changed during treatment to a state comparable to lesional skin. The large 
variation in lipid parameters between subjects and effects during treatment could, thus, 
partially be explained by the AD severity. From the result presented here, it can be 
concluded that in moderate to severe AD patients, monotherapy with this emollient 
was insufficient to counter the progression of AD.
For several patients treatment did have beneficial effect on the lipid parameters. 
Because observed effect sizes were small and it might take many cycles of cornification 
and desquamation before the barrier is properly restored, more than two weeks of 
formulation application would be desirable to sufficiently restore the lipid composition 
and organization in SC in AD patients. This should be combined with anti-inflammatory 
treatment to counter flares during this period. The results in non-lesional AD skin support 
the assumption that a vernix caseosa emollients can help restore barrier abnormalities 
in AD as it does in healthy volunteers with artificial induced barrier impairment.
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Figure S1. Ceramide structure. The ceramide consists of an acyl chain bound to a sphingoid base. The 
subclass is defined by these two parts of the ceramide. There are 3 different acyl chains indicated by the 
letters N, A, and O and one where there is an linoleic acid esterified to the omega hydroxyl (EO). There 
are 4 different sphingoid bases dS, S, P, and H. The color in the text corresponds to the structural moiety 
with the same color. The name of the ceramide subclass is a combination of the letters that define the acyl 
chain and the sphingoid base e.g. EOS is an Esterified-Omega-hydroxy acyl-Sphingosine.
Figure S2. Study design. Showing the timeline of the study and sites examined. At each time point the tests 
that were performed are indicated. Below the test the sites of the arm that were examined are shown.
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Figure S3. Difference in TEWL. Difference between T0 and T16 of non-lesional sites.







Super sterol esters Crodalan SWL Croda, UK 49.72% w/w
Crodamol GTCC miglyol Croda, UK 36.98% w/w
Squalane Galderma 6.63% w/w
Cholesterol USP/NF Croda, UK 3.63% w/w
Palmitic acid (FFAC16:0) Emery 0.83% w/w
Stearic acid (FFA 18:0)) Berg + Schmidt 0.10% w/w
Ceramide NS (C40) Evonik, Germany 1.18% w/w
Ceramide EOS (C66) Evonik, Germany 0.83% w/w
Oxynex LM (anti-oxidant; protection of 
Ceramide EOS) containing:
Merck, Germany 0.10% w/w
DL-γ-Tocopherol (Vitamin E) 0.025% w/w
Lecithin 0.025% w/w
Ascorbyl palmitate 0.020% w/w






MIXED stretch BY Treated Lesional
  /CRITERIA =CIN(95) MXITER(100) MXSTEP(10) SCORING(1) 
SINGULAR(0.000000000001) HCONVERGE(0, 
    ABSOLUTE) LCONVERGE(0, ABSOLUTE) PCON-
VERGE(0.000001, ABSOLUTE)
  /FIXE D= Treated  Lesional(Treated)| SSTYPE(3)
  /METHOD=REML
  /PRINT =SOLUTION TESTCOV
  /RANDOM = INTERCEPT | SUBJECT(Volunteer) COV-
TYPE(VC).
* Treated and lesional 
are the fixed factors 
and lesional is nested 
within Treated
* Volunteer is the 
pairing per subject.
Code used to 
plot correla-
tions
MIXED MCL BY Site WITH C34
  /CRITERIA=CIN(95) MXITER(100) MXSTEP(10) SCORING(1) 
SINGULAR(0.000000000001) HCONVERGE(0, 
    ABSOLUTE) LCONVERGE(0, ABSOLUTE) PCON-
VERGE(0.000001, ABSOLUTE)
  /FIXED=Site C34 Site*C34 | SSTYPE(3)
  /METHOD=REML
  /PRINT=SOLUTION TESTCOV.
* Site 1 to 3 are 
control, non-lesional, 
and lesional and is a 
fixed factor
* MCL and C34 
are the dependent 
variable and 
covariate. These were 
changed dependent 
on the correlation that 
was examined.
Table S1. Composition vernix caseosa formulation.
Table S2. SPSS scripts
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TEWL 1/TEWL MCL MuCER
pearson r p-value pearson r p-value pearson r p-value pearson r p-value
TEWL -8.78 <0.001 -0.806 <0.001 0.725 <0.001
1/TEWL -0.877 <0.001 0.813 <0.001 -0.765 <0.001
MCL -0.806 <0.001 0.813 <0.001 -0.670 <0.001
MuCER 0.725 <0.001 -0.765 <0.001 -0.670 <0.001
EO% -0.475 0.030 0.537 0.012 0.695 <0.001 -0.323 0.153
C34 0.845 <0.001 -0.810 <0.001 -0.906 <0.001 0.796 <0.001
Ratio -0.753 <0.001 0.850 <0.001 0.852 <0.001 -0.696 <0.001
Stretching 0.586 0.005 -0.616 0.003 -0.384 0.086 0.466 0.033
EO% C34 Ratio Stretching
pearson r p-value pearson r p-value pearson r p-value pearson r p-value
TEWL -0.475 0.030 0.845 <0.001 -0.753 <0.001 0.586 0.005
1/TEWL 0.537 0.012 -0.810 <0.001 0.850 <0.001 -0.616 0.003
MCL 0.695 <0.001 -0.906 <0.001 0.852 <0.001 -0.384 0.086
MuCER -0.323 0.1534 -.796 <0.001 -0.696 <0.001 0.466 0.033
EO% -0.483 0.0266 0.406 0.0676 -0.403 0.070
C34 -0.483 0.027 -0.819 <0.001 0.387 0.083
Ratio 0.406 0.068 -0.819 <0.001 -0.365 0.104
Stretching -0.403 0.070 0.387 0.083 -0.365 0.1037






TEWL MCL EO% MuCER
pearson r p-value pearson r p-value pearson r p-value pearson r p-value
TEWL -0.467 0.291 0.081 0.863 0.597 0.157
MCL -0.467 0.291 0.849 0.016 0.392 0.384
EO% -0.081 0.863 0.849 0.016 0.642 0.121
MuCER 0.597 0.157 0.392 0.384 0.641 0.121
C34 0.921 0.003 -0.692 0.085 -0.259 0.575 0.334 0.464
Ratio -0.871 0.011 0.457 0.302 -0.063 0.893 -0.477 0.279
Stretching 0.785 0.037 -0.177 0.705 0.277 0.547 0.640 0.121
SCORAD 0.288 0.531 -0.349 0.443 -0.505 0.248 -0.110 0.814
EASI 0.205 0.660 -0.181 0.698 -0.427 0.339 -0.063 0.893
local 
SCORAD
0.373 0.410 -0.138 0.768 0.197 0.671 0.274 0.552
C34 Ratio Stretching SCORAD
pearson r p-value pearson r p-value pearson r p-value pearson r p-value
TEWL 0.921 0.003 -0.871 0.011 -0.785 0.037 0.288 0.531
MCL -0.692 0.085 0.457 0.302 -0.177 0.705 -0.349 0.433
EO% -0.259 0.575 -0.063 0.893 0.277 0.547 -0.505 0.248
MuCER 0.334 0.464 -0.477 0.279 0.640 0.121 -0.110 0.814
C34 -0.934 0.002 0.744 0.055 0.137 0.770
Ratio -0.934 0.002 -0.815 0.026 0.114 0.808
Stretching 0.744 0.055 -0.815 0.036 0.088 0.851
SCORAD 0.137 0.770 0.114 0.808 0.088 0.851
EASI 0.017 0.971 0.233 0.615 -0.110 0.815 0.874 0.010
local 
SCORAD
0.365 0.421 -0.518 0.234 0.442 0.321 -0.093 0.842
EASI Local SCORAD
pearson r p-value pearson r p-value
TEWL 0.205 0.660 0.373 0.410
MCL -0.181 0.698 -0.138 0.768
EO% -0.427 0.339 0.197 0.671
MuCER -0.063 0.893 0.274 0.552
C34 0.017 0.971 0.365 0.421
Ratio 0.233 0.615 -0.518 0.234
Stretching -0.110 0.815 0.442 0.321













The skin consists of three layers, the hypodermis, dermis, and epidermis, and protects 
the body from the external environment by reducing transepidermal water loss and 
penetration of pathogens, allergens, and irritants. The epidermis is subdivided in 4 
strata, of which the stratum corneum (SC) is the outermost layer. The SC consists of 
terminally differentiated corneocytes embedded in a lipid matrix. The corneocytes 
and lipid matrix are assembled in a brick-and-mortar structure, in which the bricks 
represent the corneocytes and the mortar represents the lipid matrix.1 The lipid matrix is 
a major penetration pathway. The lipids in the lipid matrix are excreted at the interface 
between the viable epidermis and the SC, after de novo synthesis in the keratinocytes 
or uptake from the systemic circulation (e.g. essential fatty acids). 
Three main lipid classes in the SC are free fatty acids (FAs), ceramides (CERs), and 
cholesterol. A wide chain length distribution is observed for both FAs and CERs, as well 
as unsaturation of the carbon chain.2-5 At least 18 subclasses of CERs are identified, 
based on the chemical structure of the sphingoid base and acyl chain, see Figure 
1.6-14 The SC lipids in the extracellular matrix are highly ordered in lamellae stacked 
on top of each other, with repeat distances of 6 nm (short periodicity phase, SPP) and 
13 nm (long periodicity phase, LPP).15-19 Within the lamellae, the lipids adopt either 
an orthorhombic, hexagonal, or liquid organization (Figure 2). The relative fraction of 
lipids adopting an orthorhombic lateral packing, the relative fraction of lipid lamellae 
with a repeat distance of 13 nm, and the CER composition affect the skin barrier 
function.15,20-22 
In several inflammatory skin diseases, the skin barrier function is impaired. Although 
the underlying cause of these inflammatory diseases is different, the impaired skin 
barrier partly based on changes in lipid composition are very similar. These changes 
are e.g. increased level of CER subclass NS, decreased levels of CER NP and CER 
EOS, an increased fraction of unsaturated lipids, and a reduced average carbon 
chain length of CERs and FAs. These changes in lipid composition may contribute 
to a less dense lateral ordering, and a reduced lamellar repeat distance.4,5,17,23-31 The 
skin barrier function is most extensively studied in atopic dermatitis (AD), and many 
studies focused on possible treatment strategies. However, to date treatment of AD is 
far from optimal: corticosteroids are used to reduce the inflammatory response, but 
they are associated with side effects, such as skin atrophy.32 To reduce the absorption 
of pathogens, allergens, and irritants, topical application of endogenous skin barrier 
lipids to repair the skin barrier may be an attractive approach.33
Vernix caseosa (VC) is a white, cheesy substance covering and protecting a fetus in 
the last trimester of pregnancy and during delivery.34-36 It consists of the barrier lipids 
CERs, FAs, cholesterol, as well as squalene, wax esters, sterol esters, triglycerides, and 
phospholipids.36,37 Skin barrier repair in mice is enhanced after application of VC, but 
also after application of synthetic formulations mimicking VC.38,39 However, the skin 
barrier repair response in animal skin is different from that in human skin.40 Currently 
cultured human skin models (e.g. human skin equivalents) are often labor intensive and 






Figure 1. Ceramides subclasses in the stratum corneum lipid matrix. CERs consist of a sphingoid base 
coupled to a FA, which can both vary in molecular structure. CERs are named according to their molecular 
structure. The acyl chain can either be non-hydroxylated (N), α-hydroxylated (A), ω-hydroxylated (O), or 
esterified ω-hydroxylated (EO), whereas the sphingoid base is either a sphingosine (S), dihydrosphingosine 
(dS), phytosphingosine (P), 6-hydroxysphingosine (H), or dihydroxy dihydrosphingosine (T). 
the in vivo human skin barrier response are attractive to study topical treatment, 
especially when focusing barrier repair of AD skin or other inflammatory skin diseases. 
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Figure 2. Organization of the lipids within the stratum corneum lipid matrix. A) Schematic overview of 
the epidermal morphology. B) The corneocytes are embedded in the lipid matrix in a brick-and-mortar 
structure. C) The lipids in the matrix are stacked in lamellae in between the corneocytes. D) More details of 
the lipid lamellae. E) Two lamellar phases are identified with a repeat distance (d) of either 13 nm (LPP) or 
6 nm (SPP). F) Within the lamellae, the lipids are organized in either an orthorhombic, hexagonal, or liquid 






Aim of the study
The aim of this thesis was to determine whether a novel VC based formulation effectively 
enhances skin barrier repair in AD patients and normalizes the SC lipid composition 
and organization. In order to achieve this goal, the following studies were performed:
1. An ex vivo human skin barrier repair (SkinBaR) model was developed for 
studying the interactions between topical applied compounds and the skin 
barrier. The SC lipid properties during and after skin barrier repair process were 
examined. The lipid composition and organization in the regenerated SC of 
this SkinBaR model were compared to the lipid composition and organization 
in regenerated SC in healthy human skin in vivo.
2. The effects of a selected number of barrier FAs and/or CER subclasses applied 
in a VC based formulation on the SkinBaR model during skin barrier repair 
were examined. Especially the interactions between the VC components and 
the SC lipid matrix were studied.
3. The effect of the VC based formulation on skin barrier repair in compromised 
healthy skin, and in AD skin was assessed. 
Development of a skin barrier repair model
In order to study skin barrier repair in vitro, no suitable skin models are available. 
Generation of human skin equivalents is very labor intensive and therefore less 
attractive. In Chapter 2 a novel ex vivo human skin barrier repair (SkinBaR) model was 
developed. Cyanoacrylate was used to remove SC from the skin thereby reducing the 
barrier function. Epidermal morphology, differentiation, SC lipid composition and 
organization were examined after culturing the skin for 8 days at 37°C and 32°C. 
The results showed that the skin was actively proliferating and differentiating, which 
resulted in regeneration of SC. The lipids in the regenerated SC mainly adopted a 
hexagonal lateral lipid organization at the expense of lipids forming an orthorhombic 
lateral organization as observed in healthy native human SC. The altered skin barrier 
properties showed similarities with AD skin. Consequently, the SkinBaR model has the 
potential to study the skin barrier repair process and how this process may be influenced 
by application of topical formulations and/or by changing the environmental factors. 
In Chapter 3, the reproducibility of the stripping of the SkinBaR model was examined 
in more detail. The influence of initial degree of barrier disruption on the lipid 
organization of the regenerated SC was assessed. The results showed that when 
25%, 50%, and 75% of the SC was removed the SC is able to regenerate fully in 
a period of 8 days to a comparable number of corneocyte layers as in native SC. 
Major morphological differences (e.g. parakeratosis) and a change in lamellar structure 
were only observed when initially 75% of the SC was removed. As far as the lateral 
lipid organization was concerned, a gradual increase in degree of barrier disruption 
(percentage of SC removed) resulted in a gradually less dense packing, but the lipid 
ordering was only affected if at least 50% of the SC was removed. These results led 
to the conclusion that the degree of barrier disruption in the SkinBaR model can be 
controlled and that the SkinBaR model can be adjusted to match the desired lateral or 
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lamellar lipid organization. Therefore, the SkinBaR model offers the possibility to study 
the interaction of skin barrier repair formulations with the lipid matrix, in which the 
degree of deviation in lipid organization to that in healthy human skin can be adjusted 
on demand.
It is unknown how well the SkinBaR model reflects in detail the lipid properties in the 
regenerated SC in human skin in vivo. Hence, the lipid properties of the SkinBaR model 
were compared to those of in vivo skin after tape stripping. The studies are described in 
Chapter 4. The comparison focused on the CER composition (i.e. CER subclass, CER chain 
length, and degree of unsaturation), and lipid conformational ordering. Compared to 
control skin, in both models, levels of S subclass CERs (e.g. CER NS and CER AS, see 
Figure 1) were increased, whereas levels of P subclass CERs (e.g. CER NP, CER AP, 
and CER EOP, see Figure 1) were decreased. Furthermore, the mean ceramide chain 
length was decreased, and higher levels of CERs with i) a total chain length of 34 
carbon atoms and/or ii) mono-unsaturation were observed. The lipid chains were less 
ordered in regenerated SC of the SkinBaR model, however, this was not statistically 
significant. Overall, changes in CER composition in the SkinBaR regenerated SC were 
more pronounced than changes in CER composition in the in vivo regenerated SC. The 
only pronounced difference between the models was the level of EO ceramides, which 
was decreased in the SkinBaR model and increased in the in vivo regenerated skin. 
Nevertheless, the lipid properties in both models mimicked quite closely the ceramide 
composition in AD, but also showed similarities with other inflammatory skin diseases. 
Therefore, the SkinBaR model and in vivo tape stripped healthy skin can serve as a first 
model to study skin barrier repair of compromised inflamed skin.
Application of VC based formulations on the skin barrier repair model
Since a VC based lipid formulation was shown to enhance skin barrier repair in mice 
models, this formulation was applied on the regenerating SC of the SkinBaR model. 
In Chapter 5 we focused on the interaction of the FA component incorporated in the 
VC based formulation and studied its interaction with the SC lipid matrix. FAs with 
a chain length of either 16, 18, or 22 carbon atoms were used in the formulation. 
The lipid organization and composition of the regenerated SC on which a formulation 
was applied immediately after stripping with cyanoacrylate were examined after 
regeneration. The applied formulations, especially when incorporating FA C18 and 
C22 resulted in an increase in the fraction of lipids adopting an orthorhombic packing. 
Deuterated FAs were used in order to i) distinguish between the FAs in the formulation 
from the endogenous FAs and ii) to examine whether FAs were partitioning in the same 
lattice as the SC lipids. The thermotropic behavior of the formulated deuterated FAs 
applied on the SC matched that of native SC, indicating that the deuterated FAs are 
incorporated in the SC lipid matrix. When focusing on the lateral lipid organization, 
the studies demonstrated that i) application of FAs with a longer chain length resulted 
in a higher fraction of lipids adopting an orthorhombic lateral packing, and ii) the 
applied deuterated FAs partitioned in one lattice with the SC lipids. Analyzing the FA 
composition with LC/MS showed that a fraction of the deuterated FAs with a chain 






atoms. The studies described in this chapter demonstrate that the VC based formulation 
is able to improve the SC lipid properties of the ex vivo SkinBaR model.
Another important class of SC barrier lipids are CERs. In Chapter 6, studies are described 
in which CERs were used in the VC based formulation and applied on the SkinBaR 
model. CER subclasses NS and EOS were formulated, as well as a combination of both 
subclasses and FA with 16 carbon atoms. Compared to non-stripped and stripped control 
skin, application of the formulation with a single CER did not change the morphology 
of the cultured skin. A higher fraction of lipids adopted a dense orthorhombic lateral 
lipid packing when the formulation was applied, and CER EOS was more effective 
than CER NS. As CER NS was available with a deuterated acyl chain, interactions of 
deuterated CER NS with the SC lipid matrix were also studied, but no strong evidence 
could be obtained indicating that CER NS is incorporated in the lipid matrix. With 
regards to a formulation in which CER NS, CER EOS, and the FA were combined, 
interactions of these components with other lipids in the VC based formulation 
were examined. Interactions of CER NS with the other lipids of the formulation were 
observed as well as interactions of FA with the other formulation lipids. However, these 
studies revealed separate FA rich and CER NS rich domains. Applying the combined 
VC based formulation on regenerating SC resulted in participation of FA in the SC lipid 
matrix. When participation of CER NS from the combined formulation with the SC 
lipid matrix was examined, the thermotropic behavior of the formulation alone and 
the SC on which the formulation was applied were very similar. Therefore, changes in 
thermotropic behavior induced by application of CER NS (i.e. participation in the lipid 
matrix) could not be used to examine whether CER NS participated in the lipid matrix. 
As no deuterated CER EOS was available, it was not possible to determine participation 
of CER EOS in the SC lipid matrix. The lamellar organization of the SC lipids was not 
affected by application of either the formulations with a single CER or the formulation 
in which CER NS, CER EOS, and FA were combined. These results indicate that CERs 
enhance the fraction of lipids adopting a dense orthorhombic lateral packing and 
that the barrier lipids of the VC based formulation are, at least partly, incorporated in 
the SC lipid matrix. The VC based formulations might have the potential to restore a 
compromised skin barrier function as observed in inflammatory skin diseases.
Application of VC based formulations on human skin 
As described above, tape-stripping and regeneration of healthy human skin in vivo 
resulted in i) increased levels of S subclass CERs, especially CER NS and CER AS, ii) 
decreased levels of P subclass CERs, especially CER NP, iii) a reduced mean chain 
length, iv) a higher level of CERs with a total chain length of 34 carbon atoms, and v) 
a higher fraction of mono-unsaturated CERs. In Chapter 7 studies are described in which 
a VC based formulation was applied on tape-stripped human skin in vivo during a 
regeneration period of 14 days. The formulation contained CER NS, CER EOS, and 
two FAs with chain lengths of 16 and 18 carbon atoms. The skin barrier repair was 
monitored over time for a tape-stripped treated and a tape-stripped non-treated site. For 
both sites and two control sites (treated and non-treated), the ceramide composition, 
lateral lipid ordering, and the lamellar lipid organization were examined. Accelerated 
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barrier repair was observed after application of the VC based formulation. Application 
of the VC based formulation resulted in a CER composition that was shifting toward 
the CER composition of the control sites. The shift was most pronounced for CERs with 
a chain length of C34 carbon atoms, the subclass CER AS (both reduced in relative 
amounts), and the average chain length (increase in chain length). Furthermore, a ratio 
dividing the CERs based on their synthesis route (e.g. (dS + P + H)/S) correlated with 
skin barrier function, with a higher ratio indicating a better barrier function. As the 
changes induced by tape-stripping of the skin were partially normalized by treatment 
with the VC based formulation indicating a positive effect of the formulation on the 
skin barrier, it is of interest to study its effect on the skin barrier in AD patients. 
The promising results obtained after application of the VC based formulation on 
disrupted healthy skin justified application on naturally compromised skin of AD 
patients. A pilot study in which 8 moderate to severe AD patients were included is 
described in Chapter 8. The patients applied the formulation for 2 weeks, twice a day. 
The changes in disease activity, skin barrier function, ceramide composition, and 
lipid ordering were analyzed. After 2 weeks of treatment, the lipid ordering improved 
compared to control before treatment, indicating an improved skin barrier. For 
most patients, the transepidermal water loss decreased after applying the VC based 
formulation. Treatment did not affect the mean carbon chain length of the CERs, the 
level of CERs with 34 carbon atoms, and the level of mono-unsaturated CERs. The ratio 
between several CER subclasses ((dS + P + H)/S) showed a slight decrease. Overall, 
the lipid parameters highly correlated with transepidermal water loss and with each 
other. Some changes in parameters coincided for multiple patients, in that, if one 
was beneficial the other was as well: e.g. mean carbon chain length and level of EO 
CERs, CERs with 34 carbon atoms and transepidermal water loss, and level of mono-
unsaturated CERs and lipid ordering. The clinical outcome, however, was negatively 
affected, and the severity of the AD at the start of the study was of influence on the skin 
barrier repair. Furthermore, the treatment affected each patient differently. Emollients 
could be helpful to treat AD, however, monotherapy with only a VC based formulation 
might not be sufficient in patients with moderate to severe AD.
Conclusions
The studies in this thesis describe the development of an ex vivo SkinBaR model and 
a novel VC based formulation to treat the skin of AD patients. We showed that the 
SkinBaR model is highly reproducible and the model can be used to mimic multiple 
degrees of skin barrier disruption. The SkinBaR model shows many parallels in lipid 
composition and organization with in vivo disrupted and regenerated skin and with that 
in AD skin. Application of a VC based formulation containing CERs and FAs resulted 
in a denser lipid organization in the SC of the SkinBaR model. Furthermore, in in 
vivo regenerated healthy human skin the VC based formulation enhanced skin barrier 
repair and reduced modulation in lipid composition induced by tape-stripping and SC 
regeneration. However, when applied as monotherapy on moderate to severe AD skin, 






observed. The overall disease activity was not influenced and the local disease severity 
was increased. The optimal treatment aiming to repair the skin barrier for moderate to 
severe AD skin needs further research. 
Perspectives 
Enhancement of the SkinBaR model
The SkinBaR model has been successfully developed to study the human skin barrier 
repair response. It is an easy to use model mimicking closely the lipid properties of 
AD skin. The SkinBaR model can be used to study the skin barrier repair response in 
ex vivo conditions, with a focus on the barrier lipid composition and organization. 
Furthermore, the effect of topical formulations on the intercellular lipid matrix can be 
studied. As discussed in Chapter 4, the ex vivo SkinBaR model shows many parallels 
with in vivo compromised skin. 
Currently, the SkinBaR model reflects several aspects of AD skin. However, the 
ultimate goal is to have a SkinBaR model which reflects the lipid composition in 
healthy compromised human skin in clinical studies. However, there are several 
differences in the SkinBaR model compared to the compromised model in vivo. This 
is demonstrated by a substantially accelerated skin barrier repair response in the 
SkinBaR model compared to the in vivo compromised skin. This is demonstrated by 
a hyperproliferation indicated by a higher expression of Ki67, and more pronounced 
changes in the CER composition compared to in vivo compromised skin, especially 
the increase in ceramide subclass AS and NS, the level of CER with total chain length 
of 34 carbon atoms, and a reduction in subclass NP demonstrates an activation of 
the keratinocytes. In order to bring the SkinBaR model closer to the in vivo situation, 
changing the culturing conditions and environmental factors offer a suitable starting 
point. These are:
i) It is widely known that enzyme activity and expression are temperature 
dependent. In the skin, a temperature gradient exists from the core body 
temperature of 37°C to the skin surface temperature of around 32°C. This 
gradient might be essential for proper functioning of epidermal differentiating 
proteins and enzymes involved in lipid biosynthesis. A temperature gradient in 
the skin during culture might be obtained by maintaining the culture medium 
at 37°C and reducing the environmental temperature to 32°C, the skin surface 
temperature. 
ii) Other factors that might influence the skin barrier repair process of the ex vivo 
cultured skin are relative humidity, UV light exposure, and physical stress. 
In the in vivo situation, the relative humidity to which the skin is exposed is 
much lower than in culturing conditions. Additionally, skin is exposed to a 
certain dose of UV light and physical stress (e.g. movement, washing, clothes) 
in real-life conditions. Implementing these factors during generation of the SC 
in the SkinBaR model might lead to a SC of the SkinBaR model mimicking the 
in vivo SC generation much closer. 
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iii) In the SkinBaR model common inflammatory responses that slow down 
the skin barrier repair in healthy compromised skin is partly lacking.41 The 
inflammatory response can be established by supplementing cytokines to the 
medium of the SkinBaR model. For example, cytokines IL-1α and IL-6 attract 
immune cells to the injured site. 
iv) During the culturing period, the medium composition changes because the 
skin uses the nutrients from the medium and releases the waste products into 
the medium. This may be improved by a flow through system of the medium 
mimicking more closely the in vivo situation. 
Having a SkinBaR model which reflects healthy compromised human skin in vivo, 
offers a starting point to expand the use of the SkinBaR model to study detailed aspects 
of the skin barrier and the repair process:
i) The SkinBaR model could be used to study multiple other inflammatory 
skin diseases. Each inflammatory skin disease is characterized by a unique 
subset of changes compared to healthy human skin. These changes involve 
the lipid properties as well as protein expression and immunological aspects, 
e.g. upregulation of inflammatory cytokines.42,43 Being able to mimic several 
aspects of inflammatory skin diseases in addition to the altered lipid properties 
induced by inflammation, may be achieved by adding pro-inflammatory 
cytokines to the culture medium. This may affect the morphology, enzyme 
expression, and lipid properties.44 Mimicking these unique changes of each 
inflammatory skin disease offers the opportunity to develop disease-specific 
treatments tackling specific problems of the skin barrier repair response, 
such a disease-specific lipid composition and lipid ordering, reducing the 
inflammatory response, or influencing the expression and activity of specific 
proteins. These disease-specific treatments might involve topical formulations, 
but also medium supplements could be used to represent systemic treatment. 
ii) Systemically circulating substances could potentially be of influence on 
regeneration of the SC. Therefore, adding those substances to the culture 
medium of the SkinBaR model allows us to examine the influence of the 
uptake of systemically circulating substances on the regenerated SC. 
Improvement of the skin barrier repair formulation
The studies described in Chapter 5 and 6 of this thesis showed that the VC based 
formulation improves the lipid packing and that the applied FA with a chain length of 
16 carbon atoms are elongated in the epidermis and therefore are part of the epidermal 
biosynthesis. Application on compromised healthy skin in vivo resulted in enhanced 
skin barrier repair. However, further improvement of the VC based formulation might 
be possible by changing the composition:
i) In AD skin, the level of CER subclass NS is increased and the levels of CER 
EOS and NP is decreased.5,27,29,30,45,46 As described in Chapter 7, an increased 
CER subclass ratio ((dS+P+H)/S) correlated with an improved barrier function, 
indicating that increasing the relative level of CER NP in the SC might improve 






even be a better candidate to incorporate in the VC based formulation. 
However, due to its very stable crystal formation, CER NP is difficult to 
formulate. Natural VC consists of a combination of a large number of CER 
subclasses that are also present in human SC, including CERs NS, EOS, and 
NP and variations in CER chain length.37 Perhaps changing the CER fraction 
of the VC based formulation by using various CER subclasses with a variation 
in chain length might improve the barrier repair potential of the formulation, 
but is not an easy task. 
ii) FAs are another main lipid class in the SC lipid matrix. In healthy SC, FAs with 
a chain length of 24 and 26 carbon atoms are most abundant.2-4 Unfortunately, 
these FAs were not available for clinical studies. Furthermore, FAs with a 
chain length of only 16 carbon atoms are most abundant in VC.37 As the FA 
with 16 carbon atoms was elongated in the studies described in Chapter 5, 
this FA was used in the VC based formulation in the clinical settings. In AD 
skin, the average chain length of the lipids is reduced, and a higher abundance 
of FAs with 16 and 18 carbon atoms has been reported.4 This might indicate 
that elongation of the FAs in AD skin is impaired.47 Therefore, using FAs with 
longer chain lengths in the VC based formulation might be more beneficial in 
treating AD skin. 
In the studies described in Chapter 8, the VC based formulation was applied on the 
skin of patients with moderate to severe AD and resulted in improvements in the lipid 
composition in some patients and improved lipid conformational ordering in most 
patients when applied on non-lesional skin. Unfortunately, the local disease severity 
did not improve, but this might be expected as the local disease severity is influenced 
by the overall disease severity and thus the degree of systemic inflammation. This might 
suggest that monotherapy with a VC based formulation is not sufficient. Therefore, in 
future it might be of interest to use this formulation in the treatment of patients with 
only mild AD skin or even dry skin. Another option is to investigate the use of this 
formulation to prevent the development of AD in those humans that have a high risk 
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De huid is ontworpen om het lichaam te beschermen tegen invloeden van buitenaf. 
Hierdoor wordt het binnendringen van ziekteverwekkers, allergenen en irriterende 
stoffen beperkt. De huid bestaat uit drie lagen: het onderhuidse vetweefsel (ook wel 
hypodermis genoemd), de lederhuid (de dermis) en de opperhuid (de epidermis) met 
huidcellen die keratinocyten genoemd worden. Dit wordt schematisch weergegeven 
in Figuur 1A. De epidermis is onderverdeeld in 4 lagen, waarvan de hoornlaag de 
buitenste laag is. De hoornlaag wordt ook wel het stratum corneum (SC) genoemd. 
Het SC bestaat voornamelijk uit dode huidcellen (corneocyten) die worden omsloten 
door een lipidenmatrix (vetten). De structuur van het SC lijkt op een gemetselde muur 
waarin de corneocyten de stenen zijn en de lipidenmatrix het cement (Figuur 1B).1 
Deze intercellulaire lipiden vormen een belangrijke penetratieroute door het SC. In de 
levende epidermis worden de lipiden opgeslagen in keratinocyten en aan het grensvlak 
van de levende epidermis en het SC worden ze uitgescheiden. 
De drie hoofdklassen van de lipiden in het SC zijn vetzuren, ceramiden en 
cholesterol. Vetzuren en ceramiden hebben beide een grote variatie in lengte van de 
koolstofketens. Naast verzadigde koolstofketens, zijn ook ceramiden en vetzuren met 
een onverzadigde koolstofketen aanwezig.2-5 Ten minste 18 ceramide subklassen zijn 
inmiddels geïdentificeerd. De indeling in subklassen is gebaseerd op hun chemische 
structuur.6-14 Een ceramide bestaat uit een sfingosine en een vetzuurketen (ook wel 
acylketen genoemd), zoals weergegeven in Figuur 2. Een bijzondere groep ceramiden 
zijn die van de subklassen EO en O. Deze EO en O ceramiden hebben een extra 
vetzuur, waardoor deze ceramiden een zeer lange koolstofketen hebben. De lipiden 
in de matrix van het SC zijn georganiseerd in gestapelde lipidenlagen, ook wel de 
lamellaire lipidenstructuur genoemd. De lagen in de lamellaire structuur herhalen zich 
over een afstand van 6 of 13 nanometer, die respectievelijk de SPP (short periodicity 
phase) en de LPP (long periodicity phase) genoemd worden (Figuur 1E).15-19 Binnen 
deze lipidenlagen zijn de lipiden geordend met een bepaalde dichtheid: de laterale 
lipidenorganisatie. Het overgrote deel van de lipiden is zeer compact geordend, dit 
wordt een orthorombische organisatie genoemd. Een kleinere fractie is geordend 
in een minder compacte structuur, dit wordt een hexagonale organisatie genoemd. 
Wanneer de lipiden nog minder geordend zijn, bevinden ze zich in een vloeibare 
structuur (Figuur 1F). Zowel de aanwezigheid van een orthorombische structuur als de 
aanwezigheid van de long periodicity phase zijn belangrijk voor de barrièrefunctie van 








Figuur 1. Organisatie van de lipiden in de SC lipidenmatrix. A) Schematisch overzicht van de structuur 
van de opperhuid. B) De structuur van het SC lijkt op een gemetselde muur waarin de corneocyten de 
stenen zijn en de lipidenmatrix het cement. C) De lipiden in de matrix zijn op elkaar gestapeld en deze 
lagen worden lamellen genoemd. D) De lipidenlamellen in meer detail. E) De lengte (d) waarover zich de 
structuur herhaald wordt de repetitieafstand genoemd. In SC zijn de lange periodiciteitsfase (13 nm) en de 
korte periodiciteitsfase (6 nm) aanwezig . F) Binnen deze lamellaire structuur zijn de lipiden geordend in 
een laterale organisatie. De laterale organisatie kan een hoge dichtheid hebben (orthorombisch), een iets 




Figuur 2. Ceramide subklassen in de SC lipidenmatrix. Ceramiden bestaan uit een sfingosine (weergegeven 
in blauwe kleur) gekoppeld aan een vetzuur (weergegeven in zwart), die beide in moleculaire structuur 
kunnen variëren. De moleculaire structuur van de ceramiden bepaalt de naam. De vetzuurketen kan ofwel 
niet-gehydroxyleerd (N), α-gehydroxyleerd (A), ω-gehydroxyleerd (O), of veresterd ω-gehydroxyleerd 
(EO) zijn, terwijl de sfingosinketen ofwel een sfingosine (S), dihydrosfingosine (dS), fytosfingosine (P), 







Bij huidziekten waarbij de huid ontstoken is, is de barrièrefunctie van de huid vaak 
verminderd. Deze huidziekten worden ook wel inflammatoire huidziekten genoemd. 
Alhoewel de onderliggende factor(en) van deze inflammatoire huidziekten per ziekte 
verschilt, zijn de veranderingen in de lipidensamenstelling erg vergelijkbaar. Deze 
veranderingen zijn bijvoorbeeld een verhoogde aanwezigheid van ceramide subklasse 
NS, verlaagde aanwezigheid van ceramide subklassen NP en EOS, een verhoogde 
fractie lipiden met onverzadigde koolstofketens, en een kortere gemiddelde ketenlengte 
van de ceramiden en vetzuren. Deze veranderingen in lipidensamenstelling kunnen 
leiden tot een minder geordende laterale lipidenorganisatie en een verandering in de 
lamellaire structuur.4,5,17,23-31 De barrièrefunctie van de huid is het meest uitgebreid 
onderzocht in patiënten met constitutioneel eczeem (ook wel atopisch eczeem 
of atopische dermatitis (AD) genoemd). Veel studies richtten zich op het effect van 
mogelijke behandelmethoden. Ondanks deze inzet is de behandeling van AD nog 
steeds niet optimaal: corticosteroïden worden gebruikt om de ontstekingsreactie te 
remmen, maar ze hebben ook bijwerkingen zoals een dunner wordende huid.32 Om 
de opname in de huid van allerlei ongewenste stoffen te verminderen en daarbij de 
kans op ontsteking te verkleinen, is lokale behandeling van de huid met huideigen 
barrièrelipiden een aantrekkelijke aanpak.33 
Vernix caseosa (VC) is een witte, water bevattende, vettige substantie die op de huid 
van baby’s aanwezig is. VC beschermt de baby zowel in het laatste trimester van 
de zwangerschap als ook tijdens de geboorte.34-36 VC bestaat uit de barrièrelipiden 
ceramiden, vetzuren en cholesterol in ongeveer dezelfde samenstelling als aanwezig 
is in het SC, maar ook andere lipiden zoals squaleen, waxesters, sterolesters, 
triglyceriden en fosfolipiden zijn aanwezig.36,37 Uit studies met muizen blijkt dat het 
barrièreherstel van de huid gestimuleerd wordt na behandeling met VC in vergelijking 
met onbehandelde huid. In het lab werd een formulering ontwikkeld die veel aspecten 
van de natuurlijke VC nabootst. Ook na behandeling met deze formulering werd het 
barrièreherstel van de muizenhuid gestimuleerd.38,39 Alhoewel, het herstel van de 
huidbarrière in dierenhuid anders is dan het herstel in menselijke huid, was dit een 
belangrijke waarneming.40 
Het kweken van in vitro huidmodellen (bijv. humane huid equivalenten) is 
arbeidsintensief en tijdrovend. Minder tijdrovende huidmodellen die het herstel 
van de huidbarrière in de menselijke huid in vivo (‘in het lichaam’) nauwkeurig 
nabootsen zijn daarom erg aantrekkelijk. Vooral als het gaat om huidmodellen die de 




Het doel van het onderzoek beschreven in dit proefschrift was tweeledig. Ten eerste, 
bepalen of een formulering gebaseerd op VC effectief het barrièreherstel van huid 
van AD patiënten kan bevorderen. Ten tweede, bepalen of deze formulering de 
lipidensamenstelling en –organisatie in het SC kan normaliseren. Om deze doelen te 
bereiken zijn de volgende studies uitgevoerd:
1. Een ex vivo (‘buiten het lichaam’) huidmodel werd ontwikkeld specifiek 
om het barrièreherstel te onderzoeken (SkinBaR model). Hiertoe werd SC 
van de huid verwijderd, waarna SC door de huid werd geregenereerd onder 
gecontroleerde kweekcondities. Om de gelijkenis van het model te testen werd 
de lipidensamenstelling en –organisatie in hersteld (geregenereerd) SC van het 
SkinBaR model vergeleken met die in geregenereerd SC in vivo menselijke 
huid, waarvan het SC ook was verwijderd. 
2. Het SkinBaR model werd vervolgens gebruikt om het effect van de formulering 
gebaseerd op VC op het barrièreherstel te onderzoeken. Hierbij werd vooral 
de interacties tussen een aantal geselecteerde vetzuren en/of ceramiden 
subklassen van de VC formulering en de SC lipidenmatrix onderzocht. 
3. Het effect van de formulering gebaseerd op VC op huidbarrièreherstel in 
gezonde huid waarvan het SC verwijderd was werd onderzocht. Tenslotte 
werd het effect van de formulering op het barrièreherstel in huid van AD 
patiënten onderzocht. 
Ontwikkeling van een huidbarrièreherstel model
Momenteel zijn er geen geschikte in vitro modellen beschikbaar om het 
huidbarrièreherstel te onderzoeken. Het genereren van humane huid equivalenten is 
erg arbeidsintensief en daarom minder aantrekkelijk. In het onderzoek beschreven in 
Hoofdstuk 2 werd daarom een nieuw model ontwikkeld om huidbarrièreherstel te meten 
(het SkinBaR model). In dit model werd SC van de huid verwijderd door middel van 
‘strippen’ met cyanoacrylaat (secondelijm). Uit resultaten bleek dat de huid zich actief 
ontwikkelde en differentieerde, wat resulteerde in het herstel van het SC. Tevens werd 
de lipidensamenstelling en –organisatie in het SC onderzocht De samenstelling van 
de lipiden in het geregenereerde SC was veranderd en de lipiden waren voornamelijk 
hexagonaal geordend. Dit in tegenstelling tot de oorspronkelijk gezonde huid waarin 
de lipiden voornamelijk een orthorombische structuur vormden. De veranderingen in 
de samenstelling en organisatie van de lipiden leken veel op de lipidenorganisatie en 
samenstelling in SC van AD patiënten. Dit betekent dat het SkinBaR model een eerste 
indicatie kan geven of formuleringen het huidbarrièreherstelproces kunnen beïnvloeden 
en of de formuleringen geschikt zouden kunnen zijn voor het barrièreherstel van de 
huid van AD patiënten. 
In Hoofdstuk 3 werd onderzocht of de hoeveelheid verwijderd SC invloed heeft op het 
barrièreherstel van het SkinBaR model. Uit de resultaten bleek dat verwijdering van 







niet beïnvloedde. Grote verschillen in de structuur van de epidermis, zoals celkernen 
in de dode cellen (parakeratosis) en een verandering in de lamellaire structuur, werden 
alleen waargenomen wanneer 75% van het SC was verwijderd. Met betrekking tot de 
laterale lipidenstructuur bleek, dat wanneer er geleidelijk meer SC verwijderd was, de 
lipidenorganisatie geleidelijk minder dicht georganiseerd was in het geregenereerde 
SC. De ordening van de lipiden was alleen veranderd nadat minstens 50% van het 
SC was verwijderd. Hieruit blijkt dat de mate van verstoring van de lipidenorganisatie 
in de huidbarrière van het SkinBaR model gecontroleerd veranderd kan worden en 
dat het SkinBaR model aangepast kan worden aan de gewenste laterale of lamellaire 
lipidenstructuur om formuleringen te testen. Het SkinBaR model biedt dus de 
mogelijkheid om de wisselwerking van huidbarrièreherstelformuleringen met de 
lipidenmatrix te onderzoeken, waarin de mate van afwijking in lipidenorganisatie ten 
opzichte van gezonde huid naar wens kan worden aangepast. 
Het is onbekend in welke mate het SC van het SkinBaR model het geregenereerde SC 
nabootst van in vivo menselijke huid waarvan het SC verwijderd was. Dit is interessant 
om te onderzoeken omdat de barrièrefunctie van gestripte en herstelde in vivo huid 
wel als model gebruikt wordt voor inflammatoire huidziekten. Om dit te onderzoeken 
zijn de SC lipideneigenschappen van het SkinBaR model vergeleken met die van in 
vivo huid na het strippen en regeneratie van het SC. Deze studies zijn beschreven in 
Hoofdstuk 4. Vooral de lipiden in het SC werden onderzocht, zoals de ceramide subklasse 
samenstelling, ceramide ketenlengte, mate van onverzadiging van de ceramiden en de 
lipidenordering. In beide modellen waren de S subklasse ceramiden (bijv. ceramide 
NS en ceramide AS, zie Figuur 2) verhoogd t.o.v. de controles (niet gestripte huid). 
Tevens bleek dat de P subklasse ceramiden (bijv. ceramide NP, ceramide AP en 
ceramide EOP, zie Figuur 2) juist verlaagd waren. Daarnaast was de gemiddelde 
ketenlengte van de ceramiden korter. Hiervoor was vooral een grotere aanwezigheid 
van ceramiden met een totale ketenlengte van 34 koolstofatomen verantwoordelijk. 
Ten slotte was de fractie enkelvoudig onverzadigde ceramiden verhoogd. Het 
bleek dat in het geregenereerde SC in vitro de lipidenketens minder goed geordend 
waren dan in geregenereerd SC in vivo, alhoewel dit niet statistisch significant was. 
In het algemeen waren de veranderingen in de ceramidensamenstelling van het 
geregenereerde SC van het SkinBaR model meer uitgesproken dan de veranderingen in 
de ceramidensamenstelling van het geregenereerde SC in vivo, maar wel vergelijkbaar. 
De enige opvallende tegenstelling tussen beide modellen was de fractie EO ceramiden. 
Deze fractie was verlaagd in het SkinBaR model en verhoogd in het geregenereerde SC 
in vivo. Desalniettemin bootsten beide modellen de ceramidesamenstelling in SC van 
AD na, maar ook overeenkomsten in lipidensamenstelling met andere inflammatoire 
huidziekten werden gevonden. Daarom kunnen zowel het SkinBaR model als in vivo 
strippen met tape dienen als een eerste model om te voorspellen of formuleringen 
geschikt zouden kunnen zijn voor barrièreherstel van aangedane en ontstoken huid. 
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De interactie van formuleringen gebaseerd op VC met het SkinBaR model
Omdat de formulering gebaseerd op VC een sneller herstel van de huidbarrière in 
muizen tot gevolg had, is deze formulering aangebracht op het SkinBaR model direct 
na strippen. In Hoofdstuk 5 zijn studies beschreven waarin de interactie van vetzuren in 
de formulering met de SC lipidenmatrix werd onderzocht. De vetzuren die gebruikt 
werden, hadden een ketenlengte van 16, 18 of 22 koolstofatomen. De lipidenorganisatie 
en –samenstelling van het gegenereerde SC werden gemeten. De aangebrachte 
formuleringen, voornamelijk die waarin vetzuren met 18 of 22 koolstofatomen verwerkt 
waren, verhoogden de fractie lipiden die zich in de orthorombische fase bevinden. 
Dezelfde studies zijn ook uitgevoerd met gedeutereerde vetzuren, d.w.z. vetzuren 
waarbij de waterstofatomen in de koolstofketen vervangen zijn door deuterium. 
Gedeutereerde vetzuren zijn gebruikt i) om onderscheid te kunnen maken tussen 
vetzuren uit de formulering en huideigen vetzuren, en ii) om te kunnen onderzoeken 
of de vetzuren uit de formulering opgenomen worden in de structuur gevormd door 
de SC lipiden. Het temperatuurafhankelijke gedrag van de op de huid opgebrachte 
gedeutereerde vetzuren kwam overeen met het temperatuurafhankelijke gedrag van 
de lipiden in het controle SC (niet gestript, niet gekweekt) zonder formulering. Dit 
was een eerste aanwijzing dat de gedeutereerde vetzuren opgenomen worden in de 
lipidenmatrix van het geregenereerde SC. Betreffende de laterale lipidenorganisatie, 
bleek uit de studies dat i) het aanbrengen van vetzuren met een langere koolstofketen 
resulteerde in een grotere fractie lipiden die een orthorombische fase vormen en ii) 
de aangebrachte gedeutereerde vetzuren opgenomen worden in de SC lipidenmatrix. 
Uit de analyse van de vetzuren met massaspectrometrie (techniek gebruikt om de 
lipidensamenstelling te meten) bleek dat een gedeelte van de gedeutereerde vetzuren 
met een ketenlengte van 16 koolstofatomen werd verlengd tot een ketenlengte van 
voornamelijk 24 koolstofatomen. Uit de studies blijkt dat de formulering gebaseerd op 
VC de SC lipideneigenschappen van het ex vivo SkinBaR model verbeterde. 
Een andere belangrijke klasse barrièrelipiden zijn de ceramiden. In Hoofdstuk 6 worden 
studies beschreven waarin ceramiden gebruikt zijn in de formulering gebaseerd 
op VC. Ceramide subklassen NS en EOS werden in de formulering gebruikt, maar 
ook een combinatie van beide subklassen en het vetzuur met 16 koolstofatomen. 
Door vergelijken van niet gestripte huid en gestripte controlehuid (geen formulering 
gebruikt) bleek de structuur van de huid niet te veranderen na het aanbrengen van de 
formulering met een enkele ceramide subklasse tijdens het herstel. De fractie lipiden 
in de orthorombische fase in het SC was hoger na het aanbrengen van de formulering, 
en ceramide subklasse EOS was effectiever in het verhogen van de fractie lipiden die 
een orthorombische fase vormen dan subklasse NS. Omdat ceramide subklasse NS 
ook beschikbaar is met een gedeutereerde vetzuurketen konden de interacties tussen 
gedeutereerd ceramide NS en de SC lipidenmatrix in meer detail worden onderzocht. 
Uit de resultaten konden we echter niet de conclusie trekken dat NS werd opgenomen 
in de lipidenmatrix. Vervolgens werd de formulering onderzocht waarin zowel 
ceramide subklassen NS en EOS en het vetzuur aanwezig waren. Zowel ceramide 
NS als het vetzuur gingen interacties aan met de andere lipiden in de formulering. 







formulering aanwezig waren. Deze gecombineerde formulering werd ook op de 
gestripte huid aangebracht. Het bleek dat de vetzuren van deze formulering in de 
SC lipidenmatrix werden opgenomen. Er kon echter niet onderzocht worden of de 
opname van ceramide subklasse NS plaats vond, omdat het temperatuursafhankelijke 
gedrag van de geregenereerde huid en de VC formulering te veel op elkaar leken. De 
lamellaire organisatie in de SC lipiden matrix werd niet beïnvloed door het aanbrengen 
van een formulering. Uit deze resultaten blijkt dat de ceramiden in de formulering de 
vorming van de orthorombische fase bevorderen en dat de lipiden in de formulering 
(ten minste gedeeltelijk) worden opgenomen in de SC lipidenmatrix. Dit geeft aan 
dat de formulering gebaseerd op VC een interessante kandidaat is om de aangedane 
huidbarrièrefunctie, zoals in inflammatoire huidziekten, te herstellen.
Het testen van de formuleringen op menselijke huid in vivo 
Zoals hierboven beschreven is in hoofdstuk 4, resulteerde het strippen van menselijke 
huid in vivo met tape in i) een grotere fractie van S subklasse ceramiden, voornamelijk 
ceramiden NS, AS en EOS, ii) een kleinere fractie van P subklasse ceramiden, 
voornamelijk ceramide NP, iii) een kortere gemiddelde ketenlengte, iv) een grotere 
fractie van ceramiden met een totale ketenlengte van 34 koolstofatomen en v) een 
grotere fractie van onverzadigde ceramiden. In Hoofdstuk 7 zijn studies beschreven 
waarin de formulering gebaseerd op VC aangebracht werd op in vivo gestripte 
gezonde menselijke huid tijdens een herstelperiode van 14 dagen. De formulering 
bevatte ceramiden subklassen NS en EOS en twee vetzuren met ketenlengtes van 16 en 
18 koolstofatomen. Het huidbarrièreherstel van een gestripte behandelde plek en een 
gestripte niet-behandelde plek werd in de tijd gevolgd. Voor beide plekken en twee 
controle plekken (behandeld en niet-behandeld) werd de ceramidensamenstelling, 
de laterale lipidenorganisatie en de lamellaire lipidenorganisatie onderzocht. Het 
aanbrengen van de formulering resulteerde in een versneld herstel van de huidbarrière. 
Daarnaast was de ceramidensamenstelling van de herstelde huid na het aanbrengen 
van de formulering veranderd en gedeeltelijk genormaliseerd t.o.v. de gestripte en 
geregenereerde huid zonder formulering. Deze verschuiving was het meest zichtbaar 
bij de ceramiden met een totale ketenlengte van 34 koolstofatomen, de ceramide 
subklasse AS (beide afgenomen in relatieve hoeveelheden) en de gemiddelde ketenlengte 
(toename in ketenlengte). Daarnaast was de verhouding die ceramiden subklassen 
verdeeld op basis van hun synthese route ((dS + P + H)/S) hoger. De formulering had 
een positief effect op het huidbarrièreherstel. Daarom is het zeer interessant om het 
effect van de formulering op de huid van AD patiënten te onderzoeken. 
De veelbelovende resultaten die verkregen werden na het aanbrengen van de 
formulering gebaseerd op VC op gezonde huid met een verminderde barrièrefunctie 
rechtvaardigde het testen van de formulering op de huid van AD patiënten met een 
verminderde barrièrefunctie. Een verkenningsstudie waarin patiënten met matig tot 
ernstig AD mee deden is beschreven in Hoofdstuk 8. De patiënten smeerden de formulering 
2 weken lang, twee keer per dag. De veranderingen in de huidbarrièrefunctie, 
ceramidensamenstelling, lipidenordening en ziekteactiviteit werden geanalyseerd. Na 
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een behandeling van 2 weken was de lipidenorganisatie verbeterd vergeleken met de 
huid voor de behandeling. Voor de meeste patiënten was het waterverlies door de 
huid verlaagd na behandeling met de formulering gebaseerd op VC. De gemiddelde 
ketenlengte van de ceramiden, de fractie ceramiden met een ketenlengte van 34 
koolstofatomen en de fractie onverzadigde ceramiden waren niet beïnvloed door de 
behandeling. De verhouding tussen de ceramiden subklassen ((dS + P + H)/S) was 
licht verlaagd. Over het algemeen waren er verbanden tussen lipidenvariabelen en 
het waterverlies door de huid. Sommige veranderingen gaven hetzelfde verband voor 
meerdere patiënten. Als de ene parameter verbeterd werd, was ook de andere verbeterd, 
bijvoorbeeld: de gemiddelde ketenlengte en de fractie EO ceramiden, ceramiden met 
een ketenlengte van 34 koolstofatomen was gerelateerd aan het waterverlies door 
de huid, en de fractie onverzadigde ceramiden en de laterale lipidenorganisatie. 
De klinische uitkomst werd echter negatief beïnvloed door het aanbrengen van de 
formulering. De mate waarin AD zich manifesteerde aan het begin van de studie 
had invloed op het huidbarrièreherstel. Dit laatste is een indicatie dat systemische 
ontsteking ook een rol speelt in het barrièreherstel. Daarnaast werd elke patiënt anders 
beïnvloed door de behandeling. De formulering gebaseerd op VC zou bevorderlijk 
kunnen zijn voor de behandeling van AD, maar het gebruik van enkel de formulering 
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